<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MyelomaMan: Power-Up Your Knowledge!</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Press+Start+2P&display=swap');

        :root {
            --mario-red: #E52521;
            --mario-blue: #049CD8;
            --mario-yellow: #FBD000;
            --mario-green: #43B047;
            --mario-brown: #8B4513;
            --mario-orange: #F5A623;
            --brick-color: #C84C0C;
            --brick-dark: #9C3D0C;
            --sky-blue: #5C94FC;
            --ground-green: #00A800;
            --pipe-green: #00A800;
            --coin-gold: #FFD700;
            --cloud-white: #FCF8E8;
            --text-white: #FFFFFF;
            --text-shadow: #000000;
            --bg-dark: #000000;
            --mushroom-red: #FF0000;
            --star-yellow: #FFFF00;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Press Start 2P', cursive;
            background: linear-gradient(180deg, var(--sky-blue) 0%, var(--sky-blue) 70%, var(--ground-green) 70%, var(--ground-green) 100%);
            min-height: 100vh;
            overflow-x: hidden;
            color: var(--text-white);
            image-rendering: pixelated;
            transition: background 0.5s ease;
        }

        /* ============ HELL MODE THEME (Dr. Jakubowiak Level) ============ */
        body.hell-mode {
            background: linear-gradient(180deg,
                #0a0000 0%,
                #1a0505 20%,
                #2a0a0a 40%,
                #3a0f0f 60%,
                #1a0505 80%,
                #0a0000 100%);
        }

        body.hell-mode .cloud-container {
            display: none;
        }

        body.hell-mode::before {
            content: '';
            position: fixed;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background:
                radial-gradient(ellipse at 20% 100%, rgba(255,50,0,0.3) 0%, transparent 50%),
                radial-gradient(ellipse at 80% 100%, rgba(255,100,0,0.3) 0%, transparent 50%),
                radial-gradient(ellipse at 50% 100%, rgba(255,0,0,0.4) 0%, transparent 40%);
            pointer-events: none;
            z-index: 1;
            animation: hell-flicker 3s ease-in-out infinite;
        }

        @keyframes hell-flicker {
            0%, 100% { opacity: 0.8; }
            25% { opacity: 1; }
            50% { opacity: 0.6; }
            75% { opacity: 0.9; }
        }

        /* Hell mode flames at bottom */
        .hell-flames {
            display: none;
            position: fixed;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 150px;
            z-index: 2;
            pointer-events: none;
        }

        body.hell-mode .hell-flames {
            display: block;
        }

        .flame {
            position: absolute;
            bottom: 0;
            width: 60px;
            height: 80px;
            background: linear-gradient(0deg, #ff4500 0%, #ff6600 30%, #ffcc00 70%, transparent 100%);
            border-radius: 50% 50% 20% 20%;
            animation: flame-dance 0.5s ease-in-out infinite alternate;
            filter: blur(2px);
        }

        .flame:nth-child(odd) {
            animation-delay: 0.2s;
            height: 100px;
        }

        .flame:nth-child(3n) {
            animation-delay: 0.4s;
            height: 120px;
            background: linear-gradient(0deg, #ff0000 0%, #ff4500 40%, #ff8800 80%, transparent 100%);
        }

        @keyframes flame-dance {
            0% { transform: scaleY(1) scaleX(1); }
            100% { transform: scaleY(1.2) scaleX(0.9); }
        }

        /* Hell mode ground */
        body.hell-mode .runner-track {
            background: linear-gradient(180deg, #3a0a0a 0%, #1a0505 100%) !important;
        }

        body.hell-mode .ground-blocks .ground-block {
            background: linear-gradient(180deg, #4a1010 0%, #2a0808 100%) !important;
            border-color: #5a1515 !important;
        }

        /* Pixel art cloud animation */
        .cloud-container {
            position: fixed;
            top: 0;
            left: 0;
            width: 100%;
            height: 70%;
            pointer-events: none;
            z-index: 0;
            overflow: hidden;
        }

        .cloud {
            position: absolute;
            background: var(--cloud-white);
            border-radius: 50%;
            box-shadow:
                30px 0 0 var(--cloud-white),
                60px 0 0 var(--cloud-white),
                15px -20px 0 var(--cloud-white),
                45px -20px 0 var(--cloud-white);
            animation: float-cloud 30s linear infinite;
        }

        @keyframes float-cloud {
            from { transform: translateX(-150px); }
            to { transform: translateX(calc(100vw + 150px)); }
        }

        /* Brick pattern background */
        .brick-pattern {
            position: fixed;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 80px;
            background:
                repeating-linear-gradient(
                    90deg,
                    var(--brick-color) 0px,
                    var(--brick-color) 30px,
                    var(--brick-dark) 30px,
                    var(--brick-dark) 32px
                ),
                repeating-linear-gradient(
                    0deg,
                    var(--brick-color) 0px,
                    var(--brick-color) 15px,
                    var(--brick-dark) 15px,
                    var(--brick-dark) 17px
                );
            z-index: 0;
            border-top: 4px solid var(--brick-dark);
        }

        /* Floating coins animation */
        .coin {
            position: absolute;
            width: 20px;
            height: 24px;
            background: linear-gradient(90deg, #B8860B 0%, var(--coin-gold) 50%, #B8860B 100%);
            border-radius: 50%;
            animation: coin-spin 1s ease-in-out infinite, coin-float 3s ease-in-out infinite;
            box-shadow: inset -2px 0 0 #B8860B, 2px 2px 0 rgba(0,0,0,0.3);
        }

        .coin::after {
            content: 'Â¢';
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            font-size: 10px;
            color: #8B6914;
            font-family: Arial, sans-serif;
            font-weight: bold;
        }

        @keyframes coin-spin {
            0%, 100% { transform: scaleX(1); }
            50% { transform: scaleX(0.3); }
        }

        @keyframes coin-float {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-10px); }
        }

        /* Question block style */
        .question-block {
            background: linear-gradient(135deg, var(--mario-yellow) 0%, var(--mario-orange) 100%);
            border: 4px solid var(--brick-dark);
            border-radius: 4px;
            box-shadow:
                inset 4px 4px 0 rgba(255,255,255,0.3),
                inset -4px -4px 0 rgba(0,0,0,0.2),
                4px 4px 0 rgba(0,0,0,0.4);
            position: relative;
        }

        .question-block::before {
            content: '?';
            position: absolute;
            font-size: 2em;
            color: var(--brick-dark);
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            text-shadow: 2px 2px 0 rgba(0,0,0,0.3);
            animation: question-bounce 0.5s ease-in-out infinite;
        }

        @keyframes question-bounce {
            0%, 100% { transform: translate(-50%, -50%); }
            50% { transform: translate(-50%, -55%); }
        }

        /* Main Container */
        .game-container {
            position: relative;
            z-index: 10;
            max-width: 900px;
            margin: 0 auto;
            padding: 20px;
            padding-bottom: 220px; /* Space for runner scene below */
        }

        /* Header - Pipe style */
        .header {
            text-align: center;
            padding: 30px 20px;
            background: linear-gradient(180deg, var(--pipe-green) 0%, #007800 100%);
            border-radius: 20px 20px 0 0;
            margin-bottom: 0;
            border: 6px solid #005800;
            border-bottom: none;
            position: relative;
            box-shadow: inset 0 10px 20px rgba(255,255,255,0.2);
            z-index: 15;
        }

        .header::before, .header::after {
            content: '';
            position: absolute;
            top: -30px;
            width: 60px;
            height: 30px;
            background: var(--pipe-green);
            border: 6px solid #005800;
            border-bottom: none;
            border-radius: 10px 10px 0 0;
        }

        .header::before { left: 30px; }
        .header::after { right: 30px; }

        .title {
            font-size: 2em;
            color: var(--mario-yellow);
            text-shadow:
                4px 4px 0 var(--mario-red),
                -2px -2px 0 var(--text-shadow),
                2px -2px 0 var(--text-shadow),
                -2px 2px 0 var(--text-shadow);
            margin-bottom: 10px;
            letter-spacing: 2px;
            animation: title-bounce 2s ease-in-out infinite;
        }

        @keyframes title-bounce {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-5px); }
        }

        .subtitle {
            color: var(--cloud-white);
            font-size: 0.6em;
            text-shadow: 2px 2px 0 rgba(0,0,0,0.5);
        }

        /* Stats Bar - Coin counter style */
        .stats-bar {
            display: flex;
            justify-content: space-around;
            background: linear-gradient(180deg, #1a1a2e 0%, #16213e 100%);
            padding: 16px;
            border: 4px solid var(--mario-yellow);
            margin-bottom: 20px;
            box-shadow: inset 0 0 20px rgba(0,0,0,0.5);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5em;
            color: var(--coin-gold);
            text-shadow: 2px 2px 0 #8B6914;
        }

        .stat-label {
            font-size: 0.5em;
            color: var(--cloud-white);
            text-transform: uppercase;
            margin-top: 5px;
        }

        .streak-fire {
            color: var(--mario-red) !important;
            text-shadow: 2px 2px 0 #8B0000 !important;
            animation: fire-pulse 0.5s ease-in-out infinite;
        }

        @keyframes fire-pulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.1); }
        }

        /* Progress Bar - Mario health style */
        .progress-bar {
            height: 24px;
            background: #1a1a2e;
            border: 4px solid var(--mario-yellow);
            margin-bottom: 20px;
            position: relative;
            overflow: hidden;
        }

        .progress-fill {
            height: 100%;
            background: linear-gradient(90deg, var(--mario-red) 0%, var(--mario-orange) 50%, var(--mario-yellow) 100%);
            transition: width 0.5s ease;
            box-shadow: inset 0 -4px 0 rgba(0,0,0,0.3);
        }

        .progress-bar::after {
            content: 'POWER';
            position: absolute;
            left: 10px;
            top: 50%;
            transform: translateY(-50%);
            font-size: 0.5em;
            color: var(--cloud-white);
            text-shadow: 1px 1px 0 black;
        }

        /* Question Card - Brick block style */
        .question-card {
            background: linear-gradient(180deg, var(--brick-color) 0%, #A04000 100%);
            border: 6px solid var(--brick-dark);
            border-radius: 8px;
            padding: 28px;
            margin-bottom: 20px;
            box-shadow:
                inset 4px 4px 0 rgba(255,255,255,0.2),
                inset -4px -4px 0 rgba(0,0,0,0.3),
                8px 8px 0 rgba(0,0,0,0.4);
            position: relative;
            z-index: 15;
        }

        /* Question types - Power-up themed */
        .question-type {
            display: inline-block;
            padding: 6px 12px;
            border-radius: 4px;
            font-size: 0.5em;
            text-transform: uppercase;
            margin-bottom: 12px;
            border: 3px solid;
        }

        .type-case {
            background: var(--mushroom-red);
            color: white;
            border-color: #CC0000;
            box-shadow: inset 2px 2px 0 rgba(255,255,255,0.3);
        }
        .type-simple {
            background: var(--mario-blue);
            color: white;
            border-color: #0066AA;
        }
        .type-staging {
            background: var(--mario-green);
            color: white;
            border-color: #008800;
        }
        .type-treatment {
            background: var(--star-yellow);
            color: #333;
            border-color: #CCAA00;
        }

        /* Difficulty badges - Star themed */
        .difficulty-badge {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 4px;
            font-size: 0.45em;
            text-transform: uppercase;
            margin-left: 8px;
            border: 2px solid;
        }

        .difficulty-badge.intern {
            background: var(--mario-green);
            color: white;
            border-color: #006600;
        }
        .difficulty-badge.resident {
            background: var(--mario-blue);
            color: white;
            border-color: #0055AA;
        }
        .difficulty-badge.fellow {
            background: var(--mario-orange);
            color: white;
            border-color: #CC7700;
        }
        .difficulty-badge.attending {
            background: var(--mario-red);
            color: white;
            border-color: #AA0000;
        }
        .difficulty-badge.jakubowiak {
            background: linear-gradient(180deg, #8B0000 0%, #4a0000 100%);
            color: #ff6666;
            border-color: #ff0000;
            text-shadow: 0 0 5px #ff0000;
            animation: badge-hell-glow 1.5s ease-in-out infinite;
        }

        @keyframes badge-hell-glow {
            0%, 100% { box-shadow: 0 0 5px #ff0000; }
            50% { box-shadow: 0 0 15px #ff0000; }
        }

        .question-number {
            color: var(--cloud-white);
            font-size: 0.5em;
            margin-bottom: 8px;
            opacity: 0.8;
        }

        .question-text {
            font-size: 0.85em;
            line-height: 2.2;
            margin-bottom: 20px;
            color: var(--cloud-white);
            text-shadow: 2px 2px 0 rgba(0,0,0,0.5);
        }

        /* Case presentation - Warp pipe style */
        .case-presentation {
            background: linear-gradient(180deg, #006600 0%, #004400 100%);
            padding: 20px;
            border-radius: 8px;
            margin-bottom: 20px;
            border: 4px solid #003300;
            box-shadow: inset 0 4px 8px rgba(255,255,255,0.1);
        }

        .case-presentation h4 {
            color: var(--mario-yellow);
            margin-bottom: 10px;
            font-size: 0.6em;
            text-transform: uppercase;
        }

        .case-presentation p {
            color: var(--cloud-white);
            line-height: 2.2;
            font-size: 0.7em;
        }

        /* Lab values */
        .lab-values {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 8px;
            margin-top: 15px;
        }

        .lab-item {
            background: rgba(0, 0, 0, 0.4);
            padding: 10px 14px;
            border-radius: 4px;
            font-size: 0.6em;
            line-height: 1.8;
            color: var(--cloud-white);
            border: 2px solid #444;
        }

        .lab-item.abnormal {
            border-color: var(--mario-red);
            background: rgba(229, 37, 33, 0.2);
            animation: abnormal-blink 1s ease-in-out infinite;
        }

        @keyframes abnormal-blink {
            0%, 100% { opacity: 1; }
            50% { opacity: 0.7; }
        }

        /* Histopathology Panel Styles */
        .histopath-container {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 15px;
            margin-top: 15px;
            margin-bottom: 15px;
        }

        .histopath-panel {
            background: rgba(0,0,0,0.4);
            border-radius: 8px;
            padding: 10px;
            border: 3px solid var(--mario-yellow);
        }

        .histopath-panel-label {
            font-size: 0.45em;
            color: var(--mario-yellow);
            text-transform: uppercase;
            margin-bottom: 8px;
            text-align: center;
        }

        .histopath-image-wrapper {
            width: 100%;
            height: 120px;
            background: #1a1a2e;
            border-radius: 4px;
            overflow: hidden;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .histopath-image-wrapper img {
            width: 100%;
            height: 100%;
            object-fit: cover;
        }

        .histopath-fallback {
            color: #666;
            font-size: 0.4em;
            text-align: center;
            padding: 10px;
        }

        .histopath-caption {
            font-size: 0.4em;
            color: #888;
            text-align: center;
            margin-top: 5px;
        }

        .histopath-description {
            font-size: 0.45em;
            color: #ccc;
            line-height: 1.5;
            margin-top: 8px;
        }

        @media (max-width: 600px) {
            .histopath-container {
                grid-template-columns: 1fr;
            }
        }

        /* Answer Options - Block style */
        .options {
            display: flex;
            flex-direction: column;
            gap: 10px;
        }

        .option {
            background: linear-gradient(180deg, var(--mario-yellow) 0%, var(--mario-orange) 100%);
            padding: 16px 18px;
            border-radius: 4px;
            cursor: pointer;
            transition: all 0.15s ease;
            border: 4px solid var(--brick-dark);
            display: flex;
            align-items: flex-start;
            box-shadow:
                inset 2px 2px 0 rgba(255,255,255,0.4),
                4px 4px 0 rgba(0,0,0,0.3);
            color: #333;
        }

        .option:hover {
            transform: translateY(-4px);
            box-shadow:
                inset 2px 2px 0 rgba(255,255,255,0.4),
                6px 8px 0 rgba(0,0,0,0.3);
        }

        .option:active {
            transform: translateY(2px);
            box-shadow:
                inset 2px 2px 0 rgba(255,255,255,0.4),
                2px 2px 0 rgba(0,0,0,0.3);
        }

        .option-letter {
            width: 28px;
            height: 28px;
            min-width: 28px;
            background: var(--mario-red);
            border-radius: 4px;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 14px;
            font-weight: 600;
            font-size: 0.6em;
            color: white;
            border: 2px solid #AA0000;
        }

        .option-text {
            flex: 1;
            line-height: 2.2;
            font-size: 0.7em;
        }

        .option.correct {
            background: linear-gradient(180deg, #00CC00 0%, #009900 100%);
            border-color: #006600;
            animation: correct-bounce 0.5s ease;
        }

        @keyframes correct-bounce {
            0%, 100% { transform: translateY(0); }
            25% { transform: translateY(-10px); }
            50% { transform: translateY(0); }
            75% { transform: translateY(-5px); }
        }

        .option.correct .option-letter {
            background: var(--mario-green);
            border-color: #006600;
        }

        .option.incorrect {
            background: linear-gradient(180deg, #CC3333 0%, #AA0000 100%);
            border-color: #880000;
            animation: incorrect-shake 0.5s ease;
            color: white;
        }

        @keyframes incorrect-shake {
            0%, 100% { transform: translateX(0); }
            20%, 60% { transform: translateX(-10px); }
            40%, 80% { transform: translateX(10px); }
        }

        .option.incorrect .option-letter {
            background: #880000;
        }

        .option.disabled {
            pointer-events: none;
            opacity: 0.7;
        }

        /* Explanation - Star power style */
        .explanation {
            background: linear-gradient(180deg, #FFD700 0%, #FFA500 100%);
            padding: 20px;
            border-radius: 8px;
            margin-top: 20px;
            border: 4px solid #CC8800;
            display: none;
            color: #333;
            box-shadow: 0 0 20px rgba(255, 215, 0, 0.5);
        }

        .explanation.show {
            display: block;
            animation: star-power 0.5s ease;
        }

        @keyframes star-power {
            0% { transform: scale(0.8); opacity: 0; }
            50% { transform: scale(1.05); }
            100% { transform: scale(1); opacity: 1; }
        }

        .explanation h4 {
            color: var(--mario-red);
            margin-bottom: 10px;
            font-size: 0.6em;
            text-transform: uppercase;
        }

        .explanation p {
            line-height: 2.2;
            font-size: 0.65em;
        }

        .key-point {
            background: rgba(255, 0, 0, 0.15);
            padding: 12px 16px;
            border-radius: 4px;
            margin-top: 15px;
            border-left: 4px solid var(--mario-red);
        }

        .key-point strong {
            color: var(--mario-red);
            font-size: 0.5em;
            text-transform: uppercase;
        }

        .key-point p {
            margin-top: 6px;
            font-size: 0.6em;
            line-height: 2;
        }

        .citation {
            background: rgba(0, 0, 0, 0.1);
            padding: 10px 14px;
            border-radius: 4px;
            margin-top: 12px;
            font-size: 0.45em;
        }

        /* Reference Links */
        .ref-links {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            margin-top: 10px;
        }

        .ref-link {
            display: inline-flex;
            align-items: center;
            padding: 5px 10px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 4px;
            color: #4fc3f7;
            text-decoration: none;
            font-size: 1em;
            transition: all 0.2s;
            border: 1px solid rgba(79, 195, 247, 0.3);
        }

        .ref-link:hover {
            background: rgba(79, 195, 247, 0.3);
            transform: scale(1.05);
            border-color: #4fc3f7;
        }

        /* Next Button - Mushroom style */
        .next-btn {
            background: linear-gradient(180deg, var(--mushroom-red) 0%, #CC0000 100%);
            color: white;
            border: 4px solid #880000;
            padding: 14px 36px;
            font-size: 0.7em;
            font-family: 'Press Start 2P', cursive;
            border-radius: 8px;
            cursor: pointer;
            display: none;
            margin: 20px auto 0;
            transition: all 0.15s ease;
            box-shadow: 4px 4px 0 rgba(0,0,0,0.4);
            text-shadow: 2px 2px 0 rgba(0,0,0,0.5);
        }

        .next-btn.show {
            display: block;
        }

        .next-btn:hover {
            transform: translateY(-4px);
            box-shadow: 6px 8px 0 rgba(0,0,0,0.4);
        }

        .next-btn:active {
            transform: translateY(2px);
            box-shadow: 2px 2px 0 rgba(0,0,0,0.4);
        }

        /* Start Screen */
        .start-screen {
            text-align: center;
            padding: 40px;
        }

        .start-btn {
            background: linear-gradient(180deg, var(--mario-green) 0%, #009900 100%);
            color: white;
            border: 4px solid #006600;
            padding: 20px 50px;
            font-size: 0.8em;
            font-family: 'Press Start 2P', cursive;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 30px;
            transition: all 0.15s ease;
            box-shadow: 6px 6px 0 rgba(0,0,0,0.4);
            text-shadow: 2px 2px 0 rgba(0,0,0,0.5);
            animation: start-pulse 1s ease-in-out infinite;
        }

        @keyframes start-pulse {
            0%, 100% { transform: scale(1); }
            50% { transform: scale(1.05); }
        }

        .start-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: 8px 10px 0 rgba(0,0,0,0.4);
            animation: none;
        }

        /* Difficulty Selector */
        .difficulty-selector {
            display: flex;
            gap: 10px;
            justify-content: center;
            margin: 24px 0;
            flex-wrap: wrap;
        }

        .difficulty-btn {
            padding: 12px 20px;
            border-radius: 4px;
            cursor: pointer;
            transition: all 0.15s ease;
            border: 4px solid;
            background: rgba(0,0,0,0.3);
            font-family: 'Press Start 2P', cursive;
            font-size: 0.5em;
            box-shadow: 4px 4px 0 rgba(0,0,0,0.3);
        }

        .difficulty-btn:hover {
            transform: translateY(-2px);
        }

        .difficulty-btn.selected {
            transform: translateY(-4px);
            box-shadow: 6px 6px 0 rgba(0,0,0,0.4);
        }

        .difficulty-btn.intern {
            color: var(--mario-green);
            border-color: var(--mario-green);
        }
        .difficulty-btn.intern.selected {
            background: var(--mario-green);
            color: white;
        }

        .difficulty-btn.resident {
            color: var(--mario-blue);
            border-color: var(--mario-blue);
        }
        .difficulty-btn.resident.selected {
            background: var(--mario-blue);
            color: white;
        }

        .difficulty-btn.fellow {
            color: var(--mario-orange);
            border-color: var(--mario-orange);
        }
        .difficulty-btn.fellow.selected {
            background: var(--mario-orange);
            color: white;
        }

        .difficulty-btn.attending {
            color: var(--mario-red);
            border-color: var(--mario-red);
        }
        .difficulty-btn.attending.selected {
            background: var(--mario-red);
            color: white;
        }

        .difficulty-btn.jakubowiak {
            color: #8B0000;
            border-color: #8B0000;
            background: linear-gradient(180deg, #1a0000 0%, #0a0000 100%);
            text-shadow: 0 0 10px #ff0000;
            animation: hell-pulse 2s ease-in-out infinite;
        }
        .difficulty-btn.jakubowiak:hover {
            box-shadow: 0 0 20px #ff0000, 0 0 40px #8B0000;
        }
        .difficulty-btn.jakubowiak.selected {
            background: linear-gradient(180deg, #8B0000 0%, #4a0000 100%);
            color: #ff6666;
            box-shadow: 0 0 30px #ff0000, inset 0 0 20px rgba(255,0,0,0.3);
        }

        @keyframes hell-pulse {
            0%, 100% { box-shadow: 0 0 5px #ff0000; }
            50% { box-shadow: 0 0 20px #ff0000, 0 0 30px #8B0000; }
        }

        /* Results Screen */
        .results-screen {
            display: none;
            text-align: center;
        }

        .results-screen h2 {
            font-size: 1.2em;
            color: var(--mario-yellow);
            text-shadow: 4px 4px 0 var(--mario-red);
            margin-bottom: 30px;
        }

        .score-circle {
            width: 180px;
            height: 180px;
            border-radius: 50%;
            background: conic-gradient(var(--coin-gold) 0%, rgba(0,0,0,0.3) 0%);
            display: flex;
            align-items: center;
            justify-content: center;
            margin: 0 auto 30px;
            border: 6px solid var(--mario-yellow);
            box-shadow: 0 0 30px rgba(255, 215, 0, 0.5);
            position: relative;
        }

        .score-circle::before {
            content: '';
            position: absolute;
            width: 140px;
            height: 140px;
            background: var(--brick-color);
            border-radius: 50%;
            border: 4px solid var(--brick-dark);
        }

        .score-text {
            font-size: 1.5em;
            color: var(--coin-gold);
            text-shadow: 2px 2px 0 #8B6914;
            z-index: 1;
        }

        .grade {
            font-size: 1.5em;
            margin: 20px 0;
            text-shadow: 3px 3px 0 rgba(0,0,0,0.5);
        }

        .play-again-btn {
            background: linear-gradient(180deg, var(--mario-green) 0%, #009900 100%);
            color: white;
            border: 4px solid #006600;
            padding: 16px 40px;
            font-size: 0.7em;
            font-family: 'Press Start 2P', cursive;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 20px;
            box-shadow: 4px 4px 0 rgba(0,0,0,0.4);
            text-shadow: 2px 2px 0 rgba(0,0,0,0.5);
        }

        .play-again-btn:hover {
            transform: translateY(-4px);
            box-shadow: 6px 8px 0 rgba(0,0,0,0.4);
        }

        /* Music Controls */
        .music-controls {
            position: fixed;
            bottom: 100px;
            left: 15px;
            display: flex;
            align-items: center;
            gap: 10px;
            z-index: 10000;
        }

        .music-control {
            width: 50px;
            height: 50px;
            border-radius: 4px;
            background: linear-gradient(180deg, var(--mario-yellow) 0%, var(--mario-orange) 100%);
            border: 4px solid var(--brick-dark);
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 20px;
            box-shadow: 3px 3px 0 rgba(0,0,0,0.4);
            transition: all 0.15s ease;
        }

        .music-control:hover {
            transform: translateY(-2px);
        }

        .music-control.playing {
            animation: block-bounce 0.5s ease-in-out infinite;
        }

        @keyframes block-bounce {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-5px); }
        }

        /* Volume slider */
        .volume-slider-container {
            display: flex;
            align-items: center;
            gap: 8px;
            background: linear-gradient(180deg, #1a1a2e 0%, #16213e 100%);
            padding: 8px 12px;
            border-radius: 4px;
            border: 3px solid var(--mario-yellow);
            opacity: 0;
            transform: translateX(-10px);
            transition: all 0.3s ease;
            pointer-events: none;
        }

        .music-controls:hover .volume-slider-container {
            opacity: 1;
            transform: translateX(0);
            pointer-events: auto;
        }

        .volume-slider {
            -webkit-appearance: none;
            width: 80px;
            height: 8px;
            border-radius: 4px;
            background: #333;
            outline: none;
            cursor: pointer;
        }

        .volume-slider::-webkit-slider-thumb {
            -webkit-appearance: none;
            width: 20px;
            height: 20px;
            border-radius: 4px;
            background: var(--mario-red);
            cursor: pointer;
            border: 2px solid #880000;
        }

        .volume-value {
            font-size: 0.5em;
            color: var(--coin-gold);
            min-width: 35px;
        }

        /* Coin popup animation */
        .coin-popup {
            position: fixed;
            font-size: 1.5em;
            color: var(--coin-gold);
            text-shadow: 2px 2px 0 #8B6914;
            pointer-events: none;
            z-index: 10001;
            animation: coin-fly 1s ease-out forwards;
        }

        @keyframes coin-fly {
            0% { transform: translateY(0) scale(1); opacity: 1; }
            100% { transform: translateY(-100px) scale(1.5); opacity: 0; }
        }

        /* 1-UP animation */
        .one-up {
            position: fixed;
            font-size: 0.8em;
            color: var(--mario-green);
            text-shadow: 2px 2px 0 #006600;
            pointer-events: none;
            z-index: 10001;
            animation: one-up-fly 1.5s ease-out forwards;
        }

        @keyframes one-up-fly {
            0% { transform: translateY(0); opacity: 1; }
            100% { transform: translateY(-150px); opacity: 0; }
        }

        /* Game Over text */
        .game-over {
            position: fixed;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            font-size: 2em;
            color: var(--mario-red);
            text-shadow: 4px 4px 0 #000;
            z-index: 10000;
            animation: game-over-appear 1s ease-out;
            display: none;
        }

        @keyframes game-over-appear {
            0% { transform: translate(-50%, -50%) scale(3); opacity: 0; }
            50% { transform: translate(-50%, -50%) scale(0.9); opacity: 1; }
            100% { transform: translate(-50%, -50%) scale(1); }
        }

        /* ============ SIDE-SCROLLER RUNNER SCENE ============ */
        .runner-scene {
            position: fixed;
            bottom: 80px;
            left: 0;
            width: 100%;
            height: 180px;
            z-index: 2;
            overflow: visible;
            pointer-events: none;
        }

        /* The hero runner */
        .hero-runner {
            position: absolute;
            bottom: 0;
            left: 50px;
            width: 80px;
            height: 95px;
            z-index: 10;
            transition: bottom 0.15s ease-out;
        }

        /* Dr. Wen name tag */
        .hero-name {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-family: 'Press Start 2P', cursive;
            font-size: 9px;
            color: var(--mario-yellow);
            text-shadow: 1px 1px 0 #000, -1px -1px 0 #000, 1px -1px 0 #000, -1px 1px 0 #000;
            white-space: nowrap;
            background: rgba(0, 0, 0, 0.7);
            padding: 4px 8px;
            border-radius: 4px;
            border: 2px solid var(--mario-orange);
        }

        .hero-runner.running .hero-body {
            animation: hero-run 0.3s steps(2) infinite;
        }

        .hero-runner.jumping {
            animation: hero-jump-arc 0.8s ease-out forwards;
        }

        @keyframes hero-jump-arc {
            0% {
                bottom: 0;
                transform: translateX(0) rotate(0deg);
            }
            30% {
                bottom: 70px;
                transform: translateX(40px) rotate(-10deg);
            }
            50% {
                bottom: 80px;
                transform: translateX(60px) rotate(0deg);
            }
            70% {
                bottom: 50px;
                transform: translateX(75px) rotate(15deg);
            }
            85% {
                bottom: 10px;
                transform: translateX(80px) rotate(5deg);
            }
            100% {
                bottom: 0;
                transform: translateX(0) rotate(0deg);
            }
        }

        /* Stomp landing effect */
        .hero-runner.stomping {
            animation: hero-stomp-land 0.3s ease-out;
        }

        @keyframes hero-stomp-land {
            0% { transform: translateX(80px) scaleY(1); }
            50% { transform: translateX(80px) scaleY(0.7) scaleX(1.2); }
            100% { transform: translateX(0) scaleY(1) scaleX(1); }
        }

        @keyframes hero-run {
            0% { transform: translateY(0); }
            50% { transform: translateY(-5px); }
        }

        /* Hero sprite (pixel art style with CSS) */
        .hero-body {
            position: relative;
            width: 100%;
            height: 100%;
        }

        /* Head */
        .hero-head {
            position: absolute;
            top: 5px;
            left: 50%;
            transform: translateX(-50%);
            width: 40px;
            height: 36px;
            background: #FFD8B1;
            border-radius: 50% 50% 45% 45%;
            border: 3px solid #333;
        }

        /* Doctor cap/hair - ORANGE */
        .hero-head::before {
            content: '';
            position: absolute;
            top: -12px;
            left: -6px;
            width: 52px;
            height: 26px;
            background: var(--mario-orange);
            border-radius: 12px 12px 0 0;
            border: 3px solid #333;
            border-bottom: none;
            box-shadow: inset 0 5px 10px rgba(255,255,255,0.3);
        }

        /* Eyes */
        .hero-head::after {
            content: '';
            position: absolute;
            top: 12px;
            left: 10px;
            width: 8px;
            height: 8px;
            background: #333;
            border-radius: 50%;
            box-shadow: 14px 0 0 #333;
        }

        /* Body - white coat */
        .hero-torso {
            position: absolute;
            top: 38px;
            left: 50%;
            transform: translateX(-50%);
            width: 44px;
            height: 36px;
            background: white;
            border: 3px solid #333;
            border-radius: 5px;
        }

        /* Stethoscope */
        .hero-torso::before {
            content: '';
            position: absolute;
            top: 5px;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 3px;
            background: var(--mario-blue);
            border-radius: 2px;
        }

        /* Legs */
        .hero-legs {
            position: absolute;
            bottom: 0;
            left: 50%;
            transform: translateX(-50%);
            width: 40px;
            height: 24px;
            display: flex;
            justify-content: space-between;
        }

        .hero-leg {
            width: 16px;
            height: 24px;
            background: var(--mario-orange);
            border: 3px solid #333;
            border-radius: 0 0 5px 5px;
            animation: leg-run 0.3s steps(2) infinite;
        }

        .hero-leg:nth-child(2) {
            animation-delay: 0.15s;
        }

        @keyframes leg-run {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-4px) rotate(15deg); }
        }

        /* ============ HEMATOPOIESIS PRINCESS ============ */
        .princess-container {
            position: absolute;
            right: 30px;
            bottom: 0;
            width: 90px;
            height: 120px;
            z-index: 9;
            display: none;
        }

        .princess-container.show {
            display: block;
            animation: princess-idle 2s ease-in-out infinite;
        }

        @keyframes princess-idle {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-5px); }
        }

        .princess-container.rescued {
            animation: princess-rescued 1.5s ease-out forwards;
        }

        @keyframes princess-rescued {
            0% { transform: translateY(0) scale(1); }
            30% { transform: translateY(-30px) scale(1.1); }
            50% { transform: translateY(-20px) scale(1.05); }
            100% { transform: translateY(0) scale(1); }
        }

        /* Princess name tag */
        .princess-name {
            position: absolute;
            top: -25px;
            left: 50%;
            transform: translateX(-50%);
            font-family: 'Press Start 2P', cursive;
            font-size: 6px;
            color: #FFB6C1;
            text-shadow: 1px 1px 0 #000;
            white-space: nowrap;
            background: rgba(0, 0, 0, 0.7);
            padding: 3px 5px;
            border-radius: 3px;
            border: 1px solid #FF69B4;
            text-align: center;
            line-height: 1.4;
        }

        /* Princess body */
        .princess-body {
            position: relative;
            width: 100%;
            height: 100%;
        }

        /* Crown with stem cell motif */
        .princess-crown {
            position: absolute;
            top: 0;
            left: 50%;
            transform: translateX(-50%);
            width: 45px;
            height: 25px;
            background: linear-gradient(180deg, #FFD700 0%, #FFA500 100%);
            border: 3px solid #B8860B;
            border-radius: 5px 5px 0 0;
            clip-path: polygon(0% 100%, 10% 30%, 25% 100%, 40% 20%, 55% 100%, 70% 30%, 85% 100%, 100% 50%, 100% 100%);
        }

        /* Gems on crown (representing different blood cells) */
        .princess-crown::before {
            content: '';
            position: absolute;
            top: 8px;
            left: 8px;
            width: 8px;
            height: 8px;
            background: #FF0000;
            border-radius: 50%;
            box-shadow: 12px 0 0 #FFFFFF, 24px 0 0 #4169E1;
        }

        /* Princess head */
        .princess-head {
            position: absolute;
            top: 20px;
            left: 50%;
            transform: translateX(-50%);
            width: 40px;
            height: 38px;
            background: #FFE4C4;
            border-radius: 50% 50% 45% 45%;
            border: 3px solid #333;
        }

        /* Princess hair */
        .princess-head::before {
            content: '';
            position: absolute;
            top: -5px;
            left: -8px;
            width: 56px;
            height: 35px;
            background: linear-gradient(180deg, #8B0000 0%, #DC143C 50%, #8B0000 100%);
            border-radius: 50% 50% 30% 30%;
            z-index: -1;
        }

        /* Princess eyes */
        .princess-head::after {
            content: '';
            position: absolute;
            top: 14px;
            left: 8px;
            width: 7px;
            height: 9px;
            background: #228B22;
            border-radius: 50%;
            box-shadow: 14px 0 0 #228B22;
        }

        /* Blush */
        .princess-blush {
            position: absolute;
            top: 45px;
            left: 22px;
            width: 10px;
            height: 5px;
            background: rgba(255, 182, 193, 0.7);
            border-radius: 50%;
        }

        .princess-blush::after {
            content: '';
            position: absolute;
            left: 24px;
            width: 10px;
            height: 5px;
            background: rgba(255, 182, 193, 0.7);
            border-radius: 50%;
        }

        /* Princess dress - blood cell themed */
        .princess-dress {
            position: absolute;
            top: 55px;
            left: 50%;
            transform: translateX(-50%);
            width: 60px;
            height: 50px;
            background: linear-gradient(180deg, #DC143C 0%, #8B0000 100%);
            border: 3px solid #333;
            border-radius: 10px 10px 30px 30px;
            clip-path: polygon(15% 0%, 85% 0%, 100% 100%, 0% 100%);
        }

        /* Blood cell decorations on dress */
        .princess-dress::before {
            content: '';
            position: absolute;
            top: 15px;
            left: 10px;
            width: 12px;
            height: 12px;
            background: radial-gradient(circle at 30% 30%, #FF6B6B, #8B0000);
            border-radius: 50%;
            box-shadow: 20px 5px 0 0 rgba(255,255,255,0.3), 10px 20px 0 0 rgba(255,107,107,0.8);
        }

        /* White blood cell accent */
        .princess-dress::after {
            content: '';
            position: absolute;
            top: 10px;
            right: 12px;
            width: 10px;
            height: 10px;
            background: radial-gradient(circle at 40% 40%, #FFFFFF, #E0E0E0);
            border-radius: 40% 60% 50% 50%;
            border: 1px solid #CCC;
        }

        /* Floating stem cells around princess */
        .stem-cells {
            position: absolute;
            width: 100%;
            height: 100%;
            pointer-events: none;
        }

        .stem-cell {
            position: absolute;
            width: 15px;
            height: 15px;
            background: radial-gradient(circle at 40% 40%, #E6E6FA, #9370DB);
            border-radius: 50%;
            border: 2px solid #8A2BE2;
            animation: stem-cell-float 3s ease-in-out infinite;
        }

        .stem-cell:nth-child(1) { top: 10px; left: -10px; animation-delay: 0s; }
        .stem-cell:nth-child(2) { top: 40px; right: -15px; animation-delay: 1s; }
        .stem-cell:nth-child(3) { top: 70px; left: -5px; animation-delay: 2s; }

        .stem-cell::after {
            content: '';
            position: absolute;
            top: 4px;
            left: 4px;
            width: 5px;
            height: 5px;
            background: #4B0082;
            border-radius: 50%;
        }

        @keyframes stem-cell-float {
            0%, 100% { transform: translateY(0) rotate(0deg); opacity: 0.8; }
            50% { transform: translateY(-10px) rotate(180deg); opacity: 1; }
        }

        /* Help text above princess */
        .help-text {
            position: absolute;
            top: -50px;
            left: 50%;
            transform: translateX(-50%);
            font-family: 'Press Start 2P', cursive;
            font-size: 8px;
            color: #FF69B4;
            text-shadow: 1px 1px 0 #000;
            white-space: nowrap;
            animation: help-blink 1s ease-in-out infinite;
        }

        @keyframes help-blink {
            0%, 100% { opacity: 1; }
            50% { opacity: 0.5; }
        }

        /* Victory celebration */
        .victory-overlay {
            position: fixed;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: rgba(0, 0, 0, 0);
            display: none;
            justify-content: center;
            align-items: center;
            flex-direction: column;
            z-index: 9999;
            pointer-events: none;
        }

        .victory-overlay.show {
            display: flex;
            animation: victory-bg 2s ease-out forwards;
            pointer-events: auto;
        }

        @keyframes victory-bg {
            0% { background: rgba(0, 0, 0, 0); }
            100% { background: rgba(255, 215, 0, 0.3); }
        }

        .victory-text {
            font-family: 'Press Start 2P', cursive;
            font-size: 2.5em;
            color: var(--mario-yellow);
            text-shadow: 4px 4px 0 #8B0000, -2px -2px 0 #000;
            animation: victory-text-bounce 0.5s ease-out infinite alternate;
            text-align: center;
        }

        @keyframes victory-text-bounce {
            0% { transform: scale(1); }
            100% { transform: scale(1.05); }
        }

        .victory-subtext {
            font-family: 'Press Start 2P', cursive;
            font-size: 0.8em;
            color: #FFB6C1;
            text-shadow: 2px 2px 0 #000;
            margin-top: 20px;
            text-align: center;
        }

        /* Hearts floating during victory */
        .victory-hearts {
            position: absolute;
            width: 100%;
            height: 100%;
            pointer-events: none;
            overflow: hidden;
        }

        .victory-heart {
            position: absolute;
            font-size: 30px;
            animation: heart-float 3s ease-out forwards;
        }

        @keyframes heart-float {
            0% { transform: translateY(100vh) scale(0); opacity: 0; }
            20% { opacity: 1; transform: translateY(80vh) scale(1); }
            100% { transform: translateY(-20vh) scale(1.5); opacity: 0; }
        }

        /* Blood cells floating during victory */
        .victory-cells {
            position: absolute;
            width: 100%;
            height: 100%;
            pointer-events: none;
        }

        .victory-rbc {
            position: absolute;
            width: 25px;
            height: 25px;
            background: radial-gradient(ellipse at center, #FF6B6B 0%, #DC143C 50%, #8B0000 100%);
            border-radius: 50%;
            animation: cell-float 4s ease-in-out infinite;
        }

        .victory-rbc::before {
            content: '';
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            width: 8px;
            height: 8px;
            background: rgba(139, 0, 0, 0.5);
            border-radius: 50%;
        }

        @keyframes cell-float {
            0%, 100% { transform: translateY(0) rotate(0deg); }
            50% { transform: translateY(-30px) rotate(180deg); }
        }

        /* ============ EVIL PLASMA CELLS (with nucleus & nucleoli) ============ */
        .enemy-container {
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 100%;
        }

        .myeloma-enemy {
            position: absolute;
            bottom: 5px;
            width: 75px;
            height: 65px;
            border-radius: 45% 45% 50% 50%;
            /* Plasma cell - basophilic cytoplasm with lighter perinuclear hof */
            background:
                radial-gradient(ellipse 35% 40% at 65% 60%,
                    rgba(255,220,255,0.4) 0%,
                    transparent 70%),
                radial-gradient(circle at 30% 30%,
                    #E8B8E8 0%,
                    #C77DC7 25%,
                    #9B4F9B 50%,
                    #7A3A7A 75%,
                    #5C2A5C 100%);
            border: 3px solid #3A1A3A;
            animation: enemy-wobble 0.8s ease-in-out infinite;
            transition: all 0.3s ease;
            z-index: 8;
            box-shadow:
                inset -4px -4px 10px rgba(0,0,0,0.4),
                inset 4px 4px 8px rgba(255,200,255,0.2),
                3px 3px 6px rgba(0,0,0,0.4);
        }

        @keyframes enemy-wobble {
            0%, 100% { transform: translateY(0) scaleX(1); }
            25% { transform: translateY(-3px) scaleX(0.97); }
            50% { transform: translateY(0) scaleX(1.03); }
            75% { transform: translateY(-2px) scaleX(0.98); }
        }

        /* Eccentric nucleus - the hallmark of plasma cells */
        .plasma-nucleus {
            position: absolute;
            bottom: 8px;
            right: 8px;
            width: 32px;
            height: 32px;
            border-radius: 50%;
            /* Clock-face chromatin pattern with spokes */
            background:
                repeating-conic-gradient(
                    from 0deg,
                    #2A1040 0deg 30deg,
                    #4A2060 30deg 60deg
                ),
                radial-gradient(circle at 50% 50%,
                    #3D1A50 0%,
                    #2A1040 100%);
            background-blend-mode: overlay;
            border: 3px solid #1A0828;
            box-shadow:
                inset 2px 2px 4px rgba(255,255,255,0.15),
                inset -2px -2px 4px rgba(0,0,0,0.3);
        }

        /* Perinuclear hof (Golgi zone) - clear area around nucleus */
        .perinuclear-hof {
            position: absolute;
            bottom: 3px;
            right: 3px;
            width: 44px;
            height: 44px;
            border-radius: 50%;
            background: radial-gradient(circle,
                rgba(255,240,255,0.5) 0%,
                rgba(255,220,255,0.3) 40%,
                transparent 70%);
            pointer-events: none;
        }

        /* Nucleoli inside nucleus */
        .nucleolus {
            position: absolute;
            background: radial-gradient(circle at 30% 30%, #3A1848, #1A0828);
            border-radius: 50%;
            box-shadow: inset 1px 1px 2px rgba(255,255,255,0.2);
        }

        .nucleolus:nth-child(1) {
            width: 9px;
            height: 9px;
            top: 5px;
            left: 7px;
        }

        .nucleolus:nth-child(2) {
            width: 6px;
            height: 6px;
            top: 16px;
            left: 17px;
        }

        /* Russell bodies (eosinophilic inclusions - protein accumulation) */
        .russell-body {
            position: absolute;
            border-radius: 50%;
            background: radial-gradient(circle at 30% 30%, #FFB6C1, #FF69B4);
            opacity: 0.7;
        }

        .russell-body:nth-child(1) {
            width: 8px;
            height: 8px;
            top: 38px;
            left: 10px;
        }

        .russell-body:nth-child(2) {
            width: 5px;
            height: 5px;
            top: 32px;
            left: 20px;
        }

        /* Evil eyes on plasma cell */
        .evil-eyes {
            position: absolute;
            top: 10px;
            left: 12px;
            width: 36px;
            height: 16px;
            z-index: 5;
        }

        .evil-eye {
            position: absolute;
            width: 15px;
            height: 15px;
            background: radial-gradient(circle at 40% 40%, #fff, #ddd);
            border-radius: 50%;
            border: 2px solid #333;
            box-shadow: inset -1px -1px 2px rgba(0,0,0,0.2);
        }

        .evil-eye:nth-child(1) { left: 0; }
        .evil-eye:nth-child(2) { left: 20px; }

        /* Rough Endoplasmic Reticulum - characteristic of plasma cells */
        .endoplasmic-reticulum {
            position: absolute;
            top: 28px;
            left: 5px;
            width: 30px;
            height: 25px;
            pointer-events: none;
            opacity: 0.6;
        }

        .er-strand {
            position: absolute;
            border: 2px solid #8B5A8B;
            border-radius: 50%;
            background: transparent;
        }

        .er-strand:nth-child(1) {
            width: 28px;
            height: 10px;
            top: 0;
            left: 0;
            border-color: #9B6A9B;
        }

        .er-strand:nth-child(2) {
            width: 24px;
            height: 8px;
            top: 8px;
            left: 2px;
            border-color: #8B5A8B;
        }

        .er-strand:nth-child(3) {
            width: 20px;
            height: 8px;
            top: 14px;
            left: 4px;
            border-color: #7B4A7B;
        }

        /* Ribosomes on ER (small dots) */
        .er-strand::before,
        .er-strand::after {
            content: '';
            position: absolute;
            width: 2px;
            height: 2px;
            background: #5A3A5A;
            border-radius: 50%;
        }

        .er-strand:nth-child(1)::before { top: -1px; left: 5px; box-shadow: 6px 0 0 #5A3A5A, 12px 0 0 #5A3A5A, 18px 0 0 #5A3A5A; }
        .er-strand:nth-child(1)::after { bottom: -1px; left: 8px; box-shadow: 6px 0 0 #5A3A5A, 12px 0 0 #5A3A5A; }
        .er-strand:nth-child(2)::before { top: -1px; left: 4px; box-shadow: 5px 0 0 #5A3A5A, 10px 0 0 #5A3A5A, 15px 0 0 #5A3A5A; }
        .er-strand:nth-child(3)::before { top: -1px; left: 3px; box-shadow: 5px 0 0 #5A3A5A, 10px 0 0 #5A3A5A; }

        .evil-eye::after {
            content: '';
            position: absolute;
            width: 5px;
            height: 5px;
            background: #220011;
            border-radius: 50%;
            top: 3px;
            left: 4px;
        }

        /* Angry eyebrows */
        .evil-eye::before {
            content: '';
            position: absolute;
            width: 12px;
            height: 3px;
            background: #4A1A4A;
            top: -4px;
            left: -1px;
            transform: rotate(-15deg);
            border-radius: 2px;
        }

        .evil-eye:nth-child(2)::before {
            transform: rotate(15deg);
        }

        /* M-protein spikes */
        .m-protein-spike {
            position: absolute;
            width: 6px;
            height: 12px;
            background: linear-gradient(to top, #6B2D6B, #D4A5D9);
            border-radius: 50% 50% 0 0;
        }

        @keyframes enemy-walk {
            0%, 100% { transform: scaleX(1); }
            50% { transform: scaleX(1.05); }
        }

        @keyframes enemy-float {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-5px); }
        }

        /* Enemy getting stomped */
        .myeloma-enemy.stomped {
            animation: enemy-stomp 0.5s ease-out forwards;
        }

        @keyframes enemy-stomp {
            0% { transform: scale(1); opacity: 1; }
            30% { transform: scale(1.3, 0.3); }
            100% { transform: scale(0); opacity: 0; }
        }

        /* Enemy exits left after killing hero */
        .myeloma-enemy.exit-left {
            animation: enemy-exit-left 1.2s ease-in forwards;
        }

        @keyframes enemy-exit-left {
            0% { transform: translateX(0); }
            20% { transform: translateX(20px); }
            100% { transform: translateX(-120vw); }
        }

        /* ============ HELL MODE EVIL PLASMA CELLS ============ */
        body.hell-mode .myeloma-enemy {
            background:
                radial-gradient(ellipse 35% 40% at 65% 60%,
                    rgba(255,100,0,0.4) 0%,
                    transparent 70%),
                radial-gradient(circle at 30% 30%,
                    #4a0000 0%,
                    #6a0000 25%,
                    #8B0000 50%,
                    #5a0000 75%,
                    #3a0000 100%);
            border-color: #ff0000;
            box-shadow:
                inset -4px -4px 10px rgba(0,0,0,0.6),
                inset 4px 4px 8px rgba(255,100,0,0.3),
                0 0 20px rgba(255,0,0,0.6),
                0 0 40px rgba(255,50,0,0.3);
            animation: evil-enemy-wobble 0.5s ease-in-out infinite, evil-glow 1s ease-in-out infinite;
        }

        @keyframes evil-enemy-wobble {
            0%, 100% { transform: translateY(0) scaleX(1) rotate(-2deg); }
            25% { transform: translateY(-5px) scaleX(0.95) rotate(2deg); }
            50% { transform: translateY(0) scaleX(1.05) rotate(-1deg); }
            75% { transform: translateY(-3px) scaleX(0.97) rotate(1deg); }
        }

        @keyframes evil-glow {
            0%, 100% { filter: brightness(1); }
            50% { filter: brightness(1.3) drop-shadow(0 0 10px #ff0000); }
        }

        body.hell-mode .plasma-nucleus {
            background:
                repeating-conic-gradient(
                    from 0deg,
                    #1a0000 0deg 30deg,
                    #3a0000 30deg 60deg
                ),
                radial-gradient(circle at 50% 50%,
                    #2a0000 0%,
                    #1a0000 100%);
            border-color: #ff0000;
            box-shadow:
                inset 2px 2px 4px rgba(255,100,0,0.2),
                inset -2px -2px 4px rgba(0,0,0,0.5),
                0 0 8px rgba(255,0,0,0.5);
        }

        body.hell-mode .evil-eye {
            background: #ff0000;
            box-shadow: 0 0 8px #ff0000, 0 0 15px #ff6600;
        }

        body.hell-mode .evil-eye::after {
            background: #000;
            box-shadow: 0 0 3px #ff0000;
        }

        body.hell-mode .russell-body {
            background: radial-gradient(circle, #ff6600 0%, #ff0000 50%, #8B0000 100%);
            box-shadow: 0 0 6px rgba(255,100,0,0.8);
        }

        body.hell-mode .m-protein-spike {
            background: linear-gradient(to top, #ff0000, #ff6600);
            box-shadow: 0 0 5px #ff0000;
        }

        body.hell-mode .endoplasmic-reticulum .er-strand {
            border-color: #ff4400;
        }

        body.hell-mode .perinuclear-hof {
            background: radial-gradient(ellipse, rgba(255,100,0,0.3) 0%, transparent 70%);
        }

        /* Evil horns for hell mode enemies */
        body.hell-mode .myeloma-enemy::before {
            content: '';
            position: absolute;
            top: -15px;
            left: 15px;
            width: 0;
            height: 0;
            border-left: 6px solid transparent;
            border-right: 6px solid transparent;
            border-bottom: 18px solid #8B0000;
            transform: rotate(-15deg);
            filter: drop-shadow(0 0 3px #ff0000);
        }

        body.hell-mode .myeloma-enemy::after {
            content: '';
            position: absolute;
            top: -15px;
            right: 15px;
            width: 0;
            height: 0;
            border-left: 6px solid transparent;
            border-right: 6px solid transparent;
            border-bottom: 18px solid #8B0000;
            transform: rotate(15deg);
            filter: drop-shadow(0 0 3px #ff0000);
        }

        /* Score popup from stomped enemy */
        .stomp-score {
            position: absolute;
            font-family: 'Press Start 2P', cursive;
            font-size: 0.8em;
            color: var(--coin-gold);
            text-shadow: 2px 2px 0 #000;
            animation: stomp-score-fly 1s ease-out forwards;
            pointer-events: none;
            z-index: 20;
        }

        @keyframes stomp-score-fly {
            0% { transform: translateY(0); opacity: 1; }
            100% { transform: translateY(-80px); opacity: 0; }
        }

        /* ============ LIVES DISPLAY (Bone Marrow Icons) ============ */
        .lives-container {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 10px;
            z-index: 1000;
            background: rgba(0, 0, 0, 0.5);
            padding: 10px 15px;
            border-radius: 8px;
            border: 3px solid var(--mario-yellow);
        }

        .lives-label {
            font-family: 'Press Start 2P', cursive;
            font-size: 0.5em;
            color: var(--mario-yellow);
            margin-right: 5px;
            align-self: center;
        }

        .bone-marrow-life {
            width: 40px;
            height: 45px;
            position: relative;
            transition: all 0.3s ease;
        }

        .bone-marrow-life.lost {
            opacity: 0.2;
            filter: grayscale(100%);
        }

        .bone-marrow-life.losing {
            animation: life-lost 0.5s ease-out forwards;
        }

        @keyframes life-lost {
            0% { transform: scale(1); opacity: 1; }
            50% { transform: scale(1.3) rotate(10deg); opacity: 0.5; }
            100% { transform: scale(0.8); opacity: 0.2; filter: grayscale(100%); }
        }

        /* Bone shape */
        .bone-shaft {
            position: absolute;
            width: 12px;
            height: 35px;
            background: linear-gradient(90deg, #F5E6D3 0%, #E8D4BE 50%, #D4C4A8 100%);
            left: 50%;
            top: 5px;
            transform: translateX(-50%);
            border-radius: 3px;
            border: 2px solid #8B7355;
        }

        /* Bone ends (epiphyses) */
        .bone-end {
            position: absolute;
            width: 22px;
            height: 14px;
            background: linear-gradient(180deg, #F5E6D3 0%, #E8D4BE 100%);
            left: 50%;
            transform: translateX(-50%);
            border-radius: 50%;
            border: 2px solid #8B7355;
        }

        .bone-end.top { top: 0; }
        .bone-end.bottom { bottom: 0; }

        /* Marrow inside (red dots representing cells) */
        .marrow-cells {
            position: absolute;
            top: 12px;
            left: 50%;
            transform: translateX(-50%);
            width: 8px;
            height: 22px;
            display: flex;
            flex-wrap: wrap;
            gap: 2px;
            justify-content: center;
        }

        .marrow-cell {
            width: 4px;
            height: 4px;
            background: #CC3333;
            border-radius: 50%;
            animation: marrow-pulse 1s ease-in-out infinite;
        }

        .marrow-cell:nth-child(2) { animation-delay: 0.2s; background: #DD4444; }
        .marrow-cell:nth-child(3) { animation-delay: 0.4s; }
        .marrow-cell:nth-child(4) { animation-delay: 0.6s; background: #BB2222; }

        @keyframes marrow-pulse {
            0%, 100% { opacity: 1; transform: scale(1); }
            50% { opacity: 0.7; transform: scale(0.8); }
        }

        /* ============ HERO DEATH ANIMATION ============ */
        .hero-runner.dying {
            animation: hero-death 1s ease-out forwards;
        }

        @keyframes hero-death {
            0% { transform: translateY(0) rotate(0deg); }
            20% { transform: translateY(-50px) rotate(-20deg); }
            100% { transform: translateY(200px) rotate(-180deg); opacity: 0; }
        }

        .hero-runner.respawning {
            animation: hero-respawn 0.5s ease-out forwards;
        }

        @keyframes hero-respawn {
            0% { opacity: 0; transform: scale(0.5); }
            50% { opacity: 0.5; transform: scale(1.2); }
            100% { opacity: 1; transform: scale(1); }
        }

        /* Hero flashing invincibility after respawn */
        .hero-runner.invincible {
            animation: hero-flash 0.1s linear infinite;
        }

        @keyframes hero-flash {
            0%, 50% { opacity: 1; }
            51%, 100% { opacity: 0.3; }
        }

        /* Game Over Overlay */
        .game-over-overlay {
            position: fixed;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: rgba(0, 0, 0, 0.8);
            display: none;
            justify-content: center;
            align-items: center;
            flex-direction: column;
            z-index: 10000;
        }

        .game-over-overlay.show {
            display: flex;
            animation: fade-in 0.5s ease;
        }

        @keyframes fade-in {
            from { opacity: 0; }
            to { opacity: 1; }
        }

        .game-over-text {
            font-family: 'Press Start 2P', cursive;
            font-size: 3em;
            color: var(--mario-red);
            text-shadow: 4px 4px 0 #000, -4px -4px 0 #000;
            margin-bottom: 30px;
            animation: game-over-pulse 0.5s ease-in-out infinite alternate;
        }

        @keyframes game-over-pulse {
            from { transform: scale(1); }
            to { transform: scale(1.05); }
        }

        /* Ground track for running */
        .runner-track {
            position: absolute;
            bottom: 0;
            left: 0;
            width: 300%;
            height: 15px;
            background: repeating-linear-gradient(
                90deg,
                var(--mario-green) 0px,
                var(--mario-green) 20px,
                #008800 20px,
                #008800 40px
            );
            animation: track-scroll 18s linear infinite;
            border-top: 3px solid #006600;
            transition: transform 0.5s ease;
        }

        @keyframes track-scroll {
            0% { transform: translateX(0); }
            100% { transform: translateX(-33.33%); }
        }

        .runner-track.paused {
            animation-play-state: paused;
        }

        /* Hero position progression */
        .hero-runner {
            transition: left 0.8s ease-out, bottom 0.15s ease-out;
        }

        /* Spawn Pipe - where myeloma cells emerge */
        .spawn-pipe {
            position: absolute;
            right: 80px;
            bottom: 0;
            width: 60px;
            height: 80px;
            z-index: 6;
        }

        .pipe-top {
            position: absolute;
            top: 0;
            left: -8px;
            width: 76px;
            height: 25px;
            background: linear-gradient(180deg, #00CC00 0%, #009900 40%, #006600 100%);
            border: 4px solid #004400;
            border-bottom: none;
            border-radius: 8px 8px 0 0;
            box-shadow:
                inset 4px 0 8px rgba(255,255,255,0.2),
                inset -4px 0 8px rgba(0,0,0,0.2);
        }

        .pipe-body {
            position: absolute;
            top: 25px;
            left: 0;
            width: 60px;
            height: 55px;
            background: linear-gradient(90deg, #00AA00 0%, #008800 30%, #006600 70%, #004400 100%);
            border: 4px solid #004400;
            border-top: none;
            box-shadow:
                inset 4px 0 8px rgba(255,255,255,0.15),
                inset -4px 0 8px rgba(0,0,0,0.2);
        }

        .pipe-shadow {
            position: absolute;
            top: 25px;
            left: 4px;
            width: 8px;
            height: 50px;
            background: rgba(0,0,0,0.3);
        }

        .pipe-highlight {
            position: absolute;
            top: 5px;
            left: 8px;
            width: 10px;
            height: 60px;
            background: linear-gradient(180deg, rgba(255,255,255,0.3) 0%, rgba(255,255,255,0.1) 100%);
            border-radius: 4px;
        }

        /* Dynamic spawn pipe that appears when enemy spawns */
        .dynamic-pipe {
            position: absolute;
            bottom: 0;
            width: 50px;
            height: 70px;
            z-index: 7;
            animation: pipe-appear 0.4s ease-out forwards;
        }

        @keyframes pipe-appear {
            0% {
                transform: translateY(70px);
                opacity: 0;
            }
            60% {
                transform: translateY(-5px);
                opacity: 1;
            }
            100% {
                transform: translateY(0);
                opacity: 1;
            }
        }

        .dynamic-pipe.removing {
            animation: pipe-disappear 0.5s ease-in forwards;
        }

        @keyframes pipe-disappear {
            0% {
                transform: translateY(0);
                opacity: 1;
            }
            100% {
                transform: translateY(70px);
                opacity: 0;
            }
        }

        .dynamic-pipe .pipe-top {
            position: absolute;
            top: 0;
            left: -6px;
            width: 62px;
            height: 20px;
            background: linear-gradient(180deg, #00CC00 0%, #009900 40%, #006600 100%);
            border: 3px solid #004400;
            border-bottom: none;
            border-radius: 6px 6px 0 0;
            box-shadow: inset 3px 0 6px rgba(255,255,255,0.2);
        }

        .dynamic-pipe .pipe-body {
            position: absolute;
            top: 20px;
            left: 0;
            width: 50px;
            height: 50px;
            background: linear-gradient(90deg, #00AA00 0%, #008800 30%, #006600 70%, #004400 100%);
            border: 3px solid #004400;
            border-top: none;
        }

        /* Enemy emerging from pipe animation */
        .myeloma-enemy.emerging {
            animation: enemy-emerge-from-pipe 0.7s ease-out forwards;
        }

        @keyframes enemy-emerge-from-pipe {
            0% {
                transform: translateY(50px) scale(0.6);
                opacity: 0;
            }
            30% {
                transform: translateY(20px) scale(0.8);
                opacity: 1;
            }
            50% {
                transform: translateY(-15px) scale(1.1);
            }
            70% {
                transform: translateY(5px) scale(0.95);
            }
            100% {
                transform: translateY(0) scale(1);
            }
        }

        /* Responsive - Tablet */
        @media (max-width: 1024px) and (min-width: 601px) {
            .game-container { padding: 15px; }
            .title { font-size: 1.5em; }
        }

        /* Responsive - Mobile */
        @media (max-width: 600px) {
            .title { font-size: 1.2em; }
            .question-text { font-size: 0.6em; }
            .option-text { font-size: 0.5em; }
            .difficulty-btn { padding: 8px 12px; font-size: 0.4em; }
        }

        /* Responsive - Small Mobile */
        @media (max-width: 400px) {
            .title { font-size: 1em; }
            .question-text { font-size: 0.55em; }
        }

        /* Device info badge */
        .device-info {
            position: fixed;
            bottom: 10px;
            left: 10px;
            background: rgba(0, 0, 0, 0.7);
            border: 1px solid var(--mario-red);
            border-radius: 5px;
            padding: 6px 10px;
            font-size: 0.5em;
            color: white;
            z-index: 100;
            opacity: 0.6;
            transition: opacity 0.3s;
        }
        .device-info:hover { opacity: 1; }
        .device-info .device-type { color: var(--mario-yellow); text-transform: uppercase; }
        .device-info .resolution { color: var(--mario-red); margin-left: 8px; }
    </style>
</head>
<body>
    <!-- Background elements -->
    <div class="cloud-container">
        <div class="cloud" style="top: 10%; left: -100px; width: 40px; height: 25px; animation-delay: 0s;"></div>
        <div class="cloud" style="top: 25%; left: -100px; width: 50px; height: 30px; animation-delay: 8s;"></div>
        <div class="cloud" style="top: 15%; left: -100px; width: 35px; height: 22px; animation-delay: 15s;"></div>
        <div class="cloud" style="top: 35%; left: -100px; width: 45px; height: 28px; animation-delay: 22s;"></div>
    </div>

    <!-- Hell Mode Flames (visible only in hell mode) -->
    <div class="hell-flames" id="hellFlames"></div>

    <div class="brick-pattern"></div>

    <div class="device-info" id="deviceInfo">
        <span class="device-type" id="deviceType">--</span>
        <span class="resolution" id="resolution">--</span>
    </div>

    <!-- Lives Display (Bone Marrow Icons) -->
    <div class="lives-container" id="livesContainer" style="display: none;">
        <span class="lives-label">LIVES</span>
        <div class="bone-marrow-life" id="life1">
            <div class="bone-end top"></div>
            <div class="bone-shaft"></div>
            <div class="bone-end bottom"></div>
            <div class="marrow-cells">
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
            </div>
        </div>
        <div class="bone-marrow-life" id="life2">
            <div class="bone-end top"></div>
            <div class="bone-shaft"></div>
            <div class="bone-end bottom"></div>
            <div class="marrow-cells">
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
            </div>
        </div>
        <div class="bone-marrow-life" id="life3">
            <div class="bone-end top"></div>
            <div class="bone-shaft"></div>
            <div class="bone-end bottom"></div>
            <div class="marrow-cells">
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
                <div class="marrow-cell"></div>
            </div>
        </div>
    </div>

    <!-- Game Over Overlay -->
    <div class="game-over-overlay" id="gameOverOverlay">
        <div class="game-over-text">GAME OVER</div>
        <button class="play-again-btn" onclick="restartFromGameOver()">TRY AGAIN</button>
    </div>

    <!-- Side-scroller Runner Scene -->
    <!-- Victory Overlay -->
    <div class="victory-overlay" id="victoryOverlay">
        <div class="victory-hearts" id="victoryHearts"></div>
        <div class="victory-text">HEMATOPOIESIS<br>RESTORED!</div>
        <div class="victory-subtext">Dr. Wen saved the Princess<br>and defeated the Myeloma!</div>
    </div>

    <div class="runner-scene" id="runnerScene">
        <div class="runner-track" id="runnerTrack"></div>
        <div class="spawn-pipe" id="spawnPipe">
            <div class="pipe-top"></div>
            <div class="pipe-body">
                <div class="pipe-shadow"></div>
                <div class="pipe-highlight"></div>
            </div>
        </div>
        <div class="enemy-container" id="enemyContainer"></div>

        <!-- Hematopoiesis Princess -->
        <div class="princess-container" id="princessContainer">
            <div class="help-text">HELP ME!</div>
            <div class="princess-name">PRINCESS<br>HEMATOPOIESIS</div>
            <div class="stem-cells">
                <div class="stem-cell"></div>
                <div class="stem-cell"></div>
                <div class="stem-cell"></div>
            </div>
            <div class="princess-body">
                <div class="princess-crown"></div>
                <div class="princess-head"></div>
                <div class="princess-blush"></div>
                <div class="princess-dress"></div>
            </div>
        </div>

        <div class="hero-runner running" id="heroRunner">
            <div class="hero-name">DR. WEN</div>
            <div class="hero-body">
                <div class="hero-head"></div>
                <div class="hero-torso"></div>
                <div class="hero-legs">
                    <div class="hero-leg"></div>
                    <div class="hero-leg"></div>
                </div>
            </div>
        </div>
    </div>

    <div class="game-container">
        <div class="header">
            <h1 class="title">MYELOMA MAN</h1>
            <p class="subtitle">Power-Up Your Myeloma Knowledge!</p>
        </div>

        <!-- Start Screen -->
        <div class="question-card start-screen" id="startScreen">
            <h2 style="color: var(--coin-gold); font-size: 0.9em; margin-bottom: 20px; text-shadow: 2px 2px 0 #8B6914;">SELECT YOUR LEVEL</h2>

            <div class="difficulty-selector">
                <button class="difficulty-btn intern selected" onclick="selectDifficulty('intern')">
                    INTERN
                    <span style="display: block; font-size: 0.7em; margin-top: 5px; opacity: 0.8;">ââââ</span>
                </button>
                <button class="difficulty-btn resident" onclick="selectDifficulty('resident')">
                    RESIDENT
                    <span style="display: block; font-size: 0.7em; margin-top: 5px; opacity: 0.8;">ââââ</span>
                </button>
                <button class="difficulty-btn fellow" onclick="selectDifficulty('fellow')">
                    FELLOW
                    <span style="display: block; font-size: 0.7em; margin-top: 5px; opacity: 0.8;">ââââ</span>
                </button>
                <button class="difficulty-btn attending" onclick="selectDifficulty('attending')">
                    ATTENDING
                    <span style="display: block; font-size: 0.7em; margin-top: 5px; opacity: 0.8;">ââââ</span>
                </button>
                <button class="difficulty-btn jakubowiak" onclick="selectDifficulty('jakubowiak')">
                    DR. JAKUBOWIAK
                    <span style="display: block; font-size: 0.6em; margin-top: 5px; opacity: 0.9;">ð¥ EXTREME ð¥</span>
                </button>
            </div>

            <button class="start-btn" onclick="startGame()">START GAME!</button>

            <p style="margin-top: 30px; font-size: 0.45em; color: var(--cloud-white); opacity: 0.8;">
                Collect coins by answering correctly!<br>
                Based on NCCN Guidelines & IMWG Criteria
            </p>
        </div>

        <!-- Game Screen -->
        <div id="gameScreen" style="display: none;">
            <div class="stats-bar">
                <div class="stat">
                    <div class="stat-value" id="scoreValue">0</div>
                    <div class="stat-label">COINS</div>
                </div>
                <div class="stat">
                    <div class="stat-value streak-fire" id="streakValue">0</div>
                    <div class="stat-label">COMBO</div>
                </div>
                <div class="stat">
                    <div class="stat-value" id="correctValue">0/0</div>
                    <div class="stat-label">CORRECT</div>
                </div>
            </div>

            <div class="progress-bar">
                <div class="progress-fill" id="progressFill" style="width: 0%"></div>
            </div>

            <div class="question-card" id="questionCard">
                <!-- Question content loads here -->
            </div>
        </div>

        <!-- Results Screen -->
        <div class="question-card results-screen" id="resultsScreen">
            <h2>LEVEL COMPLETE!</h2>
            <div class="score-circle" id="scoreCircle">
                <span class="score-text" id="finalScore">0%</span>
            </div>
            <div class="grade" id="gradeText"></div>
            <p id="resultsMessage" style="font-size: 0.5em; margin: 20px 0; line-height: 2;"></p>
            <button class="play-again-btn" onclick="restartGame()">PLAY AGAIN</button>
        </div>
    </div>

    <!-- Music Controls -->
    <div class="music-controls" id="musicControls">
        <div class="music-control" onclick="toggleMusic()" title="Toggle Music" id="musicBtn">ðµ</div>
        <div class="volume-slider-container">
            <span>ð</span>
            <input type="range" class="volume-slider" id="volumeSlider" min="0" max="100" value="50" oninput="setVolume(this.value)">
            <span class="volume-value" id="volumeValue">50%</span>
        </div>
    </div>

    <script>
        // Device Detection System
        const DeviceDetector = {
            getDeviceType: function() {
                const width = window.innerWidth;
                const userAgent = navigator.userAgent.toLowerCase();
                const isMobileUA = /android|webos|iphone|ipod|blackberry|iemobile|opera mini/i.test(userAgent);
                const isTabletUA = /ipad|tablet|playbook|silk/i.test(userAgent) || (isMobileUA && width >= 768);
                if (width <= 480 || (isMobileUA && !isTabletUA && width < 768)) return 'mobile';
                else if (width <= 1024 || isTabletUA) return 'tablet';
                else return 'desktop';
            },
            getResolution: function() { return `${window.innerWidth}x${window.innerHeight}`; },
            updateDisplay: function() {
                document.getElementById('deviceType').textContent = this.getDeviceType();
                document.getElementById('resolution').textContent = this.getResolution();
                document.body.classList.remove('device-mobile', 'device-tablet', 'device-desktop');
                document.body.classList.add('device-' + this.getDeviceType());
            },
            init: function() {
                this.updateDisplay();
                window.addEventListener('resize', () => this.updateDisplay());
                window.addEventListener('orientationchange', () => setTimeout(() => this.updateDisplay(), 100));
            }
        };
        DeviceDetector.init();

        // Reference Links Helper
        function renderReferenceLinks(question) {
            let links = '';
            if (question.pmid) {
                links += `<a href="https://pubmed.ncbi.nlm.nih.gov/${question.pmid}/" target="_blank" rel="noopener" class="ref-link" title="View on PubMed">ð PubMed</a>`;
            }
            if (question.doi) {
                links += `<a href="https://doi.org/${question.doi}" target="_blank" rel="noopener" class="ref-link" title="View Full Text">ð DOI</a>`;
            }
            if (question.guideline) {
                links += `<a href="${question.guideline.url}" target="_blank" rel="noopener" class="ref-link" title="View Guidelines">ð ${question.guideline.name}</a>`;
            }
            return links ? `<div class="ref-links">${links}</div>` : '';
        }

        // Audio Context for Mario-style sounds
        let audioCtx = null;
        let musicPlaying = false;
        let musicInterval = null;
        let masterGain = null;
        let musicVolume = 0.5;

        function initAudio() {
            if (!audioCtx) {
                audioCtx = new (window.AudioContext || window.webkitAudioContext)();
                masterGain = audioCtx.createGain();
                masterGain.gain.setValueAtTime(musicVolume, audioCtx.currentTime);
                masterGain.connect(audioCtx.destination);
            }
            return audioCtx;
        }

        function getOutput() {
            initAudio();
            return masterGain;
        }

        // Mario coin sound
        function playCoinSound() {
            const ctx = initAudio();
            const osc = ctx.createOscillator();
            const gain = ctx.createGain();

            osc.connect(gain);
            gain.connect(getOutput());

            osc.type = 'square';
            const now = ctx.currentTime;

            osc.frequency.setValueAtTime(988, now); // B5
            osc.frequency.setValueAtTime(1319, now + 0.1); // E6

            gain.gain.setValueAtTime(0.3, now);
            gain.gain.exponentialDecayTo = 0.01;
            gain.gain.setValueAtTime(0.3, now);
            gain.gain.exponentialRampToValueAtTime(0.01, now + 0.3);

            osc.start(now);
            osc.stop(now + 0.3);
        }

        // Mario power-up sound
        function playPowerUpSound() {
            const ctx = initAudio();
            const notes = [130, 165, 196, 262, 330, 392, 523, 659, 784];

            notes.forEach((freq, i) => {
                const osc = ctx.createOscillator();
                const gain = ctx.createGain();

                osc.connect(gain);
                gain.connect(getOutput());

                osc.type = 'square';
                osc.frequency.value = freq;

                const startTime = ctx.currentTime + i * 0.05;
                gain.gain.setValueAtTime(0.2, startTime);
                gain.gain.exponentialRampToValueAtTime(0.01, startTime + 0.1);

                osc.start(startTime);
                osc.stop(startTime + 0.1);
            });
        }

        // Mario death/wrong sound
        function playWrongSound() {
            const ctx = initAudio();
            const notes = [494, 466, 440, 415, 392];

            notes.forEach((freq, i) => {
                const osc = ctx.createOscillator();
                const gain = ctx.createGain();

                osc.connect(gain);
                gain.connect(getOutput());

                osc.type = 'square';
                osc.frequency.value = freq;

                const startTime = ctx.currentTime + i * 0.12;
                gain.gain.setValueAtTime(0.25, startTime);
                gain.gain.exponentialRampToValueAtTime(0.01, startTime + 0.15);

                osc.start(startTime);
                osc.stop(startTime + 0.2);
            });
        }

        // Mario 1-UP sound
        function play1UpSound() {
            const ctx = initAudio();
            const notes = [330, 392, 523, 392, 523, 698];

            notes.forEach((freq, i) => {
                const osc = ctx.createOscillator();
                const gain = ctx.createGain();

                osc.connect(gain);
                gain.connect(getOutput());

                osc.type = 'square';
                osc.frequency.value = freq;

                const startTime = ctx.currentTime + i * 0.08;
                gain.gain.setValueAtTime(0.2, startTime);
                gain.gain.exponentialRampToValueAtTime(0.01, startTime + 0.12);

                osc.start(startTime);
                osc.stop(startTime + 0.12);
            });
        }

        // Mario theme music (8-bit style) - EXTENDED 10x LONGER
        function playMarioTheme() {
            const ctx = initAudio();
            // Extended Mario theme melody - full overworld theme
            const melody = [
                // Intro phrase (classic opening)
                { note: 659, duration: 0.12 },  // E5
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },    // rest
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },    // rest
                { note: 523, duration: 0.12 },  // C5
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },    // rest
                { note: 784, duration: 0.24 },  // G5
                { note: 0, duration: 0.24 },    // rest
                { note: 392, duration: 0.24 },  // G4
                { note: 0, duration: 0.24 },    // rest

                // Main theme part 1
                { note: 523, duration: 0.18 },  // C5
                { note: 0, duration: 0.06 },
                { note: 392, duration: 0.18 },  // G4
                { note: 0, duration: 0.06 },
                { note: 330, duration: 0.18 },  // E4
                { note: 0, duration: 0.06 },
                { note: 440, duration: 0.12 },  // A4
                { note: 494, duration: 0.12 },  // B4
                { note: 466, duration: 0.12 },  // Bb4
                { note: 440, duration: 0.18 },  // A4
                { note: 0, duration: 0.06 },

                // Triplet section
                { note: 392, duration: 0.12 },  // G4
                { note: 659, duration: 0.12 },  // E5
                { note: 784, duration: 0.12 },  // G5
                { note: 880, duration: 0.18 },  // A5
                { note: 0, duration: 0.06 },
                { note: 698, duration: 0.12 },  // F5
                { note: 784, duration: 0.12 },  // G5
                { note: 0, duration: 0.12 },
                { note: 659, duration: 0.18 },  // E5
                { note: 0, duration: 0.06 },
                { note: 523, duration: 0.12 },  // C5
                { note: 587, duration: 0.12 },  // D5
                { note: 494, duration: 0.12 },  // B4
                { note: 0, duration: 0.18 },

                // Main theme part 2
                { note: 523, duration: 0.18 },  // C5
                { note: 0, duration: 0.06 },
                { note: 392, duration: 0.18 },  // G4
                { note: 0, duration: 0.06 },
                { note: 330, duration: 0.18 },  // E4
                { note: 0, duration: 0.06 },
                { note: 440, duration: 0.12 },  // A4
                { note: 494, duration: 0.12 },  // B4
                { note: 466, duration: 0.12 },  // Bb4
                { note: 440, duration: 0.18 },  // A4
                { note: 0, duration: 0.06 },

                // High melody
                { note: 392, duration: 0.12 },  // G4
                { note: 659, duration: 0.12 },  // E5
                { note: 784, duration: 0.12 },  // G5
                { note: 880, duration: 0.18 },  // A5
                { note: 0, duration: 0.06 },
                { note: 698, duration: 0.12 },  // F5
                { note: 784, duration: 0.12 },  // G5
                { note: 0, duration: 0.12 },
                { note: 659, duration: 0.18 },  // E5
                { note: 0, duration: 0.06 },
                { note: 523, duration: 0.12 },  // C5
                { note: 587, duration: 0.12 },  // D5
                { note: 494, duration: 0.12 },  // B4
                { note: 0, duration: 0.18 },

                // Bridge section
                { note: 0, duration: 0.12 },
                { note: 784, duration: 0.12 },  // G5
                { note: 740, duration: 0.12 },  // F#5
                { note: 698, duration: 0.12 },  // F5
                { note: 622, duration: 0.18 },  // D#5
                { note: 0, duration: 0.06 },
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },
                { note: 415, duration: 0.12 },  // G#4
                { note: 440, duration: 0.12 },  // A4
                { note: 523, duration: 0.12 },  // C5
                { note: 0, duration: 0.12 },
                { note: 440, duration: 0.12 },  // A4
                { note: 523, duration: 0.12 },  // C5
                { note: 587, duration: 0.12 },  // D5
                { note: 0, duration: 0.18 },

                // Bridge part 2
                { note: 0, duration: 0.12 },
                { note: 784, duration: 0.12 },  // G5
                { note: 740, duration: 0.12 },  // F#5
                { note: 698, duration: 0.12 },  // F5
                { note: 622, duration: 0.18 },  // D#5
                { note: 0, duration: 0.06 },
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },
                { note: 1047, duration: 0.12 }, // C6
                { note: 1047, duration: 0.12 }, // C6
                { note: 1047, duration: 0.24 }, // C6
                { note: 0, duration: 0.24 },

                // Descending phrase
                { note: 784, duration: 0.12 },  // G5
                { note: 740, duration: 0.12 },  // F#5
                { note: 698, duration: 0.12 },  // F5
                { note: 622, duration: 0.18 },  // D#5
                { note: 0, duration: 0.06 },
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },
                { note: 415, duration: 0.12 },  // G#4
                { note: 440, duration: 0.12 },  // A4
                { note: 523, duration: 0.12 },  // C5
                { note: 0, duration: 0.12 },
                { note: 440, duration: 0.12 },  // A4
                { note: 523, duration: 0.12 },  // C5
                { note: 587, duration: 0.12 },  // D5
                { note: 0, duration: 0.18 },

                // Ending phrase
                { note: 622, duration: 0.18 },  // Eb5
                { note: 0, duration: 0.06 },
                { note: 587, duration: 0.18 },  // D5
                { note: 0, duration: 0.12 },
                { note: 523, duration: 0.36 },  // C5
                { note: 0, duration: 0.24 },

                // Repeat of intro (variation)
                { note: 659, duration: 0.12 },  // E5
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },
                { note: 523, duration: 0.12 },  // C5
                { note: 659, duration: 0.12 },  // E5
                { note: 0, duration: 0.12 },
                { note: 784, duration: 0.24 },  // G5
                { note: 0, duration: 0.12 },

                // Underground hint
                { note: 262, duration: 0.12 },  // C4
                { note: 330, duration: 0.12 },  // E4
                { note: 392, duration: 0.12 },  // G4
                { note: 523, duration: 0.18 },  // C5
                { note: 0, duration: 0.06 },
                { note: 392, duration: 0.12 },  // G4
                { note: 330, duration: 0.12 },  // E4
                { note: 262, duration: 0.18 },  // C4
                { note: 0, duration: 0.12 },

                // Final flourish
                { note: 659, duration: 0.1 },   // E5
                { note: 587, duration: 0.1 },   // D5
                { note: 523, duration: 0.1 },   // C5
                { note: 494, duration: 0.1 },   // B4
                { note: 440, duration: 0.1 },   // A4
                { note: 392, duration: 0.1 },   // G4
                { note: 349, duration: 0.1 },   // F4
                { note: 330, duration: 0.1 },   // E4
                { note: 294, duration: 0.1 },   // D4
                { note: 262, duration: 0.24 },  // C4
                { note: 0, duration: 0.36 },

                // Bonus coins sound pattern
                { note: 988, duration: 0.08 },  // B5
                { note: 1319, duration: 0.08 }, // E6
                { note: 0, duration: 0.08 },
                { note: 988, duration: 0.08 },  // B5
                { note: 1319, duration: 0.08 }, // E6
                { note: 0, duration: 0.08 },
                { note: 988, duration: 0.08 },  // B5
                { note: 1319, duration: 0.08 }, // E6
                { note: 0, duration: 0.24 },

                // Victory phrase
                { note: 523, duration: 0.15 },  // C5
                { note: 659, duration: 0.15 },  // E5
                { note: 784, duration: 0.15 },  // G5
                { note: 1047, duration: 0.3 },  // C6
                { note: 0, duration: 0.15 },
                { note: 880, duration: 0.15 },  // A5
                { note: 988, duration: 0.15 },  // B5
                { note: 1047, duration: 0.3 },  // C6
                { note: 0, duration: 0.3 },
            ];

            let time = ctx.currentTime;
            melody.forEach(({ note, duration }) => {
                if (note > 0) {
                    const osc = ctx.createOscillator();
                    const gain = ctx.createGain();

                    osc.connect(gain);
                    gain.connect(getOutput());

                    osc.type = 'square';
                    osc.frequency.value = note;

                    gain.gain.setValueAtTime(0.15, time);
                    gain.gain.setValueAtTime(0.15, time + duration * 0.8);
                    gain.gain.exponentialRampToValueAtTime(0.01, time + duration);

                    osc.start(time);
                    osc.stop(time + duration);
                }
                time += duration;
            });
        }

        // Background music loop
        function startBackgroundMusic() {
            if (musicPlaying) return;
            musicPlaying = true;
            document.getElementById('musicBtn').classList.add('playing');

            playMarioTheme();
            // Extended music loop is ~20 seconds
            musicInterval = setInterval(() => {
                if (musicPlaying) playMarioTheme();
            }, 20000);
        }

        function stopBackgroundMusic() {
            musicPlaying = false;
            document.getElementById('musicBtn').classList.remove('playing');
            if (musicInterval) {
                clearInterval(musicInterval);
                musicInterval = null;
            }
        }

        function toggleMusic() {
            initAudio();
            if (musicPlaying) {
                stopBackgroundMusic();
            } else {
                startBackgroundMusic();
            }
        }

        function setVolume(value) {
            musicVolume = value / 100;
            document.getElementById('volumeValue').textContent = value + '%';
            if (masterGain && audioCtx) {
                masterGain.gain.setValueAtTime(musicVolume, audioCtx.currentTime);
            }
        }

        // Show coin popup
        function showCoinPopup(x, y, text = '+10') {
            const popup = document.createElement('div');
            popup.className = 'coin-popup';
            popup.textContent = text;
            popup.style.left = x + 'px';
            popup.style.top = y + 'px';
            document.body.appendChild(popup);
            setTimeout(() => popup.remove(), 1000);
        }

        // Show 1-UP popup
        function show1UpPopup(x, y) {
            const popup = document.createElement('div');
            popup.className = 'one-up';
            popup.textContent = '1-UP!';
            popup.style.left = x + 'px';
            popup.style.top = y + 'px';
            document.body.appendChild(popup);
            setTimeout(() => popup.remove(), 1500);
        }

        // ============ SIDE-SCROLLER ENEMY SYSTEM ============
        let enemies = [];
        let enemyIdCounter = 0;
        let gameActive = false;

        // ============ LIVES SYSTEM ============
        let lives = 3;
        let heroPosition = 50; // Starting position (pixels from left)
        let isHeroDead = false;
        const HERO_START_POS = 50;
        let HERO_END_POS = 300; // Will be calculated based on screen width

        // Calculate end position based on screen width
        function calculateHeroEndPosition() {
            const screenWidth = window.innerWidth;
            // Hero should end up about 150px from the right edge (where princess will be)
            HERO_END_POS = screenWidth - 200;
            return HERO_END_POS;
        }

        // Recalculate on window resize
        window.addEventListener('resize', () => {
            calculateHeroEndPosition();
            if (gameActive) {
                updateHeroPosition();
            }
        });

        // Show the lives display
        function showLivesDisplay() {
            const container = document.getElementById('livesContainer');
            if (container) container.style.display = 'flex';
        }

        // Hide the lives display
        function hideLivesDisplay() {
            const container = document.getElementById('livesContainer');
            if (container) container.style.display = 'none';
        }

        // Update the lives display (bone marrow icons)
        function updateLivesDisplay() {
            for (let i = 1; i <= 3; i++) {
                const lifeElement = document.getElementById('life' + i);
                if (lifeElement) {
                    if (i > lives) {
                        lifeElement.classList.add('lost');
                    } else {
                        lifeElement.classList.remove('lost');
                        lifeElement.classList.remove('losing');
                    }
                }
            }
        }

        // Animate losing a life
        function animateLifeLoss() {
            const lifeElement = document.getElementById('life' + (lives + 1));
            if (lifeElement) {
                lifeElement.classList.add('losing');
            }
        }

        // Hero dies (wrong answer)
        function heroDeath() {
            if (isHeroDead) return;
            isHeroDead = true;

            const hero = document.getElementById('heroRunner');
            if (!hero) return;

            // Play death sound
            playDeathSound();

            // Stop running, add dying animation
            hero.classList.remove('running');
            hero.classList.add('dying');

            // Pause the track
            pauseRunnerScene();
        }

        // Play death sound (Mario-style)
        function playDeathSound() {
            const ctx = initAudio();
            const osc = ctx.createOscillator();
            const gain = ctx.createGain();

            osc.connect(gain);
            gain.connect(getOutput());

            osc.type = 'square';
            const now = ctx.currentTime;

            // Descending "wah wah wah" death sound
            osc.frequency.setValueAtTime(392, now);        // G4
            osc.frequency.setValueAtTime(349, now + 0.15); // F4
            osc.frequency.setValueAtTime(330, now + 0.3);  // E4
            osc.frequency.setValueAtTime(262, now + 0.45); // C4
            osc.frequency.setValueAtTime(196, now + 0.6);  // G3
            osc.frequency.setValueAtTime(131, now + 0.75); // C3

            gain.gain.setValueAtTime(0.3, now);
            gain.gain.setValueAtTime(0.3, now + 0.7);
            gain.gain.exponentialRampToValueAtTime(0.01, now + 1);

            osc.start(now);
            osc.stop(now + 1);
        }

        // Hero respawns after death
        function heroRespawn() {
            const hero = document.getElementById('heroRunner');
            if (!hero) return;

            isHeroDead = false;

            // Remove death animation, add respawn
            hero.classList.remove('dying');
            hero.classList.add('respawning');

            setTimeout(() => {
                hero.classList.remove('respawning');
                hero.classList.add('running');
                hero.classList.add('invincible');

                // Resume running
                resumeRunnerScene();

                // Remove invincibility after 2 seconds
                setTimeout(() => {
                    hero.classList.remove('invincible');
                }, 2000);
            }, 500);
        }

        // Lose a life (called on wrong answer)
        function loseLife() {
            if (lives <= 0) return;

            lives--;
            animateLifeLoss();
            heroDeath();

            setTimeout(() => {
                updateLivesDisplay();

                if (lives <= 0) {
                    // Game over!
                    showGameOver();
                } else {
                    // Respawn hero
                    heroRespawn();
                }
            }, 1000);
        }

        // Show game over overlay
        function showGameOver() {
            const overlay = document.getElementById('gameOverOverlay');
            if (overlay) overlay.classList.add('show');
            hidePrincess();
        }

        // ============ PRINCESS & VICTORY FUNCTIONS ============

        // Show the princess at the right side of the screen
        function showPrincess() {
            const princess = document.getElementById('princessContainer');
            if (princess) {
                princess.classList.add('show');
                princess.classList.remove('rescued');
            }
        }

        // Hide the princess
        function hidePrincess() {
            const princess = document.getElementById('princessContainer');
            if (princess) {
                princess.classList.remove('show');
            }
        }

        // Play victory fanfare sound
        function playVictorySound() {
            const ctx = initAudio();
            const now = ctx.currentTime;

            // Victory fanfare melody
            const notes = [
                { freq: 523, time: 0, dur: 0.15 },     // C5
                { freq: 659, time: 0.15, dur: 0.15 },  // E5
                { freq: 784, time: 0.3, dur: 0.15 },   // G5
                { freq: 1047, time: 0.45, dur: 0.3 },  // C6
                { freq: 784, time: 0.8, dur: 0.15 },   // G5
                { freq: 1047, time: 1.0, dur: 0.5 },   // C6 (long)
            ];

            notes.forEach(n => {
                const osc = ctx.createOscillator();
                const gain = ctx.createGain();
                osc.connect(gain);
                gain.connect(getOutput());
                osc.type = 'square';
                osc.frequency.setValueAtTime(n.freq, now + n.time);
                gain.gain.setValueAtTime(0.25, now + n.time);
                gain.gain.exponentialRampToValueAtTime(0.01, now + n.time + n.dur);
                osc.start(now + n.time);
                osc.stop(now + n.time + n.dur + 0.1);
            });
        }

        // Spawn floating hearts for victory
        function spawnVictoryHearts() {
            const container = document.getElementById('victoryHearts');
            if (!container) return;

            const hearts = ['â¤ï¸', 'ð', 'ð', 'ð', 'ð©¸', 'ð´', 'âª'];
            for (let i = 0; i < 20; i++) {
                setTimeout(() => {
                    const heart = document.createElement('div');
                    heart.className = 'victory-heart';
                    heart.textContent = hearts[Math.floor(Math.random() * hearts.length)];
                    heart.style.left = Math.random() * 100 + '%';
                    heart.style.animationDelay = Math.random() * 0.5 + 's';
                    container.appendChild(heart);

                    // Remove after animation
                    setTimeout(() => heart.remove(), 3500);
                }, i * 150);
            }
        }

        // Play the victory/rescue animation
        function playVictoryAnimation() {
            const hero = document.getElementById('heroRunner');
            const princess = document.getElementById('princessContainer');
            const victoryOverlay = document.getElementById('victoryOverlay');

            // Stop hero running
            if (hero) {
                hero.classList.remove('running');
            }

            // Princess rescued animation
            if (princess) {
                princess.classList.add('rescued');
                // Remove "HELP ME!" text
                const helpText = princess.querySelector('.help-text');
                if (helpText) helpText.style.display = 'none';
            }

            // Play victory sound
            playVictorySound();

            // Show victory overlay after a short delay
            setTimeout(() => {
                if (victoryOverlay) {
                    victoryOverlay.classList.add('show');
                }
                spawnVictoryHearts();
            }, 1500);

            // Continue spawning hearts
            setTimeout(() => spawnVictoryHearts(), 3000);
        }

        // Hide victory overlay
        function hideVictoryOverlay() {
            const victoryOverlay = document.getElementById('victoryOverlay');
            if (victoryOverlay) {
                victoryOverlay.classList.remove('show');
            }
        }

        // Restart from game over
        function restartFromGameOver() {
            const overlay = document.getElementById('gameOverOverlay');
            if (overlay) overlay.classList.remove('show');

            // Recalculate hero end position
            calculateHeroEndPosition();

            // Reset lives and hero position
            lives = 3;
            heroPosition = HERO_START_POS;
            isHeroDead = false;
            updateLivesDisplay();
            updateHeroPosition();

            // Show the princess again
            showPrincess();

            // Respawn hero
            const hero = document.getElementById('heroRunner');
            if (hero) {
                hero.classList.remove('dying');
                hero.classList.add('running');
            }
            resumeRunnerScene();

            // Clear enemies
            clearEnemies();

            // Restart the game
            currentQuestion = 0;
            score = 0;
            streak = 0;
            maxStreak = 0;
            correctAnswers = 0;
            loadQuestion();
            updateStats();
        }

        // Update hero position (moves right as questions progress)
        function updateHeroPosition() {
            const hero = document.getElementById('heroRunner');
            if (!hero) return;

            // Calculate progress through questions
            const totalQuestions = filteredQuestions.length || 1;
            const progress = currentQuestion / totalQuestions;

            // Move hero from start to end position based on progress
            heroPosition = HERO_START_POS + (HERO_END_POS - HERO_START_POS) * progress;
            hero.style.left = heroPosition + 'px';
        }

        // Spawn a plasma cell enemy (with proper nucleus and nucleoli)
        // Spawn enemy near the hero (called when question is answered)
        function spawnEnemyFromPipe() {
            const container = document.getElementById('enemyContainer');
            const hero = document.getElementById('heroRunner');
            if (!container || !hero || isHeroDead) return null;

            // Calculate spawn position (to the right of Dr. Wen)
            const heroRect = hero.getBoundingClientRect();
            const containerRect = container.getBoundingClientRect();
            const spawnX = (heroRect.right - containerRect.left) + 40;

            // Create dynamic pipe first
            const pipe = document.createElement('div');
            pipe.className = 'dynamic-pipe';
            pipe.style.left = (spawnX - 5) + 'px';
            pipe.innerHTML = '<div class="pipe-top"></div><div class="pipe-body"></div>';
            container.appendChild(pipe);

            // Create enemy after pipe appears
            setTimeout(() => {
                const enemy = document.createElement('div');
                enemy.className = 'myeloma-enemy emerging';
                enemy.id = 'enemy-' + enemyIdCounter++;

                // Add perinuclear hof (Golgi zone) - must be added first (behind other elements)
                const hof = document.createElement('div');
                hof.className = 'perinuclear-hof';
                enemy.appendChild(hof);

                // Add endoplasmic reticulum (characteristic of plasma cells)
                const er = document.createElement('div');
                er.className = 'endoplasmic-reticulum';
                er.innerHTML = '<div class="er-strand"></div><div class="er-strand"></div><div class="er-strand"></div>';
                enemy.appendChild(er);

                // Add evil eyes
                const eyes = document.createElement('div');
                eyes.className = 'evil-eyes';
                eyes.innerHTML = '<div class="evil-eye"></div><div class="evil-eye"></div>';
                enemy.appendChild(eyes);

                // Add eccentric nucleus (plasma cell characteristic)
                const nucleus = document.createElement('div');
                nucleus.className = 'plasma-nucleus';

                // Add nucleoli inside nucleus (clock-face chromatin)
                const nucleolus1 = document.createElement('div');
                nucleolus1.className = 'nucleolus';
                const nucleolus2 = document.createElement('div');
                nucleolus2.className = 'nucleolus';
                nucleus.appendChild(nucleolus1);
                nucleus.appendChild(nucleolus2);
                enemy.appendChild(nucleus);

                // Add Russell bodies (protein accumulation - myeloma characteristic)
                const russell1 = document.createElement('div');
                russell1.className = 'russell-body';
                const russell2 = document.createElement('div');
                russell2.className = 'russell-body';
                enemy.appendChild(russell1);
                enemy.appendChild(russell2);

                // Add M-protein spikes (representing paraprotein secretion)
                const spikePositions = [
                    { top: '-10px', left: '18px', rotate: '-15deg' },
                    { top: '-12px', left: '35px', rotate: '0deg' },
                    { top: '-10px', right: '18px', rotate: '15deg' }
                ];
                spikePositions.forEach(pos => {
                    const spike = document.createElement('div');
                    spike.className = 'm-protein-spike';
                    spike.style.top = pos.top;
                    if (pos.left) spike.style.left = pos.left;
                    if (pos.right) spike.style.right = pos.right;
                    spike.style.transform = `rotate(${pos.rotate})`;
                    enemy.appendChild(spike);
                });

                // Position enemy at pipe location
                enemy.style.left = spawnX + 'px';
                container.appendChild(enemy);

                const enemyObj = {
                    element: enemy,
                    x: spawnX,
                    id: enemy.id,
                    alive: true,
                    pipe: pipe
                };
                enemies.push(enemyObj);

                // Remove emerging class after animation
                setTimeout(() => {
                    enemy.classList.remove('emerging');
                }, 700);

                // Store enemyObj for return
                pipe._enemyObj = enemyObj;
            }, 350); // Wait for pipe to appear

            // Return a promise-like object that resolves to the enemy
            return {
                getEnemy: () => pipe._enemyObj,
                pipe: pipe
            };
        }

        // Remove pipe after enemy is stomped or dies
        function removeDynamicPipe(pipe) {
            if (!pipe) return;
            pipe.classList.add('removing');
            setTimeout(() => {
                if (pipe.parentNode) {
                    pipe.parentNode.removeChild(pipe);
                }
            }, 500);
        }

        // Legacy function for backward compatibility
        function spawnEnemy() {
            return spawnEnemyFromPipe();
        }

        // Animate enemy walking toward hero
        function animateEnemy(enemy, startX) {
            let x = startX;
            const speed = 2 + Math.random() * 1.5; // Variable speed

            function move() {
                if (!enemy.classList.contains('stomped') && document.body.contains(enemy)) {
                    x -= speed;
                    enemy.style.left = x + 'px';

                    // Remove if off screen left
                    if (x < -100) {
                        enemy.remove();
                        enemies = enemies.filter(e => e.element !== enemy);
                    } else {
                        requestAnimationFrame(move);
                    }
                }
            }
            requestAnimationFrame(move);
        }

        // Hero jumps and stomps the nearest enemy
        function heroStompEnemy() {
            const hero = document.getElementById('heroRunner');
            if (!hero || enemies.length === 0) return;

            // Find the closest alive enemy
            const heroRect = hero.getBoundingClientRect();
            let closestEnemy = null;
            let closestDist = Infinity;

            enemies.forEach(e => {
                if (e.alive && e.element) {
                    const enemyRect = e.element.getBoundingClientRect();
                    const dist = enemyRect.left - heroRect.right;
                    if (dist > -50 && dist < 300 && dist < closestDist) {
                        closestDist = dist;
                        closestEnemy = e;
                    }
                }
            });

            // Hero jump animation
            hero.classList.add('jumping');
            setTimeout(() => hero.classList.remove('jumping'), 500);

            // If enemy in range, stomp it
            if (closestEnemy && closestDist < 200) {
                setTimeout(() => {
                    stompEnemy(closestEnemy);
                }, 250);
            }
        }

        // Hero jumps and stomps a specific newly spawned enemy
        function heroStompNewEnemy(enemyObj) {
            if (!enemyObj || !enemyObj.alive) return;

            const hero = document.getElementById('heroRunner');
            if (!hero) return;

            // Hero jump animation - 0.8s total
            hero.classList.remove('running');
            hero.classList.add('jumping');

            // Stomp the enemy at peak of jump (around 70% through animation = 560ms)
            setTimeout(() => {
                stompEnemy(enemyObj);
            }, 500);

            // Return to running after jump completes
            setTimeout(() => {
                hero.classList.remove('jumping');
                hero.classList.add('stomping');
            }, 800);

            // Remove stomping class and resume running
            setTimeout(() => {
                hero.classList.remove('stomping');
                hero.classList.add('running');
            }, 1100);
        }

        // Stomp the enemy
        function stompEnemy(enemy) {
            if (!enemy.alive) return;
            enemy.alive = false;

            const element = enemy.element;
            element.classList.add('stomped');

            // Play stomp sound
            playStompSound();

            // Show score popup
            const rect = element.getBoundingClientRect();
            const scorePopup = document.createElement('div');
            scorePopup.className = 'stomp-score';
            scorePopup.textContent = '+100';
            scorePopup.style.left = rect.left + 'px';
            scorePopup.style.top = rect.top + 'px';
            document.body.appendChild(scorePopup);
            setTimeout(() => scorePopup.remove(), 1000);

            // Remove enemy after animation
            setTimeout(() => {
                element.remove();
                enemies = enemies.filter(e => e.id !== enemy.id);
            }, 500);
        }

        // Stomp sound effect
        function playStompSound() {
            const ctx = initAudio();
            const osc = ctx.createOscillator();
            const gain = ctx.createGain();

            osc.connect(gain);
            gain.connect(getOutput());

            osc.type = 'square';
            const now = ctx.currentTime;

            // Quick descending "bop" sound
            osc.frequency.setValueAtTime(400, now);
            osc.frequency.exponentialRampToValueAtTime(100, now + 0.1);

            gain.gain.setValueAtTime(0.3, now);
            gain.gain.exponentialRampToValueAtTime(0.01, now + 0.15);

            osc.start(now);
            osc.stop(now + 0.15);
        }

        // Clear all enemies
        function clearEnemies() {
            enemies.forEach(e => {
                if (e.element) e.element.remove();
            });
            enemies = [];
        }

        // Start the runner scene when game begins
        function startRunnerScene() {
            gameActive = true;
            const track = document.getElementById('runnerTrack');
            const hero = document.getElementById('heroRunner');
            if (track) track.classList.remove('paused');
            if (hero) hero.classList.add('running');
        }

        // Pause the runner scene
        function pauseRunnerScene() {
            const track = document.getElementById('runnerTrack');
            if (track) track.classList.add('paused');
        }

        // Resume the runner scene
        function resumeRunnerScene() {
            const track = document.getElementById('runnerTrack');
            if (track) track.classList.remove('paused');
        }

        // Game State
        let currentQuestion = 0;
        let score = 0;
        let streak = 0;
        let maxStreak = 0;
        let correctAnswers = 0;
        let selectedDifficulty = 'intern';
        let filteredQuestions = [];

        // MYELOMA QUESTION BANK
        const questions = [
            // ============ INTERN LEVEL ============
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What is the hallmark protein produced by malignant plasma cells in multiple myeloma?",
                options: [
                    "Albumin",
                    "Monoclonal immunoglobulin (M-protein)",
                    "C-reactive protein",
                    "Ferritin"
                ],
                correct: 1,
                explanation: "Multiple myeloma is characterized by clonal plasma cell proliferation producing a monoclonal immunoglobulin (M-protein or paraprotein). This can be detected by serum protein electrophoresis (SPEP) as an M-spike.",
                keyPoint: "The M-protein (paraprotein) is the biochemical hallmark of myeloma. It's detected by SPEP/UPEP and characterized by immunofixation.",
                citation: "Rajkumar SV. Multiple myeloma: 2020 update. Am J Hematol. 2020;95:548-567",
                pmid: "32212178",
                doi: "10.1002/ajh.25791",
                guideline: { name: "NCCN MM", url: "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445" }
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "What percentage of bone marrow plasma cells is required for a diagnosis of multiple myeloma?",
                options: [
                    "â¥5%",
                    "â¥10%",
                    "â¥20%",
                    "â¥30%"
                ],
                correct: 1,
                explanation: "Per IMWG criteria, multiple myeloma requires â¥10% clonal bone marrow plasma cells OR a biopsy-proven plasmacytoma, PLUS evidence of myeloma-defining events (CRAB criteria or biomarkers of malignancy).",
                keyPoint: "MM diagnosis: â¥10% clonal BM plasma cells + myeloma-defining event (CRAB or SLiM criteria).",
                citation: "Rajkumar SV, et al. Lancet Oncol. 2014;15:e538-e548",
                pmid: "25439696",
                doi: "10.1016/S1470-2045(14)70442-5"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "What does CRAB stand for in multiple myeloma?",
                options: [
                    "Calcium, Renal, Albumin, Bones",
                    "Calcium, Renal, Anemia, Bone lesions",
                    "Creatinine, Recurrence, Anemia, Bleeding",
                    "Calcium, Resistance, Anemia, Beta-2"
                ],
                correct: 1,
                explanation: "CRAB criteria represent end-organ damage in myeloma: Calcium elevation (>11 mg/dL), Renal insufficiency (creatinine >2 mg/dL or CrCl <40), Anemia (Hgb <10 or 2g below normal), and Bone disease (lytic lesions on imaging).",
                keyPoint: "CRAB = Calcium â, Renal failure, Anemia, Bone lesions. These are myeloma-defining events indicating need for treatment.",
                citation: "International Myeloma Working Group criteria 2014",
                pmid: "25439696",
                doi: "10.1016/S1470-2045(14)70442-5"
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "Which immunoglobulin type is most commonly produced in multiple myeloma?",
                options: [
                    "IgA",
                    "IgG",
                    "IgM",
                    "IgD"
                ],
                correct: 1,
                explanation: "IgG myeloma accounts for approximately 50-60% of cases, followed by IgA (~20%), light chain only (~15-20%), and rare types (IgD, IgE, IgM). IgM-producing plasma cell neoplasms are typically Waldenstrom macroglobulinemia.",
                keyPoint: "Myeloma isotype frequency: IgG (50-60%) > IgA (20%) > Light chain only (15-20%) > IgD/IgE (rare).",
                citation: "Kyle RA, et al. Mayo Clin Proc. 2003;78:21-33",
                pmid: "12528874",
                doi: "10.4065/78.1.21"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "What is the most sensitive imaging modality for detecting myeloma bone disease?",
                options: [
                    "Plain X-rays (skeletal survey)",
                    "CT scan",
                    "Whole-body low-dose CT or PET/CT",
                    "Bone scan (technetium-99m)"
                ],
                correct: 2,
                explanation: "Whole-body low-dose CT and PET/CT are more sensitive than plain radiographs for detecting lytic lesions. Bone scans are NOT useful in myeloma because lytic lesions lack osteoblastic activity needed for tracer uptake.",
                keyPoint: "Bone scan is NOT useful in myeloma (lytic lesions don't take up tracer). Use low-dose whole-body CT, PET/CT, or MRI.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" },
                guideline: { name: "NCCN MM", url: "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445" }
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What is the difference between MGUS and smoldering myeloma?",
                options: [
                    "M-protein level and plasma cell percentage",
                    "Presence of symptoms only",
                    "Age of the patient",
                    "Type of immunoglobulin"
                ],
                correct: 0,
                explanation: "MGUS: M-protein <3 g/dL AND <10% BM plasma cells AND no CRAB. Smoldering MM: M-protein â¥3 g/dL OR â¥10% BM plasma cells, but NO CRAB criteria or myeloma-defining events.",
                keyPoint: "MGUS vs SMM: Both lack CRAB/end-organ damage. SMM has higher tumor burden (M-protein â¥3 OR plasma cells â¥10%).",
                citation: "Rajkumar SV, et al. Blood. 2015;125:3069-3075",
                pmid: "25838344",
                doi: "10.1182/blood-2014-09-568899"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "intern",
                question: "Which class of drugs are proteasome inhibitors used in myeloma?",
                options: [
                    "Bortezomib, Carfilzomib, Ixazomib",
                    "Lenalidomide, Pomalidomide, Thalidomide",
                    "Daratumumab, Isatuximab, Elotuzumab",
                    "Dexamethasone, Prednisone, Methylprednisolone"
                ],
                correct: 0,
                explanation: "Proteasome inhibitors (PIs) include bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro). They block the proteasome, causing accumulation of misfolded proteins and plasma cell death.",
                keyPoint: "Proteasome inhibitors: Bortezomib (V), Carfilzomib (K), Ixazomib (oral). Key toxicity: peripheral neuropathy (bortezomib), cardiac (carfilzomib).",
                citation: "Moreau P, et al. Lancet. 2021;397:2361-2371",
                pmid: "34097854",
                doi: "10.1016/S0140-6736(21)00592-4"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "intern",
                question: "What is the target of daratumumab in multiple myeloma?",
                options: [
                    "BCMA",
                    "CD38",
                    "CD20",
                    "SLAMF7"
                ],
                correct: 1,
                explanation: "Daratumumab is a monoclonal antibody targeting CD38, which is highly expressed on myeloma cells. It works through multiple mechanisms including ADCC, CDC, and direct apoptosis induction.",
                keyPoint: "CD38-targeting antibodies: Daratumumab (Darzalex), Isatuximab (Sarclisa). SLAMF7 = Elotuzumab. BCMA = CAR-T and bispecifics.",
                citation: "Lokhorst HM, et al. N Engl J Med. 2015;373:1207-1219",
                pmid: "26308596",
                doi: "10.1056/NEJMoa1506348"
            },
            {
                type: "simple",
                typeLabel: "Supportive Care",
                difficulty: "intern",
                question: "Which medication should be given to prevent bone complications in myeloma patients?",
                options: [
                    "Aspirin",
                    "Bisphosphonates (zoledronic acid) or denosumab",
                    "Calcium supplements only",
                    "Vitamin K"
                ],
                correct: 1,
                explanation: "Bisphosphonates (zoledronic acid, pamidronate) or denosumab are recommended for all myeloma patients with bone disease. They reduce skeletal-related events. Dental evaluation is required before starting due to osteonecrosis of jaw risk.",
                keyPoint: "All MM patients with bone disease need bone-modifying agents. Dental clearance required. Monitor renal function with bisphosphonates.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" },
                guideline: { name: "NCCN MM", url: "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445" }
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What is the typical presentation of myeloma bone pain?",
                options: [
                    "Sharp, radiating pain worse at night",
                    "Dull, persistent pain in the back or ribs, worse with movement",
                    "Joint pain with morning stiffness",
                    "Burning pain in the extremities"
                ],
                correct: 1,
                explanation: "Myeloma bone pain is typically persistent, affects the axial skeleton (back, ribs, pelvis), and worsens with movement. It results from osteoclast activation and lytic bone destruction. Pathologic fractures are common.",
                keyPoint: "MM bone pain: axial skeleton, worse with movement, lytic lesions. Vertebral compression fractures cause acute back pain.",
                citation: "Kyle RA, Rajkumar SV. Blood. 2008;111:2962-2972",
                pmid: "18332230",
                doi: "10.1182/blood-2007-10-078022"
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What is the median age at diagnosis for multiple myeloma?",
                options: [
                    "45-50 years",
                    "55-60 years",
                    "65-70 years",
                    "75-80 years"
                ],
                correct: 2,
                explanation: "The median age at diagnosis for multiple myeloma is approximately 69 years. It is rare in patients under 40, with only 2-3% of cases occurring in this age group.",
                keyPoint: "MM is a disease of the elderly. Median age ~69 years. Very rare <40 years old.",
                citation: "SEER Cancer Statistics Review, National Cancer Institute",
                url: "https://seer.cancer.gov/statfacts/html/mulmy.html"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "Which test is used to detect and quantify M-protein in serum?",
                options: [
                    "Complete blood count",
                    "Serum protein electrophoresis (SPEP)",
                    "Liver function tests",
                    "Urinalysis"
                ],
                correct: 1,
                explanation: "Serum protein electrophoresis (SPEP) separates proteins and can detect an M-spike (monoclonal protein). Immunofixation electrophoresis (IFE) is then used to confirm and characterize the type of M-protein.",
                keyPoint: "SPEP detects M-spike. IFE confirms and characterizes the immunoglobulin type (heavy and light chain).",
                citation: "Dispenzieri A, et al. Mayo Clin Proc. 2007;82:323-341",
                pmid: "17352369",
                doi: "10.4065/82.3.323"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "intern",
                question: "Why are myeloma patients at increased risk of infections?",
                options: [
                    "Low platelet count",
                    "Immunoparesis (suppression of normal immunoglobulins)",
                    "Elevated white blood cell count",
                    "Iron deficiency"
                ],
                correct: 1,
                explanation: "Myeloma causes immunoparesis - suppression of normal (polyclonal) immunoglobulin production while the malignant clone produces non-functional M-protein. This leads to increased susceptibility to infections, especially encapsulated organisms.",
                keyPoint: "Immunoparesis = low normal Igs despite high M-protein. Increases infection risk. Encapsulated bacteria are particularly dangerous.",
                citation: "Nucci M, Anaissie E. Clin Infect Dis. 2009;49:1211-1225",
                pmid: "19769539",
                doi: "10.1086/605664"
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What type of light chain is more common in myeloma?",
                options: [
                    "Lambda",
                    "Kappa",
                    "Alpha",
                    "Gamma"
                ],
                correct: 1,
                explanation: "Kappa light chains are more common than lambda, with a ratio of approximately 2:1. The serum free light chain assay measures both kappa and lambda, and an abnormal ratio suggests a clonal process.",
                keyPoint: "Kappa:Lambda ratio normally ~2:1. Abnormal FLC ratio (>100 or <0.01) can be a myeloma-defining event.",
                citation: "Dispenzieri A, et al. Leukemia. 2009;23:215-224",
                pmid: "19020545",
                doi: "10.1038/leu.2008.307"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "intern",
                question: "What class of drugs does lenalidomide belong to?",
                options: [
                    "Proteasome inhibitors",
                    "Immunomodulatory drugs (IMiDs)",
                    "Monoclonal antibodies",
                    "Alkylating agents"
                ],
                correct: 1,
                explanation: "Lenalidomide is an immunomodulatory drug (IMiD) derived from thalidomide. IMiDs have multiple mechanisms including direct anti-myeloma effects, immune modulation, and anti-angiogenic properties.",
                keyPoint: "IMiDs: Thalidomide, Lenalidomide, Pomalidomide. Key toxicities: VTE risk (need prophylaxis), cytopenias, teratogenicity.",
                citation: "Quach H, et al. Leukemia. 2010;24:22-32",
                pmid: "19907437",
                doi: "10.1038/leu.2009.236"
            },
            {
                type: "simple",
                typeLabel: "Supportive Care",
                difficulty: "intern",
                question: "What VTE prophylaxis is recommended for myeloma patients on IMiD therapy?",
                options: [
                    "No prophylaxis needed",
                    "Aspirin, LMWH, or warfarin based on risk",
                    "Compression stockings only",
                    "Vitamin K supplements"
                ],
                correct: 1,
                explanation: "IMiDs increase VTE risk, especially combined with dexamethasone. Prophylaxis is required: aspirin for low-risk, LMWH or warfarin for high-risk patients (prior VTE, immobility, hyperviscosity).",
                keyPoint: "All IMiD patients need VTE prophylaxis. Aspirin for low risk; anticoagulation for high risk.",
                citation: "Palumbo A, et al. Leukemia. 2008;22:414-423",
                pmid: "17928881",
                doi: "10.1038/sj.leu.2405062"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "What is plasmacytoma?",
                options: [
                    "A type of lymphoma",
                    "A solitary tumor of plasma cells without systemic disease",
                    "Plasma cells in the peripheral blood",
                    "Bone marrow failure"
                ],
                correct: 1,
                explanation: "Plasmacytoma is a localized collection of clonal plasma cells. Solitary bone plasmacytoma occurs in bone; extramedullary plasmacytoma occurs in soft tissue. Many progress to myeloma over time.",
                keyPoint: "Solitary plasmacytoma: single lesion, <10% BM plasma cells, no CRAB. ~60% progress to MM in 10 years.",
                citation: "Soutar R, et al. Br J Haematol. 2004;125:717-726",
                pmid: "15500518",
                doi: "10.1111/j.1365-2141.2004.04973.x"
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What is the difference between symptomatic and asymptomatic myeloma?",
                options: [
                    "M-protein level only",
                    "Presence or absence of CRAB features or myeloma-defining events",
                    "Age of the patient",
                    "Type of light chain"
                ],
                correct: 1,
                explanation: "Symptomatic (active) myeloma has CRAB criteria or SLiM biomarkers requiring treatment. Asymptomatic (smoldering) myeloma has no end-organ damage and is typically observed.",
                keyPoint: "Active MM = needs treatment (has CRAB/SLiM). SMM = observation (no CRAB/SLiM). High-risk SMM may benefit from early treatment.",
                citation: "Rajkumar SV, et al. Lancet Oncol. 2014;15:e538-e548",
                pmid: "25439696",
                doi: "10.1016/S1470-2045(14)70442-5"
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What is the annual risk of MGUS progressing to myeloma?",
                options: [
                    "About 1% per year",
                    "About 5% per year",
                    "About 10% per year",
                    "About 25% per year"
                ],
                correct: 0,
                explanation: "MGUS has approximately 1% per year risk of progression to myeloma or related malignancy. Risk factors for progression include M-protein level, type (non-IgG), and abnormal FLC ratio.",
                keyPoint: "MGUS progression risk: ~1%/year. Higher risk: M-protein >1.5 g/dL, non-IgG type, abnormal FLC ratio.",
                citation: "Kyle RA, et al. N Engl J Med. 2002;346:564-569",
                pmid: "11856795",
                doi: "10.1056/NEJMoa012689"
            },

            // ============ RESIDENT LEVEL ============
            {
                type: "simple",
                typeLabel: "Staging",
                difficulty: "resident",
                question: "What are the three stages of the Revised International Staging System (R-ISS)?",
                options: [
                    "Based on tumor size, lymph node involvement, metastases",
                    "Based on Î²2-microglobulin, albumin, LDH, and high-risk cytogenetics",
                    "Based on M-protein level only",
                    "Based on bone marrow plasma cell percentage"
                ],
                correct: 1,
                explanation: "R-ISS incorporates ISS (Î²2M and albumin) plus LDH and high-risk cytogenetics [t(4;14), t(14;16), del(17p)]. Stage I: ISS I + normal LDH + no high-risk. Stage III: ISS III + high LDH or high-risk cytogenetics. Stage II: neither I nor III.",
                keyPoint: "R-ISS adds LDH and cytogenetics to ISS. High-risk: t(4;14), t(14;16), del(17p). R-ISS III = worst prognosis.",
                citation: "Palumbo A, et al. J Clin Oncol. 2015;33:2863-2869",
                pmid: "26240224",
                doi: "10.1200/JCO.2015.61.2267"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "resident",
                question: "What are the SLiM criteria that define myeloma-defining events?",
                options: [
                    "Sixty percent plasma cells, Light chain ratio, MRI lesions",
                    "Serum calcium, LDH, M-protein",
                    "Stage, Lymphadenopathy, Marrow involvement",
                    "Symptoms, Laboratory values, Imaging"
                ],
                correct: 0,
                explanation: "SLiM criteria (biomarkers of malignancy): S = Sixty percent (â¥60%) clonal BM plasma cells, Li = Light chain ratio â¥100 (involved/uninvolved), M = >1 focal lesion on MRI (â¥5mm). Meeting any = myeloma requiring treatment.",
                keyPoint: "SLiM = â¥60% BM plasma cells, FLC ratio â¥100, >1 MRI lesion (â¥5mm). Any one = treat as MM (not SMM).",
                citation: "Rajkumar SV, et al. Lancet Oncol. 2014;15:e538-e548",
                pmid: "25439696",
                doi: "10.1016/S1470-2045(14)70442-5"
            },
            {
                type: "simple",
                typeLabel: "Cytogenetics",
                difficulty: "resident",
                question: "Which cytogenetic abnormality in myeloma is associated with the worst prognosis?",
                options: [
                    "Hyperdiploidy",
                    "t(11;14)",
                    "del(17p) / TP53 deletion",
                    "t(6;14)"
                ],
                correct: 2,
                explanation: "Del(17p) involves loss of TP53 tumor suppressor and confers the worst prognosis in myeloma with shorter PFS and OS. Other high-risk features: t(4;14), t(14;16), t(14;20), gain 1q21. t(11;14) is standard risk.",
                keyPoint: "High-risk cytogenetics: del(17p), t(4;14), t(14;16), t(14;20), gain 1q. Standard-risk: t(11;14), hyperdiploidy.",
                citation: "Sonneveld P, et al. Blood. 2016;127:2955-2962",
                pmid: "27002115",
                doi: "10.1182/blood-2016-01-691618"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What is the current standard frontline induction for transplant-eligible myeloma?",
                options: [
                    "VRd (bortezomib, lenalidomide, dexamethasone)",
                    "Rd (lenalidomide, dexamethasone)",
                    "MP (melphalan, prednisone)",
                    "Dara-VRd (daratumumab + VRd)"
                ],
                correct: 3,
                explanation: "Per NCCN 2025, Dara-VRd (daratumumab + bortezomib, lenalidomide, dexamethasone) is now the preferred induction for transplant-eligible patients based on PERSEUS and GRIFFIN trials showing improved depth of response and PFS.",
                keyPoint: "Dara-VRd is now preferred induction for transplant-eligible MM per NCCN 2025. Quadruplet > triplet for fit patients.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025; Sonneveld P, et al. N Engl J Med. 2024",
                guideline: { name: "NCCN MM", url: "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445" }
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What is the role of autologous stem cell transplant (ASCT) in myeloma?",
                options: [
                    "Curative in all patients",
                    "Consolidation after induction to deepen response and prolong PFS",
                    "Only for relapsed disease",
                    "Replaced by CAR-T therapy"
                ],
                correct: 1,
                explanation: "ASCT following induction remains standard of care for eligible patients. It deepens response and prolongs PFS, though not OS in most studies. Age alone is not a contraindication; fitness assessment is key.",
                keyPoint: "ASCT deepens response and improves PFS. Standard for fit patients. Not curative but extends remission duration.",
                citation: "Attal M, et al. N Engl J Med. 2017;376:1311-1320",
                pmid: "28379796",
                doi: "10.1056/NEJMoa1611750"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What maintenance therapy is standard after ASCT in myeloma?",
                options: [
                    "No maintenance needed",
                    "Bortezomib weekly",
                    "Lenalidomide until progression",
                    "Dexamethasone alone"
                ],
                correct: 2,
                explanation: "Lenalidomide maintenance post-ASCT until progression is standard of care. Meta-analyses show improved PFS and OS. For high-risk disease, adding bortezomib may be considered.",
                keyPoint: "Post-ASCT maintenance: Lenalidomide until progression (category 1). Consider adding bortezomib for high-risk patients.",
                citation: "McCarthy PL, et al. N Engl J Med. 2012;366:1770-1781",
                pmid: "22571201",
                doi: "10.1056/NEJMoa1114083"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "resident",
                question: "What is the cause of renal failure in myeloma (myeloma kidney)?",
                options: [
                    "Glomerulonephritis only",
                    "Cast nephropathy from free light chains",
                    "Renal artery stenosis",
                    "Polycystic kidney disease"
                ],
                correct: 1,
                explanation: "Cast nephropathy (myeloma kidney) is caused by free light chains forming casts with Tamm-Horsfall protein in distal tubules. Other causes: hypercalcemia, dehydration, contrast, NSAIDs, amyloidosis, light chain deposition disease.",
                keyPoint: "Myeloma kidney = light chain cast nephropathy. Avoid dehydration, nephrotoxins, IV contrast. Treat underlying MM urgently.",
                citation: "Kumar S, et al. Lancet Oncol. 2016;17:e328-e346 (IMWG Response Criteria)",
                pmid: "27511158",
                doi: "10.1016/S1470-2045(16)30206-6"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "resident",
                question: "What is the mechanism of myeloma-induced hypercalcemia?",
                options: [
                    "PTH production by myeloma cells",
                    "Osteoclast activation by myeloma-secreted factors (RANKL, IL-6)",
                    "Vitamin D intoxication",
                    "Milk-alkali syndrome"
                ],
                correct: 1,
                explanation: "Myeloma cells secrete osteoclast-activating factors (RANKL, MIP-1Î±, IL-3, IL-6) causing excessive bone resorption and calcium release. Additionally, myeloma inhibits osteoblast function, preventing new bone formation.",
                keyPoint: "MM hypercalcemia: osteoclast activation + osteoblast inhibition. Treatment: hydration, bisphosphonates, treat MM.",
                citation: "Terpos E, et al. Pathogenesis of bone disease in MM. Blood Cancer J. 2018;8:12.",
                pmid: "29330358",
                doi: "10.1038/s41408-017-0037-4"
            },
            {
                type: "simple",
                typeLabel: "Monitoring",
                difficulty: "resident",
                question: "How is response assessed in multiple myeloma?",
                options: [
                    "Bone marrow biopsy only",
                    "M-protein (SPEP/UPEP), serum FLC, bone marrow, imaging",
                    "CT scan only",
                    "Patient symptoms only"
                ],
                correct: 1,
                explanation: "IMWG response criteria use M-protein reduction (SPEP/24h UPEP), serum free light chains (especially in oligo/non-secretory), bone marrow assessment, and imaging (PET/CT for CR confirmation). MRD assessment increasingly important.",
                keyPoint: "Response assessment: SPEP, UPEP, FLC ratio, BM biopsy. CR needs negative IF, normalized FLC, <5% BM plasma cells. MRD-negativity = deeper response.",
                citation: "Kumar S, et al. Lancet Oncol. 2016;17:e328-e346",
                pmid: "27511158",
                doi: "10.1016/S1470-2045(16)30206-6"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "resident",
                case: {
                    presentation: "A 68-year-old woman presents with fatigue, back pain for 3 months, and recent onset confusion. Labs show Ca 13.2 mg/dL, Cr 2.8 mg/dL, Hgb 9.1 g/dL. SPEP shows M-spike 4.2 g/dL (IgG kappa). Bone marrow shows 45% plasma cells.",
                    labs: [
                        { name: "Calcium", value: "13.2 mg/dL", abnormal: true },
                        { name: "Creatinine", value: "2.8 mg/dL", abnormal: true },
                        { name: "Hemoglobin", value: "9.1 g/dL", abnormal: true },
                        { name: "M-spike", value: "4.2 g/dL", abnormal: true }
                    ]
                },
                question: "What is the diagnosis and initial management priority?",
                options: [
                    "Smoldering myeloma; observation",
                    "Multiple myeloma with hypercalcemic crisis; IV fluids and bisphosphonates urgently",
                    "MGUS; routine follow-up",
                    "Waldenstrom macroglobulinemia; plasmapheresis"
                ],
                correct: 1,
                explanation: "This patient has symptomatic multiple myeloma meeting CRAB criteria (all four: Calcium elevated, Renal failure, Anemia, and likely Bone lesions given back pain). Hypercalcemic crisis is oncologic emergency requiring IV hydration, bisphosphonates, and urgent myeloma treatment.",
                keyPoint: "Hypercalcemic crisis: IV NS (200-300 mL/hr initially), zoledronic acid or denosumab, calcitonin for rapid action. Start MM treatment promptly.",
                citation: "Rajkumar SV. Am J Hematol. 2024;99:1802-1824.",
                pmid: "38943315",
                doi: "10.1002/ajh.27422"
            },
            {
                type: "simple",
                typeLabel: "Cytogenetics",
                difficulty: "resident",
                question: "What percentage of myeloma patients have high-risk cytogenetics at diagnosis?",
                options: [
                    "5-10%",
                    "15-25%",
                    "40-50%",
                    "60-70%"
                ],
                correct: 1,
                explanation: "Approximately 15-25% of newly diagnosed myeloma patients have high-risk cytogenetic abnormalities. This proportion increases at relapse, with up to 50% acquiring high-risk features.",
                keyPoint: "High-risk cytogenetics in ~20% at diagnosis, increases with relapse. Always perform FISH on CD138-selected plasma cells.",
                citation: "Sonneveld P, et al. Blood. 2016;127:2955-2962",
                pmid: "27002115",
                doi: "10.1182/blood-2016-01-691618"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What is the purpose of stem cell collection in transplant-eligible patients?",
                options: [
                    "To cure the disease immediately",
                    "To provide stem cells for high-dose melphalan and autologous rescue",
                    "To replace the bone marrow permanently",
                    "To reduce M-protein levels"
                ],
                correct: 1,
                explanation: "Stem cells are collected after initial induction to allow high-dose melphalan conditioning (200 mg/m2) followed by autologous stem cell rescue. This deepens response but is not curative.",
                keyPoint: "Collect enough stem cells for 2 transplants (â¥4 million CD34+ cells/kg). High-dose melphalan 200 mg/m2 is standard conditioning.",
                citation: "Giralt S, et al. Biol Blood Marrow Transplant. 2015;21:1864-1869",
                pmid: "26428082",
                doi: "10.1016/j.bbmt.2015.09.016"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "resident",
                question: "What is the significance of extramedullary disease in myeloma?",
                options: [
                    "It has no prognostic significance",
                    "It indicates more aggressive disease with worse prognosis",
                    "It responds better to standard therapy",
                    "It only occurs in MGUS"
                ],
                correct: 1,
                explanation: "Extramedullary disease (EMD) indicates biologically aggressive myeloma with worse outcomes. It's more common at relapse and often associated with high-risk cytogenetics and clonal evolution.",
                keyPoint: "EMD = aggressive biology, worse prognosis. More common at relapse. Consider intensified therapy and clinical trials.",
                citation: "Pour L, et al. Soft-tissue extramedullary MM prognosis. Haematologica. 2014;99:360-4.",
                pmid: "24038024",
                doi: "10.3324/haematol.2013.094409"
            },
            {
                type: "simple",
                typeLabel: "Monitoring",
                difficulty: "resident",
                question: "What is minimal residual disease (MRD) in myeloma?",
                options: [
                    "Visible disease on PET scan",
                    "Detectable disease below the threshold of conventional testing (10^-5 to 10^-6)",
                    "M-protein <1 g/dL",
                    "Less than 10% bone marrow plasma cells"
                ],
                correct: 1,
                explanation: "MRD refers to detection of residual myeloma cells at sensitivity of 10^-5 or 10^-6 using next-generation flow cytometry or next-generation sequencing. MRD-negativity correlates with improved outcomes.",
                keyPoint: "MRD negativity (10^-5 or 10^-6) = deeper response, better PFS/OS. Sustained MRD negativity is the goal.",
                citation: "Munshi NC, et al. JAMA Oncol. 2017;3:28-35",
                pmid: "27632282",
                doi: "10.1001/jamaoncol.2016.3160"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "resident",
                question: "What is AL amyloidosis and how is it related to myeloma?",
                options: [
                    "It is a type of kidney stone",
                    "It is deposition of misfolded light chains causing organ damage",
                    "It is the same as multiple myeloma",
                    "It is a viral infection"
                ],
                correct: 1,
                explanation: "AL (light chain) amyloidosis results from deposition of misfolded monoclonal light chains in tissues causing organ dysfunction. About 10-15% of myeloma patients have concurrent AL amyloidosis.",
                keyPoint: "AL amyloidosis: light chain deposition â organ damage (heart, kidney, nerve, GI). Requires tissue biopsy with Congo red staining.",
                citation: "Merlini G, et al. N Engl J Med. 2003;349:583-596",
                pmid: "12842378",
                doi: "10.1056/NEJMra023144"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What is the mechanism of action of proteasome inhibitors in myeloma?",
                options: [
                    "Block DNA replication",
                    "Inhibit protein degradation causing ER stress and apoptosis",
                    "Block cell surface receptors",
                    "Prevent angiogenesis only"
                ],
                correct: 1,
                explanation: "Proteasome inhibitors block the 26S proteasome, preventing degradation of misfolded proteins. Plasma cells produce large amounts of immunoglobulin, making them highly dependent on proteasome function.",
                keyPoint: "PIs cause ER stress â unfolded protein response â apoptosis. Plasma cells are uniquely sensitive due to high Ig production.",
                citation: "Obeng EA, et al. Blood. 2006;107:4907-4916.",
                pmid: "16507771",
                doi: "10.1182/blood-2005-08-3531"
            },
            {
                type: "simple",
                typeLabel: "Supportive Care",
                difficulty: "resident",
                question: "What vaccines should myeloma patients receive?",
                options: [
                    "No vaccines are safe",
                    "Inactivated vaccines (flu, pneumococcal, COVID); avoid live vaccines",
                    "Only live vaccines",
                    "Vaccines are not effective so don't give any"
                ],
                correct: 1,
                explanation: "Myeloma patients should receive inactivated vaccines including influenza, pneumococcal (PCV13 and PPSV23), and COVID-19. Live vaccines (MMR, varicella, zoster live) are contraindicated.",
                keyPoint: "Give inactivated vaccines. Avoid live vaccines (use Shingrix instead of Zostavax). Response may be blunted; consider checking titers.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "resident",
                question: "What is hyperviscosity syndrome and how does it present?",
                options: [
                    "Low blood viscosity causing bleeding",
                    "Thick blood causing neurological symptoms, bleeding, and visual changes",
                    "High blood pressure only",
                    "Low platelet count"
                ],
                correct: 1,
                explanation: "Hyperviscosity occurs when high M-protein (especially IgA or IgM) increases blood viscosity. Symptoms include headache, blurred vision, mucosal bleeding, and altered mental status. Treatment is plasmapheresis.",
                keyPoint: "Hyperviscosity: headache, blurred vision, bleeding, confusion. More common in IgA/IgM. Emergent plasmapheresis indicated.",
                citation: "Gertz MA. Am J Hematol. 2018;93:1169-1180.",
                pmid: "30040145",
                doi: "10.1002/ajh.25149"
            },

            // ============ FELLOW LEVEL ============
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "fellow",
                case: {
                    presentation: "A 55-year-old man with newly diagnosed MM (IgA lambda, R-ISS II) completes 4 cycles of Dara-VRd induction. SPEP shows 90% reduction in M-protein. He is transplant-eligible with good performance status.",
                    labs: [
                        { name: "M-protein", value: "0.3 g/dL (from 3.0)", abnormal: false },
                        { name: "FLC ratio", value: "Normal", abnormal: false },
                        { name: "BM plasma cells", value: "8%", abnormal: false }
                    ]
                },
                question: "What is the next step in management?",
                options: [
                    "Continue induction indefinitely",
                    "Proceed to high-dose melphalan and autologous SCT",
                    "Switch to lenalidomide maintenance only",
                    "Observe without further treatment"
                ],
                correct: 1,
                explanation: "For transplant-eligible patients achieving good response to induction, proceeding to high-dose melphalan (200 mg/mÂ²) and ASCT is standard of care. This deepens response and prolongs PFS. Stem cells are collected before ASCT.",
                keyPoint: "Transplant-eligible patients: Induction â stem cell collection â high-dose melphalan â ASCT â maintenance.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "Which myeloma patients should be considered for upfront tandem (double) ASCT?",
                options: [
                    "All patients",
                    "Patients with high-risk cytogenetics not achieving CR after first ASCT",
                    "Only elderly patients",
                    "Never indicated"
                ],
                correct: 1,
                explanation: "Tandem ASCT may benefit high-risk patients (del17p, t(4;14), t(14;16)) who don't achieve CR/VGPR after first ASCT. The StaMINA trial showed potential benefit in high-risk disease. Not routinely recommended for standard-risk.",
                keyPoint: "Tandem ASCT: Consider for high-risk cytogenetics with suboptimal response to first ASCT. Standard-risk: single ASCT sufficient.",
                citation: "Stadtmauer EA, et al. J Clin Oncol. 2019;37:589-597",
                pmid: "30653422",
                doi: "10.1200/JCO.18.00685"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "fellow",
                case: {
                    presentation: "A 62-year-old woman with MM is starting lenalidomide-dexamethasone. She has history of DVT 5 years ago and is concerned about clot risk.",
                    labs: [
                        { name: "PLT", value: "245,000/Î¼L", abnormal: false },
                        { name: "PT/INR", value: "Normal", abnormal: false }
                    ]
                },
                question: "What VTE prophylaxis is recommended for this patient on IMiD therapy?",
                options: [
                    "No prophylaxis needed",
                    "Aspirin 81-325mg daily only",
                    "Full-dose anticoagulation (LMWH or DOAC)",
                    "Compression stockings only"
                ],
                correct: 2,
                explanation: "IMiDs (lenalidomide, pomalidomide) increase VTE risk, especially with dexamethasone. For patients with prior VTE (high-risk), therapeutic anticoagulation is recommended. Low-risk patients may use aspirin. Intermediate risk: prophylactic LMWH or DOAC.",
                keyPoint: "IMiD VTE prophylaxis: Prior VTE = therapeutic anticoagulation. Low-risk = ASA. Intermediate = prophylactic anticoagulation.",
                citation: "Palumbo A, et al. Blood. 2015;125:2068-2074 (IMWG Frailty Score)",
                pmid: "25628469",
                doi: "10.1182/blood-2014-12-615187"
            },
            {
                type: "simple",
                typeLabel: "Relapsed Disease",
                difficulty: "fellow",
                question: "What defines 'lenalidomide-refractory' myeloma?",
                options: [
                    "Any prior lenalidomide exposure",
                    "Progression during or within 60 days of completing lenalidomide therapy",
                    "Allergic reaction to lenalidomide",
                    "Failure to achieve CR with lenalidomide"
                ],
                correct: 1,
                explanation: "Refractory disease = progression on therapy or within 60 days of last dose. This impacts treatment selection as lenalidomide-refractory patients need pomalidomide-based or len-free regimens.",
                keyPoint: "Refractory = progression on or within 60 days of completing therapy. Len-refractory: switch to pomalidomide or other backbone.",
                citation: "IMWG criteria for refractory myeloma"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the mechanism of action of selinexor in myeloma?",
                options: [
                    "Proteasome inhibition",
                    "XPO1 (exportin 1) inhibition - blocks nuclear export",
                    "CD38 targeting",
                    "BCMA targeting"
                ],
                correct: 1,
                explanation: "Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1, causing nuclear retention and activation of tumor suppressor proteins. Approved for relapsed/refractory MM. Key toxicities: nausea, fatigue, cytopenias, hyponatremia.",
                keyPoint: "Selinexor (Xpovio): XPO1 inhibitor. Used in heavily pretreated MM. Give with antiemetics (5-HT3 blocker). Monitor sodium.",
                citation: "Chari A, et al. N Engl J Med. 2019;381:727-738",
                pmid: "31433920",
                doi: "10.1056/NEJMoa1903455"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "Which BCMA-targeted therapies are approved for relapsed/refractory myeloma?",
                options: [
                    "Daratumumab and isatuximab only",
                    "Ide-cel, cilta-cel (CAR-T), teclistamab, elranatamab (bispecifics)",
                    "Venetoclax only",
                    "Ibrutinib and acalabrutinib"
                ],
                correct: 1,
                explanation: "BCMA-targeting agents include CAR-T therapies (idecabtagene vicleucel, ciltacabtagene autoleucel), bispecific antibodies (teclistamab, elranatamab), and ADC (belantamab mafodotin - currently withdrawn). These represent major advances for RRMM.",
                keyPoint: "BCMA-directed therapies: CAR-T (ide-cel, cilta-cel), bispecifics (teclistamab, elranatamab). Transforming RRMM treatment.",
                citation: "Munshi NC, et al. N Engl J Med. 2021;384:705-716",
                pmid: "33626253",
                doi: "10.1056/NEJMoa2024850",
                pmid: "33626253",
                doi: "10.1056/NEJMoa2024850"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "fellow",
                case: {
                    presentation: "A 58-year-old man receives teclistamab for triple-class refractory MM. Day 3 after step-up dosing, he develops fever 39.5Â°C, tachycardia, hypotension (BP 85/50), and confusion.",
                    labs: [
                        { name: "Ferritin", value: "12,500 ng/mL", abnormal: true },
                        { name: "CRP", value: "185 mg/L", abnormal: true },
                        { name: "IL-6", value: "Markedly elevated", abnormal: true }
                    ]
                },
                question: "What is the diagnosis and management?",
                options: [
                    "Sepsis; broad-spectrum antibiotics only",
                    "Cytokine release syndrome; tocilizumab and supportive care",
                    "Drug allergy; discontinue and give epinephrine",
                    "Tumor lysis syndrome; rasburicase"
                ],
                correct: 1,
                explanation: "This is grade 3 CRS (fever + hypotension + hypoxia/confusion). Bispecific antibodies and CAR-T cause CRS via T-cell activation and cytokine release. Management: tocilizumab (IL-6R blocker) Â± corticosteroids for higher grades. Rule out infection concurrently.",
                keyPoint: "CRS grading: Grade 1 = fever only. Grade 2 = hypotension responsive to fluids. Grade 3 = hypotension requiring vasopressors. Tocilizumab first-line.",
                citation: "Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638",
                pmid: "30592986",
                doi: "10.1016/j.bbmt.2018.12.758"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "fellow",
                question: "What is ICANS and how does it differ from CRS?",
                options: [
                    "Same as CRS, just a different name",
                    "Immune effector cell-associated neurotoxicity; CNS symptoms distinct from CRS",
                    "Infectious complication only",
                    "Cardiac toxicity syndrome"
                ],
                correct: 1,
                explanation: "ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) presents with confusion, aphasia, tremor, and can progress to seizures/cerebral edema. May occur with or after CRS. Management: dexamethasone (not tocilizumab for isolated ICANS). ICE score for grading.",
                keyPoint: "ICANS: confusion, word-finding difficulty, tremor, seizures. Grade with ICE score. Treat with dexamethasone. Tocilizumab doesn't cross BBB.",
                citation: "Neelapu SS, et al. Nat Rev Clin Oncol. 2018;15:47-62",
                pmid: "28925994",
                doi: "10.1038/nrclinonc.2017.148"
            },
            {
                type: "simple",
                typeLabel: "Special Populations",
                difficulty: "fellow",
                question: "What is the recommended management for solitary plasmacytoma?",
                options: [
                    "Systemic chemotherapy",
                    "Definitive radiation therapy with curative intent",
                    "Observation only",
                    "Autologous stem cell transplant"
                ],
                correct: 1,
                explanation: "Solitary plasmacytoma (bone or extramedullary) without systemic myeloma is treated with definitive radiation therapy (40-50 Gy). This is potentially curative. ~50-70% of bone plasmacytomas progress to MM within 10 years; surveillance essential.",
                keyPoint: "Solitary plasmacytoma: RT is curative intent. No systemic therapy unless progression. Long-term monitoring required - high rate of conversion to MM.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the role of tandem autologous transplant in myeloma?",
                options: [
                    "Standard for all patients",
                    "May benefit high-risk patients who don't achieve CR after first transplant",
                    "Never indicated",
                    "Only for relapsed disease"
                ],
                correct: 1,
                explanation: "Tandem (double) ASCT may benefit high-risk patients who don't achieve CR/VGPR after first transplant. Studies show conflicting results, but selected high-risk patients may derive benefit.",
                keyPoint: "Tandem ASCT: consider for high-risk patients not achieving optimal response after first ASCT. Collect enough cells upfront.",
                citation: "Moreau P, et al. Lancet. 2019;394:29-38 (CASSIOPEIA)",
                pmid: "31171419",
                doi: "10.1016/S0140-6736(19)31240-1"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the mechanism of action of selinexor in myeloma?",
                options: [
                    "Proteasome inhibition",
                    "XPO1 (exportin 1) inhibition causing nuclear retention of tumor suppressors",
                    "CD38 targeting",
                    "IMiD-like immunomodulation"
                ],
                correct: 1,
                explanation: "Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1, causing nuclear accumulation of tumor suppressor proteins and growth regulators, leading to cell cycle arrest and apoptosis.",
                keyPoint: "Selinexor = XPO1 inhibitor. Used in heavily pretreated patients. Key toxicities: nausea, fatigue, thrombocytopenia, anorexia.",
                citation: "Chari A, et al. N Engl J Med. 2019;381:727-738",
                pmid: "31433920",
                doi: "10.1056/NEJMoa1903455"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "fellow",
                question: "What defines ultra-high-risk myeloma?",
                options: [
                    "R-ISS stage II",
                    "Multiple high-risk cytogenetic abnormalities (double/triple hit) or early relapse within 18 months",
                    "IgA myeloma",
                    "Age over 70"
                ],
                correct: 1,
                explanation: "Ultra-high-risk (functional high-risk) includes: multiple adverse cytogenetics (e.g., del(17p) + t(4;14)), early relapse (<18 months from diagnosis or <12 months from ASCT), and extramedullary disease at diagnosis.",
                keyPoint: "Ultra-high-risk = double/triple hit cytogenetics, early relapse, primary refractory, EMD at diagnosis. Consider clinical trials and intensified approaches.",
                citation: "Usmani SZ, et al. Haematologica. 2012;97:1761-7.",
                pmid: "22689675",
                doi: "10.3324/haematol.2012.065698"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What antibodies target BCMA in myeloma treatment?",
                options: [
                    "Daratumumab and isatuximab",
                    "Teclistamab, elranatamab, and BCMA-directed CAR-T (ide-cel, cilta-cel)",
                    "Rituximab and obinutuzumab",
                    "Elotuzumab only"
                ],
                correct: 1,
                explanation: "BCMA (B-cell maturation antigen) is targeted by bispecific antibodies (teclistamab, elranatamab) and CAR-T products (idecabtagene vicleucel, ciltacabtagene autoleucel). These are transforming relapsed/refractory myeloma treatment.",
                keyPoint: "BCMA-targeting: CAR-T (ide-cel, cilta-cel) and bispecifics (teclistamab, elranatamab). High response rates in heavily pretreated patients.",
                citation: "San-Miguel J, et al. N Engl J Med. 2023;388:1002-1014",
                pmid: "35661166",
                doi: "10.1056/NEJMoa2203478"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "fellow",
                question: "What is cytokine release syndrome (CRS) and when does it occur in myeloma treatment?",
                options: [
                    "Allergic reaction to IMiDs",
                    "Systemic inflammatory response from T-cell activation with bispecifics or CAR-T",
                    "Reaction to bisphosphonates",
                    "Side effect of radiation"
                ],
                correct: 1,
                explanation: "CRS results from massive cytokine release (IL-6, TNF-Î±) when T-cells are activated by bispecific antibodies or CAR-T cells. Presents with fever, hypotension, hypoxia. Treated with tocilizumab and corticosteroids.",
                keyPoint: "CRS: fever, hypotension, hypoxia. Grading 1-4. Tocilizumab (IL-6R blocker) is first-line treatment. Steroids for refractory cases.",
                citation: "Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638",
                pmid: "30592986",
                doi: "10.1016/j.bbmt.2018.12.758"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the recommended approach for transplant-ineligible newly diagnosed myeloma?",
                options: [
                    "Best supportive care only",
                    "Dara-VRd or Dara-Rd followed by maintenance",
                    "Single-agent dexamethasone",
                    "Radiation therapy"
                ],
                correct: 1,
                explanation: "For transplant-ineligible patients, Dara-VRd (if tolerable) or Dara-Rd are preferred regimens per NCCN. Continued therapy until progression, with attention to dose modifications for frailty.",
                keyPoint: "Transplant-ineligible: Dara-VRd or Dara-Rd preferred. Frailty assessment important for dose adjustments. VMP-based regimens are alternatives.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Monitoring",
                difficulty: "fellow",
                question: "How often should myeloma patients be monitored during maintenance therapy?",
                options: [
                    "Every 6 months",
                    "Every 1-3 months with labs (SPEP, FLC, CBC, metabolic panel)",
                    "Only when symptomatic",
                    "Annually"
                ],
                correct: 1,
                explanation: "During maintenance, patients should be monitored every 1-3 months with SPEP, serum FLC, CBC, and chemistry panel. Bone marrow biopsy and imaging are performed for clinical indications or suspected relapse.",
                keyPoint: "Maintenance monitoring: every 1-3 months. Track M-protein/FLC trends. Bone marrow/imaging for suspected progression.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "fellow",
                question: "What is immune effector cell-associated neurotoxicity syndrome (ICANS)?",
                options: [
                    "Peripheral neuropathy from bortezomib",
                    "Neurological toxicity from CAR-T or bispecifics causing confusion, aphasia, seizures",
                    "Memory problems from chemotherapy",
                    "Neuropathy from lenalidomide"
                ],
                correct: 1,
                explanation: "ICANS is a CNS toxicity from T-cell engaging therapies, presenting as confusion, word-finding difficulty, tremor, or seizures. Related to blood-brain barrier disruption and CNS inflammation.",
                keyPoint: "ICANS: encephalopathy, aphasia, seizures. Can occur with or after CRS. Dexamethasone is first-line treatment.",
                citation: "Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638",
                pmid: "30592986",
                doi: "10.1016/j.bbmt.2018.12.758"
            },

            // ============ ATTENDING LEVEL ============
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "attending",
                case: {
                    presentation: "A 70-year-old man with standard-risk MM (t(11;14)) progresses 18 months after Dara-VRd and ASCT. He had VGPR lasting 12 months post-transplant. Now M-protein rising, new bone lesions. ECOG PS 1.",
                    labs: [
                        { name: "M-protein", value: "2.1 g/dL (from undetectable)", abnormal: true },
                        { name: "Creatinine", value: "1.2 mg/dL", abnormal: false },
                        { name: "LDH", value: "Normal", abnormal: false }
                    ]
                },
                question: "Given his t(11;14) and early relapse, which regimen deserves special consideration?",
                options: [
                    "Repeat same Dara-VRd regimen",
                    "Venetoclax-based regimen (VenDd or VenPd)",
                    "Selinexor-based regimen only",
                    "Immediate CAR-T therapy"
                ],
                correct: 1,
                explanation: "t(11;14) myeloma has high BCL2 expression, conferring sensitivity to venetoclax. The BELLINI and ongoing trials show excellent responses to venetoclax combinations in t(11;14) patients. This represents precision medicine in myeloma.",
                keyPoint: "t(11;14) = BCL2 high expression = venetoclax-sensitive. Consider venetoclax-dex Â± PI/IMiD for this biomarker-driven approach.",
                citation: "Kumar S, et al. Lancet Oncol. 2020;21:1630-1642 (BELLINI trial)"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the significance of MRD-negativity in multiple myeloma?",
                options: [
                    "No clinical significance, only research interest",
                    "Strongly associated with prolonged PFS and OS across treatment settings",
                    "Only relevant post-transplant",
                    "Indicates need for more aggressive treatment"
                ],
                correct: 1,
                explanation: "MRD-negativity (at 10â»âµ or 10â»â¶ by NGS/NGF) is associated with significantly improved PFS and OS in newly diagnosed, transplant-eligible/ineligible, and relapsed settings. Sustained MRD-negativity has even better outcomes. MRD is increasingly used as endpoint.",
                keyPoint: "MRD-negative = deep response, better outcomes. NGS/NGF at 10â»âµ sensitivity. Sustained MRD-negativity (â¥12 months) = best prognosis.",
                citation: "Munshi NC, et al. JAMA Oncol. 2017;3:28-35",
                pmid: "27632282",
                doi: "10.1001/jamaoncol.2016.3160"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "attending",
                case: {
                    presentation: "A 52-year-old woman with high-risk MM (del17p, gain 1q) completes induction, ASCT, and 2 years of Rd maintenance. She achieves sustained MRD-negativity. She asks about stopping maintenance.",
                    labs: [
                        { name: "M-protein", value: "Undetectable", abnormal: false },
                        { name: "FLC", value: "Normal ratio", abnormal: false },
                        { name: "MRD", value: "Negative (10â»â¶)", abnormal: false }
                    ]
                },
                question: "What is the recommendation regarding maintenance duration?",
                options: [
                    "Stop immediately given MRD-negativity",
                    "Continue lenalidomide maintenance indefinitely (until progression)",
                    "Switch to observation with MRD monitoring only",
                    "Intensify treatment given high-risk cytogenetics"
                ],
                correct: 1,
                explanation: "Despite MRD-negativity, current standard is to continue maintenance until progression, especially in high-risk disease. The SWOG S0777 and other trials support continuous therapy. Stopping therapy, even with MRD-negativity, is not yet standard (clinical trials ongoing).",
                keyPoint: "High-risk MM: continue maintenance until progression regardless of MRD status. Trials like PERSEUS exploring fixed-duration therapy.",
                citation: "Moreau P, et al. N Engl J Med. 2024;391:1593-1605 (PERSEUS)",
                pmid: "38084760",
                doi: "10.1056/NEJMoa2312054"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the optimal sequencing of CAR-T vs bispecific antibodies in RRMM?",
                options: [
                    "CAR-T first always",
                    "Bispecifics first always",
                    "No clear optimal sequence; consider patient factors, access, urgency",
                    "Neither - use conventional therapy"
                ],
                correct: 2,
                explanation: "Optimal sequencing is undefined. CAR-T offers one-time therapy with durable responses but requires time (manufacturing, bridging). Bispecifics are immediately available, continuous therapy. Consider: disease kinetics, patient fitness, logistics, insurance. Post-BCMA CAR-T options are being studied.",
                keyPoint: "No established sequence for BCMA-directed therapies. Rapid progressors may favor bispecifics (immediate). Fit patients with time favor CAR-T (one-time).",
                citation: "Costa LJ, et al. Blood. 2024;143:597-603.",
                pmid: "38048552",
                doi: "10.1182/blood.2023022083"
            },
            {
                type: "simple",
                typeLabel: "Emerging Therapies",
                difficulty: "attending",
                question: "What is the mechanism and promise of CELMoDs in myeloma?",
                options: [
                    "Same as IMiDs, just newer formulation",
                    "Cereblon E3 ligase modulators with enhanced degradation of IKZF1/3, active in IMiD-refractory disease",
                    "Checkpoint inhibitors",
                    "Proteasome inhibitors"
                ],
                correct: 1,
                explanation: "CELMoDs (mezigdomide, iberdomide) are next-generation cereblon modulators with enhanced degradation of Ikaros/Aiolos (IKZF1/3). They show activity in lenalidomide/pomalidomide-refractory patients, representing a significant advance for IMiD-refractory disease.",
                keyPoint: "CELMoDs: Mezigdomide, iberdomide. Active in IMiD-refractory MM. Enhanced cereblon-mediated substrate degradation.",
                citation: "Moreau P, et al. Lancet. 2021;397:2361-2371.",
                pmid: "34097854",
                doi: "10.1016/S0140-6736(21)00612-7"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "attending",
                case: {
                    presentation: "A 75-year-old man with newly diagnosed MM (IgG kappa, R-ISS II) is deemed transplant-ineligible due to cardiac comorbidities. He has moderate renal insufficiency (CrCl 35 mL/min).",
                    labs: [
                        { name: "Creatinine", value: "2.0 mg/dL", abnormal: true },
                        { name: "CrCl", value: "35 mL/min", abnormal: true },
                        { name: "EF", value: "40%", abnormal: true }
                    ]
                },
                question: "What is the optimal induction regimen considering his comorbidities?",
                options: [
                    "VRd with full-dose lenalidomide",
                    "Dara-Rd or Dara-VMP with renal/cardiac dose adjustments",
                    "High-dose dexamethasone monotherapy",
                    "Thalidomide-dexamethasone"
                ],
                correct: 1,
                explanation: "For transplant-ineligible patients, Dara-Rd or Dara-VMP are preferred. With CrCl 35 mL/min, lenalidomide dose should be reduced (10mg daily or every other day). Avoid carfilzomib given cardiac dysfunction. Bortezomib can be used (not renally cleared) with cardiac monitoring.",
                keyPoint: "Transplant-ineligible: Dara-Rd or Dara-VMP preferred. Lenalidomide dose-adjust for renal function. Avoid carfilzomib in cardiac dysfunction.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Special Situations",
                difficulty: "attending",
                question: "How should light chain-only (oligo-secretory) myeloma be monitored?",
                options: [
                    "SPEP only",
                    "Serum free light chains (FLC) as primary marker",
                    "Urine protein only",
                    "PET scan only"
                ],
                correct: 1,
                explanation: "In light chain-only myeloma (no intact immunoglobulin), serum free light chains are the primary monitoring tool. The involved/uninvolved FLC ratio is key. 24-hour urine for Bence Jones protein is supplementary. Non-secretory MM requires imaging and bone marrow for monitoring.",
                keyPoint: "Light chain MM: FLC ratio is primary. Non-secretory MM (~3%): imaging + bone marrow for monitoring. FLC ratio â¥100 is a myeloma-defining event.",
                citation: "Dispenzieri A, et al. Leukemia. 2009;23:215-224",
                pmid: "19020545",
                doi: "10.1038/leu.2008.307"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "attending",
                case: {
                    presentation: "A 63-year-old woman with MM and renal failure (Cr 5.2 mg/dL) is found to have AL amyloidosis on renal biopsy with kappa light chain deposits. Her NT-proBNP is 850 pg/mL (elevated) and troponin is mildly elevated.",
                    labs: [
                        { name: "Creatinine", value: "5.2 mg/dL", abnormal: true },
                        { name: "NT-proBNP", value: "850 pg/mL", abnormal: true },
                        { name: "dFLC", value: "285 mg/L", abnormal: true }
                    ]
                },
                question: "What modification is needed for her myeloma treatment given AL amyloidosis?",
                options: [
                    "No modification; treat as standard myeloma",
                    "Use Dara-VCd (ANDROMEDA regimen); consider reduced dexamethasone, avoid cardiotoxic agents",
                    "Chemotherapy is contraindicated in AL amyloidosis",
                    "Autologous SCT is first-line"
                ],
                correct: 1,
                explanation: "AL amyloidosis with cardiac involvement requires careful therapy. The ANDROMEDA regimen (Dara-VCd) is now standard for AL amyloidosis. Reduce dexamethasone in severe heart failure. Avoid cardiotoxic agents (carfilzomib). ASCT reserved for select patients with limited organ involvement.",
                keyPoint: "AL amyloidosis: Dara-VCd (ANDROMEDA) is standard. Stage cardiac involvement with NT-proBNP/troponin. Reduce steroids in cardiac AL. dFLC for response monitoring.",
                citation: "Kastritis E, et al. N Engl J Med. 2021;385:46-58",
                pmid: "34192431",
                doi: "10.1056/NEJMoa2028631"
            },
            {
                type: "simple",
                typeLabel: "Prognosis",
                difficulty: "attending",
                question: "What defines 'double-hit' or ultra-high-risk myeloma based on current understanding?",
                options: [
                    "Any two cytogenetic abnormalities",
                    "ISS III + high-risk cytogenetics (especially bi-allelic TP53 or â¥2 high-risk features)",
                    "Relapsed within 2 years",
                    "Age >70 with any cytogenetics"
                ],
                correct: 1,
                explanation: "Ultra-high-risk MM includes: bi-allelic TP53 inactivation (del17p + TP53 mutation), or combinations of high-risk features (del17p + 1q gain, t(4;14) + del17p). These patients have poor outcomes even with modern therapy and are focus of clinical trials.",
                keyPoint: "Ultra-high-risk: bi-allelic TP53, or â¥2 high-risk cytogenetics. Median PFS <12 months with standard therapy. Consider clinical trials.",
                citation: "Walker BA, et al. Leukemia. 2019;33:159-170 (Double-Hit)",
                pmid: "29967379",
                doi: "10.1038/s41375-018-0226-4"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the role of allogeneic stem cell transplant in multiple myeloma?",
                options: [
                    "Standard first-line treatment",
                    "Considered in young patients with ultra-high-risk disease or early relapse, preferably in clinical trials",
                    "Never indicated",
                    "Only for elderly patients"
                ],
                correct: 1,
                explanation: "Allogeneic SCT offers graft-versus-myeloma effect but carries significant TRM (15-20%). Not standard of care but may be considered in young patients with high-risk features and early relapse, ideally within clinical trials. Reduced-intensity conditioning used.",
                keyPoint: "Allo-SCT: high TRM, potential cure. Consider for young, high-risk, early relapse patients. Always weigh GvM benefit vs. TRM.",
                citation: "Costa LJ, et al. Biol Blood Marrow Transplant. 2019;25:2163-2173.",
                pmid: "31229651",
                doi: "10.1016/j.bbmt.2019.06.014"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "When should CAR-T therapy be considered over bispecific antibodies in relapsed myeloma?",
                options: [
                    "They are interchangeable",
                    "CAR-T for patients able to wait for manufacturing; bispecifics for rapidly progressive disease",
                    "Bispecifics are always superior",
                    "CAR-T is never preferred"
                ],
                correct: 1,
                explanation: "CAR-T requires 4-6 weeks manufacturing time but offers one-time treatment. Bispecifics are immediately available but require ongoing dosing. For aggressive disease requiring immediate treatment, bispecifics may be preferred.",
                keyPoint: "CAR-T: manufacturing delay but one-time. Bispecifics: immediate availability but continuous therapy. Consider disease tempo.",
                citation: "Shah N, et al. Lancet. 2023;401:2206-2217",
                pmid: "34175021",
                doi: "10.1016/S0140-6736(21)00933-8"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the significance of gain(1q21) in myeloma?",
                options: [
                    "It is a favorable prognostic marker",
                    "It confers high-risk status and is associated with IMiD and PI resistance",
                    "It has no clinical significance",
                    "It predicts excellent response to daratumumab"
                ],
                correct: 1,
                explanation: "Gain/amplification of 1q21 (often 3+ copies) is associated with worse outcomes and represents a high-risk feature. It's the most common chromosomal abnormality in myeloma and may confer resistance to IMiDs.",
                keyPoint: "1q21 gain = high-risk, especially with â¥4 copies. Associated with shorter PFS/OS. Consider intensified therapy.",
                citation: "Schmidt TM, et al. Blood. 2019;134:1721-1731.",
                pmid: "31537534",
                doi: "10.1182/blood.2019000119"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "How should venetoclax be used in myeloma?",
                options: [
                    "Standard of care for all myeloma",
                    "Preferentially in t(11;14) patients due to BCL-2 overexpression; with PI combination",
                    "Never indicated",
                    "Only as monotherapy"
                ],
                correct: 1,
                explanation: "Venetoclax (BCL-2 inhibitor) shows high activity in t(11;14) myeloma due to BCL-2 dependency. BELLINI showed OS concerns with venetoclax-dexamethasone but benefit with PI backbone. FDA approved with bortezomib-dex for t(11;14).",
                keyPoint: "Venetoclax: most effective in t(11;14). Use with PI backbone. Watch for infections (TLS rare in MM).",
                citation: "Kumar SK, et al. Lancet Oncol. 2020;21:1630-1642",
                pmid: "33129376",
                doi: "10.1016/S1470-2045(20)30525-8"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the management of daratumumab-refractory myeloma?",
                options: [
                    "Continue daratumumab at higher doses",
                    "Switch to bispecific antibodies or CAR-T; consider isatuximab combinations",
                    "Best supportive care only",
                    "Re-treat with daratumumab after 6 months"
                ],
                correct: 1,
                explanation: "After daratumumab refractoriness, options include BCMA-targeting agents (bispecifics, CAR-T), isatuximab-based combinations (different epitope on CD38), or other novel agents. Clinical trials are preferred.",
                keyPoint: "Post-daratumumab: BCMA-targeting (CAR-T/bispecifics), isatuximab combinations, selinexor combinations, clinical trials.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Special Topics",
                difficulty: "attending",
                question: "What is the approach to myeloma during pregnancy?",
                options: [
                    "Standard chemotherapy can be used",
                    "Avoid IMiDs and most PIs; dexamethasone and supportive care; multidisciplinary approach",
                    "Immediate pregnancy termination required",
                    "Observation only without any treatment"
                ],
                correct: 1,
                explanation: "Myeloma in pregnancy is rare but challenging. IMiDs are teratogenic, PIs have limited safety data. Options include dexamethasone, plasmapheresis if hyperviscosity, and timing of delivery. Close multidisciplinary care essential.",
                keyPoint: "Pregnancy + MM: Avoid teratogens (IMiDs). Dexamethasone relatively safe. Multidisciplinary care. Weigh maternal and fetal risks.",
                citation: "Lishner M, et al. Leuk Lymphoma. 2016;57:1748-1760.",
                pmid: "26763285",
                doi: "10.3109/10428194.2015.1121259"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the role of belantamab mafodotin in current myeloma treatment?",
                options: [
                    "First-line therapy",
                    "BCMA-targeted ADC; limited by corneal toxicity; used in combinations or after other BCMA therapies",
                    "Never indicated",
                    "Used only in CAR-T bridge therapy"
                ],
                correct: 1,
                explanation: "Belantamab mafodotin is an antibody-drug conjugate targeting BCMA. Corneal toxicity (keratopathy) requires ophthalmologic monitoring. Initially withdrawn, being studied in combinations with improved dosing schedules.",
                keyPoint: "Belantamab: BCMA ADC. Corneal toxicity main limitation. Being studied in combinations with modified schedules.",
                citation: "Lonial S, et al. Lancet Oncol. 2020;21:207-221",
                pmid: "31859245",
                doi: "10.1016/S1470-2045(19)30788-0"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "How do you sequence therapies in penta-refractory myeloma?",
                options: [
                    "Repeat prior effective regimens",
                    "BCMA-targeting (CAR-T or bispecifics), clinical trials, novel combinations",
                    "Best supportive care only",
                    "Allogeneic transplant for all patients"
                ],
                correct: 1,
                explanation: "Penta-refractory (refractory to 2 PIs, 2 IMiDs, and anti-CD38) has poor prognosis. Options include BCMA-targeting therapies, clinical trials with novel targets, or novel combinations. Survival has improved dramatically with new therapies.",
                keyPoint: "Penta-refractory: CAR-T, bispecifics (BCMA or others), selinexor-based, clinical trials. Median OS improving with new agents.",
                citation: "Gandhi UH, et al. Leukemia. 2019;33:2266-2275",
                pmid: "30886299",
                doi: "10.1038/s41375-019-0435-7"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the recommended duration of bisphosphonate therapy in myeloma patients with bone disease?",
                options: [
                    "6 months only",
                    "2 years, then consider stopping or extending interval based on response and side effects",
                    "Lifelong monthly therapy",
                    "Only during active treatment, stop at maintenance"
                ],
                correct: 1,
                explanation: "Per ASCO and IMWG guidelines, bisphosphonates are recommended for 2 years. Beyond 2 years, consider stopping (if in remission) or extending to every 3 months based on individual risk-benefit. Monitor for ONJ and renal function.",
                keyPoint: "Bisphosphonates: 2 years standard, then individualize. Watch for ONJ (dental exam before starting), renal toxicity. Denosumab is an alternative.",
                citation: "Terpos E, et al. J Clin Oncol. 2013;31:2347-2357",
                pmid: "23690408",
                doi: "10.1200/JCO.2012.47.7901"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "attending",
                question: "A patient on carfilzomib develops dyspnea and lower extremity edema. Echo shows new EF reduction to 40% (baseline 60%). What is the most appropriate management?",
                options: [
                    "Continue carfilzomib at same dose with diuretics",
                    "Hold carfilzomib, treat heart failure, and consider switching to bortezomib or ixazomib if PI needed",
                    "This is expected and self-limiting; no intervention needed",
                    "Increase carfilzomib dose to complete therapy faster"
                ],
                correct: 1,
                explanation: "Carfilzomib-associated cardiotoxicity (CHF, decreased EF) requires holding the drug. Heart failure treatment should be initiated. When PI is still needed, bortezomib or ixazomib (which have lower cardiac risk) can be considered. Baseline cardiac assessment is important.",
                keyPoint: "Carfilzomib cardiotoxicity: hold drug, treat HF. Alternative PIs (bortezomib, ixazomib) have lower cardiac risk. Baseline echo recommended for high-risk patients.",
                citation: "Cornell RF, et al. JACC CardioOncol. 2019;1:146-154.",
                pmid: "34396177",
                doi: "10.1016/j.jaccao.2019.09.007"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "attending",
                case: {
                    presentation: "A 72-year-old frail man (IMWG frailty score: frail) with newly diagnosed standard-risk myeloma asks about treatment options. He lives independently but has COPD, DM, and mild CKD (eGFR 45).",
                    labs: [
                        { name: "eGFR", value: "45 mL/min", abnormal: true },
                        { name: "ECOG PS", value: "2", abnormal: true },
                        { name: "Frailty score", value: "Frail", abnormal: true }
                    ]
                },
                question: "What is the most appropriate initial treatment approach?",
                options: [
                    "Full-dose VRd followed by ASCT - frailty should not affect treatment intensity",
                    "Dose-reduced Dara-Rd or Dara-VRd with close monitoring, attenuated dexamethasone (20mg), and consideration of treatment holidays",
                    "Best supportive care only given frailty",
                    "Single-agent daratumumab until progression"
                ],
                correct: 1,
                explanation: "Frail elderly patients benefit from treatment but require dose modifications. Reduced-intensity regimens (attenuated doses, weekly dex 20mg, treatment breaks) with daratumumab backbone provide efficacy with manageable toxicity. Full-intensity therapy increases toxicity without survival benefit in frail patients.",
                keyPoint: "Frail elderly: dose-reduce (dex 20mg weekly, attenuated PI/IMiD), use daratumumab, consider holidays. Frailty tools guide modifications. Don't withhold treatment entirely.",
                citation: "Larocca A, et al. Blood. 2020;136:2513-2523.",
                pmid: "32645135",
                doi: "10.1182/blood.2020006817"
            },
            {
                type: "simple",
                typeLabel: "Monitoring",
                difficulty: "attending",
                question: "In a patient achieving stringent complete response (sCR), what is the role of routine surveillance bone marrow biopsies?",
                options: [
                    "Mandatory every 6 months to detect relapse early",
                    "Not routinely recommended in sCR; perform only if clinical/lab signs of relapse or for MRD assessment in trials",
                    "Required annually per IMWG guidelines",
                    "Should be replaced entirely by PET-CT imaging"
                ],
                correct: 1,
                explanation: "In patients with sCR and stable labs, routine BM biopsies are not recommended outside clinical trials. BM is performed if relapse is suspected (rising M-protein/FLC, new symptoms) or for MRD assessment in study protocols. PET-CT complements but doesn't replace BM when needed.",
                keyPoint: "sCR surveillance: routine BM not needed. Monitor labs (SPEP/FLC) every 1-3 months. BM for suspected relapse or MRD studies. PET for EMD concerns.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Special Populations",
                difficulty: "attending",
                question: "How does renal impairment affect dosing of common myeloma drugs?",
                options: [
                    "All drugs require dose reduction in CKD",
                    "Lenalidomide requires significant dose reduction; bortezomib and daratumumab do not require renal adjustment; carfilzomib needs monitoring",
                    "Only IV drugs need adjustment; oral drugs are safe at full dose",
                    "Dialysis patients cannot receive any myeloma therapy"
                ],
                correct: 1,
                explanation: "Lenalidomide is renally cleared and requires dose reduction (10mg daily for CrCl 30-60, 15mg every 48h for <30). Bortezomib and daratumumab don't need renal adjustment. Carfilzomib doesn't need adjustment but requires careful monitoring. Dialysis patients can receive adapted therapy.",
                keyPoint: "Renal dosing: lenalidomide needs reduction (renally cleared), bortezomib/daratumumab safe, carfilzomib monitor carefully. Myeloma itself often causes renal impairment that may improve with treatment.",
                citation: "Dimopoulos MA, et al. Clin Cancer Res. 2016;22:5358-5367.",
                pmid: "27281559",
                doi: "10.1158/1078-0432.CCR-16-0330"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the significance of t(4;14) in the era of proteasome inhibitor-based therapy?",
                options: [
                    "Remains ultra-high-risk regardless of treatment",
                    "Risk is partially mitigated by bortezomib-based therapy but still requires intensified approach and close monitoring",
                    "Completely normalized by modern quadruplet therapy",
                    "Only prognostic at relapse, not at diagnosis"
                ],
                correct: 1,
                explanation: "t(4;14) was historically high-risk but bortezomib-containing regimens partially overcome the adverse prognosis. However, patients still have shorter remissions and require intensified therapy (quadruplet, consideration of tandem ASCT, PI maintenance). Risk is attenuated but not eliminated.",
                keyPoint: "t(4;14): PI therapy improves but doesn't normalize outcomes. Still high-risk requiring intensification. FGFR3/MMSET overexpression drives biology.",
                citation: "Avet-Loiseau H, et al. Blood. 2010;116:1578-1583.",
                pmid: "20495074",
                doi: "10.1182/blood-2010-03-274639"
            },

            // ============ DR. JAKUBOWIAK LEVEL (EXTREME) ============
            // These questions feature nuanced clinical scenarios with plausible distractors
            {
                type: "case",
                typeLabel: "Ultra-Complex Case",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 52-year-old man presents with newly diagnosed IgA lambda myeloma. FISH shows del(17p) in 85% of cells, t(4;14), AND gain(1q21) x4 copies. R-ISS III with LDH 2x ULN and Î²2M 12 mg/L. He has EMD at diagnosis with two paraspinal masses. After 4 cycles of Dara-KRd, he achieves VGPR but remains MRD-positive at 10^-5.",
                    labs: [
                        { name: "Beta-2-microglobulin", value: "12 mg/L â 2.8 mg/L", abnormal: false },
                        { name: "M-protein", value: "3.2 â 0.18 g/dL", abnormal: true },
                        { name: "MRD (10^-5)", value: "Positive", abnormal: true },
                        { name: "EMD on PET", value: "Resolved", abnormal: false }
                    ]
                },
                question: "What is the MOST appropriate next step for this patient?",
                options: [
                    "Proceed to single ASCT followed by lenalidomide maintenance given VGPR achievement",
                    "Proceed to ASCT, consider tandem transplant, use bortezomib-containing maintenance, and strongly consider consolidation with a T-cell engaging therapy or clinical trial",
                    "Switch to BCMA-targeted CAR-T therapy now given persistent MRD positivity",
                    "Continue Dara-KRd for 4 more cycles to achieve MRD negativity before transplant"
                ],
                correct: 1,
                explanation: "Triple-hit myeloma requires intensified approach even with VGPR. Tandem ASCT should be considered for high-risk patients not achieving deep response. Bortezomib-containing (not lenalidomide-only) maintenance is preferred for high-risk. Early T-cell engaging therapies in trials may provide benefit. CAR-T is not yet standard frontline, and delaying transplant risks progression.",
                keyPoint: "Triple-hit with MRD+ after induction: ASCT (consider tandem), PI maintenance, early novel consolidation. Don't delay transplant; don't use lenalidomide-only maintenance in high-risk.",
                citation: "Lakshman A, et al. Blood Cancer J. 2020;10:75.",
                pmid: "32719337",
                doi: "10.1038/s41408-020-00341-y"
            },
            {
                type: "simple",
                typeLabel: "Genomic Nuance",
                difficulty: "jakubowiak",
                question: "A patient has del(17p) detected in 8% of plasma cells by FISH. According to current evidence, how should this finding influence management?",
                options: [
                    "Ignore it as the clone is too small to be clinically significant",
                    "Treat as standard-risk since del(17p) <20% does not impact outcomes",
                    "Consider as high-risk; even subclonal del(17p) at low percentages is associated with adverse outcomes and clonal expansion at relapse",
                    "Repeat FISH in 3 months to see if the clone expands before making treatment decisions"
                ],
                correct: 2,
                explanation: "Studies show that even subclonal del(17p) at levels as low as 5-10% is associated with worse outcomes. These subclones often expand at relapse. There is no validated 'safe' threshold, and most experts treat any detectable del(17p) as high-risk. The IMWG uses 5% as a detection threshold.",
                keyPoint: "Any detectable del(17p) = high-risk. No safe threshold. Subclones expand at relapse. Treat aggressively regardless of percentage.",
                citation: "Thakurta A, et al. Blood. 2019;133:1217-1221.",
                pmid: "30541743",
                doi: "10.1182/blood-2018-11-886050"
            },
            {
                type: "case",
                typeLabel: "Bispecific Dilemma",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 67-year-old man with relapsed myeloma (5 prior lines including ASCT, lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab) is being considered for teclistamab. Day 1 step-up dose is given. Six hours later, he develops fever 39.2Â°C, BP 95/60 (baseline 130/80), HR 110, SpO2 94% on room air.",
                    labs: [
                        { name: "Temperature", value: "39.2Â°C", abnormal: true },
                        { name: "Blood pressure", value: "95/60 mmHg", abnormal: true },
                        { name: "Ferritin", value: "2,400 ng/mL", abnormal: true },
                        { name: "CRP", value: "180 mg/L", abnormal: true }
                    ]
                },
                question: "This patient has Grade 2 CRS. What is the MOST appropriate initial management?",
                options: [
                    "Administer tocilizumab 8 mg/kg IV and continue close monitoring; hold dexamethasone to preserve T-cell function",
                    "Administer dexamethasone 10 mg IV first, as steroids are preferred over tocilizumab for bispecific-associated CRS",
                    "Administer tocilizumab 8 mg/kg IV; add dexamethasone 10 mg IV if no improvement in 1-2 hours",
                    "Transfer to ICU immediately for vasopressor support before any immunosuppressive therapy"
                ],
                correct: 2,
                explanation: "For Grade 2 CRS (hypotension responsive to fluids, O2 requirement <40%), tocilizumab is first-line per ASTCT guidelines. Dexamethasone can be added if no improvement in 1-2 hours. Holding steroids is outdated; modern data shows steroids don't significantly impair efficacy. ICU is for Grade 3-4 CRS with vasopressor requirement.",
                keyPoint: "Grade 2 CRS: tocilizumab first, add steroids if refractory. Steroids don't significantly impair T-cell therapy efficacy. Grade 3+ = ICU.",
                citation: "Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638",
                pmid: "30592986",
                doi: "10.1016/j.bbmt.2018.12.758"
            },
            {
                type: "simple",
                typeLabel: "Trial Interpretation",
                difficulty: "jakubowiak",
                question: "The DETERMINATION trial compared Dara-VRd followed by ASCT vs. Dara-VRd without ASCT in transplant-eligible NDMM. Which statement BEST describes the findings?",
                options: [
                    "ASCT provided significant PFS and OS benefit, confirming transplant should never be deferred",
                    "ASCT provided significant PFS benefit (~2 years) but no OS difference at median follow-up, with similar MRD negativity rates eventually achieved",
                    "No difference in PFS or OS, suggesting ASCT is obsolete in the daratumumab era",
                    "ASCT was inferior due to treatment-related mortality outweighing disease control benefits"
                ],
                correct: 1,
                explanation: "DETERMINATION showed ASCT provided ~24 month PFS benefit (67.5 vs 46.2 months) but no OS difference at median 76 months follow-up. Both arms achieved similar MRD negativity rates eventually. This supports early ASCT but allows for informed patient discussions about deferral with salvage ASCT at relapse.",
                keyPoint: "DETERMINATION: ASCT = significant PFS benefit, no OS difference yet. Both arms reach similar MRD rates. ASCT remains standard but deferral is discussable.",
                citation: "Richardson PG, et al. N Engl J Med. 2022;387:132-147",
                pmid: "35660812",
                doi: "10.1056/NEJMoa2204925"
            },
            {
                type: "simple",
                typeLabel: "Molecular Resistance",
                difficulty: "jakubowiak",
                question: "Which mechanism is MOST commonly implicated in acquired resistance to lenalidomide in multiple myeloma?",
                options: [
                    "Upregulation of BCL-2 leading to apoptosis resistance",
                    "Mutations or decreased expression of cereblon (CRBN), the target of IMiD-induced degradation",
                    "Overexpression of P-glycoprotein drug efflux pumps",
                    "Acquired t(4;14) translocation affecting FGFR3"
                ],
                correct: 1,
                explanation: "Cereblon (CRBN) is the direct target of IMiDs. CRBN binds lenalidomide/pomalidomide and recruits IKZF1/3 for degradation. Acquired resistance most commonly involves CRBN mutations, decreased CRBN expression, or downstream pathway alterations. BCL-2 upregulation occurs but is not the primary IMiD resistance mechanism.",
                keyPoint: "IMiD resistance: CRBN mutations/downregulation most common. CELMoDs may overcome some resistance. Consider switching drug class.",
                citation: "Kronke J, et al. Science. 2014;343:301-305",
                pmid: "24436409",
                doi: "10.1126/science.1244851"
            },
            {
                type: "case",
                typeLabel: "t(11;14) Decisions",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 58-year-old woman has t(11;14) standard-risk myeloma, relapsed after Dara-VRd and ASCT (PFS 28 months). She achieved CR post-ASCT. Now with biochemical relapse: M-protein 0.8 g/dL. ECOG 0. She asks about venetoclax-based therapy.",
                    labs: [
                        { name: "Cytogenetics", value: "t(11;14) only", abnormal: false },
                        { name: "M-protein", value: "0.8 g/dL", abnormal: true },
                        { name: "BCL2/MCL1 ratio", value: "High BCL2", abnormal: false },
                        { name: "Creatinine", value: "0.9 mg/dL", abnormal: false }
                    ]
                },
                question: "What is the MOST evidence-based approach for venetoclax in this patient?",
                options: [
                    "Venetoclax-dexamethasone alone is FDA-approved and preferred for t(11;14) myeloma",
                    "Venetoclax should be combined with a proteasome inhibitor (bortezomib or carfilzomib) based on BELLINI subgroup analysis showing synergy and improved safety",
                    "Venetoclax is contraindicated after prior bortezomib exposure due to cross-resistance",
                    "Wait for third relapse before using venetoclax to preserve this option for later lines"
                ],
                correct: 1,
                explanation: "BELLINI showed venetoclax-Vd had OS concerns in unselected patients but significant benefit in t(11;14) subgroup (HR 0.11 for PFS). The PI backbone is critical as bortezomib downregulates MCL-1 (a BCL-2 resistance mechanism). Venetoclax-dex alone is NOT FDA-approved. Combination with PI is the evidence-based approach.",
                keyPoint: "Venetoclax in t(11;14): MUST combine with PI (not dex alone). Bortezomib synergy via MCL-1 downregulation. FDA approved ven-bor-dex for t(11;14).",
                citation: "Kumar SK, et al. Lancet Oncol. 2020;21:1630-1642"
            },
            {
                type: "simple",
                typeLabel: "CAR-T Sequencing",
                difficulty: "jakubowiak",
                question: "Based on current evidence, which factor is MOST predictive of response to BCMA-targeted CAR-T therapy in relapsed myeloma?",
                options: [
                    "Baseline BCMA expression level on plasma cells",
                    "Number of prior lines of therapy (fewer = better)",
                    "Adequate lymphodepletion and CAR-T cell expansion/persistence",
                    "Presence or absence of extramedullary disease"
                ],
                correct: 2,
                explanation: "CAR-T expansion and persistence are the strongest predictors of response. Baseline BCMA expression has not consistently predicted outcomes. While EMD and prior lines affect prognosis, adequate lymphodepletion (flu/cy) and subsequent CAR-T expansion are most critical. Low CAR-T persistence correlates with early relapse.",
                keyPoint: "CAR-T response: expansion/persistence most predictive. BCMA expression level not reliably predictive. Lymphodepletion quality matters.",
                citation: "Munshi NC, et al. N Engl J Med. 2021;384:705-716",
                pmid: "33626253",
                doi: "10.1056/NEJMoa2024850"
            },
            {
                type: "case",
                typeLabel: "Infection Dilemma",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 62-year-old man is day +45 post-teclistamab initiation with ongoing weekly dosing. He presents with fever 38.8Â°C, cough, and hypoxia (SpO2 88% on RA). CXR shows bilateral infiltrates. He has severe hypogammaglobulinemia (IgG 180 mg/dL). COVID and respiratory viral panel are negative.",
                    labs: [
                        { name: "IgG", value: "180 mg/dL", abnormal: true },
                        { name: "ANC", value: "0.8 x10^9/L", abnormal: true },
                        { name: "Procalcitonin", value: "0.9 ng/mL", abnormal: true },
                        { name: "Beta-D-glucan", value: "Negative", abnormal: false }
                    ]
                },
                question: "In addition to broad-spectrum antibiotics, what is the MOST important specific intervention for this patient's current and future infection risk?",
                options: [
                    "Discontinue teclistamab permanently due to unacceptable infection risk",
                    "IVIG replacement (target IgG >400 mg/dL), PJP prophylaxis, and consider G-CSF; continue teclistamab with close monitoring",
                    "Switch to a GPRC5D-targeted bispecific as it has lower infection rates than BCMA-targeting",
                    "Prophylactic antifungals are the priority given bilateral infiltrates; IVIG is not beneficial"
                ],
                correct: 1,
                explanation: "Hypogammaglobulinemia is nearly universal with T-cell engaging therapies. IVIG replacement (monthly, target IgG >400-500) significantly reduces infection risk. PJP prophylaxis and antiviral prophylaxis are standard. G-CSF for neutropenia. Bispecifics can often be continued with supportive care; permanent discontinuation is rarely needed for manageable infections.",
                keyPoint: "Bispecific infections: IVIG replacement critical (IgG >400), PJP/antiviral prophylaxis mandatory, G-CSF for neutropenia. Don't reflexively stop therapy.",
                citation: "Mazahreh F, et al. Blood. 2023;141:1306-1315.",
                pmid: "36473025",
                doi: "10.1182/blood.2022018166"
            },
            {
                type: "simple",
                typeLabel: "MRD Technology",
                difficulty: "jakubowiak",
                question: "When comparing next-generation flow cytometry (NGF) and next-generation sequencing (NGS) for MRD detection in myeloma, which statement is MOST accurate?",
                options: [
                    "NGS is always superior due to higher sensitivity (10^-6 vs 10^-5)",
                    "NGF is preferred as it doesn't require a baseline sample and provides faster turnaround, though both achieve similar sensitivity at 10^-5",
                    "NGS should replace NGF as the sole MRD modality given its ability to detect extramedullary disease",
                    "MRD by either method has no correlation with outcomes in the era of quadruplet therapy"
                ],
                correct: 1,
                explanation: "NGF (EuroFlow) and NGS (clonoSEQ) both achieve 10^-5 sensitivity and correlate with outcomes. NGF doesn't require baseline sample, has faster turnaround (same-day possible), and is more widely available. NGS requires diagnostic sample for clone identification. Neither detects EMD (requires imaging). Both are validated for myeloma MRD.",
                keyPoint: "NGF vs NGS: similar sensitivity (10^-5), NGF faster and no baseline needed, NGS needs diagnostic sample. Both valid; neither detects EMD.",
                citation: "Avet-Loiseau H, et al. Blood. 2020;136:2111-2119.",
                pmid: "32641731",
                doi: "10.1182/blood.2020006519"
            },
            {
                type: "case",
                typeLabel: "Refractory Definition",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A patient completed 8 cycles of Dara-Rd with best response of VGPR. Six months after completing therapy (18 months from start), M-protein has increased from 0.2 to 1.8 g/dL with new bone lesions. She previously received VRd-ASCT with relapse at 24 months. She has received daratumumab, lenalidomide, bortezomib, and dexamethasone.",
                    labs: [
                        { name: "M-protein", value: "1.8 g/dL", abnormal: true },
                        { name: "Time since last Rd", value: "6 months", abnormal: false },
                        { name: "Time since last dara", value: "6 months", abnormal: false }
                    ]
                },
                question: "This patient is BEST classified as:",
                options: [
                    "Triple-class exposed; retreatment with daratumumab-containing regimen is reasonable",
                    "Triple-class refractory; eligible for BCMA-targeting therapies as next line",
                    "Daratumumab-refractory but not lenalidomide-refractory; can use pomalidomide-based regimen with daratumumab",
                    "Lenalidomide-refractory but not daratumumab-refractory; retreat with isatuximab-Pd"
                ],
                correct: 1,
                explanation: "Refractory = progression on therapy OR within 60 days of last dose. This patient progressed 6 months (>60 days) after Dara-Rd, making her NOT refractory to either. She is triple-class EXPOSED but not refractory. Retreatment with a daratumumab-containing regimen (different backbone) is reasonable. BCMA-targeting is appropriate but not mandated.",
                keyPoint: "Refractory = progression ON or within 60 days. >60 days = exposed, not refractory. Retreatment possible if good prior response and not truly refractory.",
                citation: "Rajkumar SV, et al. Blood Cancer J. 2022;12:94.",
                pmid: "35701408",
                doi: "10.1038/s41408-022-00688-4"
            },
            {
                type: "simple",
                typeLabel: "Cytogenetic Nuance",
                difficulty: "jakubowiak",
                question: "Which statement about t(11;14) myeloma is MOST accurate?",
                options: [
                    "It is uniformly standard-risk with excellent outcomes regardless of treatment approach",
                    "It is standard-risk but associated with CD20 expression, lower response to IMiDs, and sensitivity to venetoclax due to BCL-2 overexpression",
                    "It should be treated identically to hyperdiploidy with IMiD-based maintenance",
                    "It is high-risk when combined with any secondary cytogenetic abnormality"
                ],
                correct: 1,
                explanation: "t(11;14) is standard-risk but has unique biology: cyclin D1 overexpression, BCL-2 dependence (venetoclax sensitivity), frequent CD20 expression, and relatively lower response to IMiDs compared to hyperdiploidy. Treatment should leverage venetoclax when available. Not all secondary abnormalities confer high-risk.",
                keyPoint: "t(11;14): standard-risk but unique biology. BCL-2 dependent (venetoclax-sensitive). Lower IMiD sensitivity. CD20 expression common.",
                citation: "Lakshman A, et al. Blood Cancer J. 2021;11:166"
            },
            {
                type: "simple",
                typeLabel: "Bispecific Logistics",
                difficulty: "jakubowiak",
                question: "A patient on weekly teclistamab for 6 months with sustained deep response asks about dose frequency. Based on current evidence, what is the MOST appropriate approach?",
                options: [
                    "Continue weekly dosing indefinitely; any de-escalation leads to relapse",
                    "Consider extending to every-2-week dosing after 6+ months of sustained response; prospective trials are evaluating this approach",
                    "Switch to monthly dosing immediately as efficacy is maintained with any schedule",
                    "Discontinue therapy entirely; 6 months of MRD-negative remission is curative"
                ],
                correct: 1,
                explanation: "Dose de-escalation (weekly â every 2 weeks) is being studied in MonumenTAL-3 and real-world practice for patients with sustained deep responses. Early data suggests maintained efficacy with extended intervals. However, this is not yet standard, and complete discontinuation is associated with relapse in most patients.",
                keyPoint: "Bispecific de-escalation: being studied for sustained responders. Q2W reasonable to consider after 6+ months. Full discontinuation leads to relapse in most.",
                citation: "Moreau P, et al. Blood. 2023;142:1047-1057"
            },
            {
                type: "case",
                typeLabel: "SMM Risk",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 55-year-old woman is found to have IgG kappa M-protein 2.8 g/dL, serum FLC kappa 180 mg/L (ratio 45), BM 35% plasma cells. No CRAB. No SLiM criteria. PET-CT shows no lytic lesions or FDG-avid disease. She is diagnosed with smoldering myeloma.",
                    labs: [
                        { name: "M-protein", value: "2.8 g/dL", abnormal: true },
                        { name: "FLC ratio", value: "45", abnormal: true },
                        { name: "BM plasma cells", value: "35%", abnormal: true },
                        { name: "Hemoglobin", value: "13.2 g/dL", abnormal: false }
                    ]
                },
                question: "Using the 2/20/20 Mayo risk model for SMM, what is this patient's risk classification and 2-year progression rate?",
                options: [
                    "Low-risk (0 factors); ~5% 2-year progression rate; observation appropriate",
                    "Intermediate-risk (1 factor); ~20% 2-year progression rate; observation vs. clinical trial",
                    "High-risk (2 factors: M-protein >2g/dL, FLC ratio >20); ~50% 2-year progression rate; consider early treatment",
                    "Ultra-high-risk meeting SLiM criteria; requires immediate treatment"
                ],
                correct: 2,
                explanation: "The 20/2/20 model: M-protein >2g/dL (â), FLC ratio >20 (â), BM plasma cells >20% (â). This patient has all 3 factors = high-risk SMM with ~50% 2-year progression. However, she does NOT meet SLiM criteria (no FLC ratio â¥100, no â¥60% PC, no >1 MRI lesion). Early treatment in high-risk SMM is controversial but being studied.",
                keyPoint: "20/2/20 model: M>2, FLC>20, BMPC>20%. This = high-risk (~50% 2-yr prog). NOT SLiM (which requires FLCâ¥100, â¥60% PC, or MRI lesions).",
                citation: "Lakshman A, et al. Blood Cancer J. 2018;8:59"
            },
            {
                type: "simple",
                typeLabel: "Mechanism Precision",
                difficulty: "jakubowiak",
                question: "What is the PRIMARY mechanism by which daratumumab induces myeloma cell death?",
                options: [
                    "Direct apoptosis induction through CD38 signaling",
                    "Complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP) are the dominant mechanisms, with ADCC and direct effects contributing",
                    "Exclusively through NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC)",
                    "Inhibition of CD38's enzymatic NADase activity depleting cellular NAD+"
                ],
                correct: 1,
                explanation: "Daratumumab works through multiple mechanisms: CDC and ADCP are dominant, with ADCC and direct effects (apoptosis, modulation of enzymatic activity) contributing. Unlike rituximab where ADCC dominates, daratumumab's mechanism is more balanced. This explains activity even in NK-depleted states.",
                keyPoint: "Daratumumab: CDC and ADCP dominant, ADCC contributory, direct effects minor. Multi-mechanism explains broad activity.",
                citation: "de Weers M, et al. J Immunol. 2011;186:1840-1848",
                pmid: "21187443",
                doi: "10.4049/jimmunol.1003032"
            },
            {
                type: "case",
                typeLabel: "CAR-T Failure",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 60-year-old received ide-cel (BCMA CAR-T) 8 months ago with initial VGPR. He now has rising M-protein and PET-avid bone lesions. Flow cytometry on bone marrow shows plasma cells with reduced BCMA expression (MFI 800, pre-CAR-T was 4500). He is being considered for additional therapy.",
                    labs: [
                        { name: "M-protein", value: "1.2 g/dL (from 0.1)", abnormal: true },
                        { name: "BCMA MFI", value: "800 (was 4500)", abnormal: true },
                        { name: "CAR-T cells (blood)", value: "Undetectable", abnormal: true }
                    ]
                },
                question: "What does this pattern of relapse MOST likely indicate, and what is the optimal next approach?",
                options: [
                    "CAR-T cell exhaustion; re-infuse with the same CAR-T product after lymphodepletion",
                    "Antigen escape with BCMA downregulation; a GPRC5D-targeted therapy (talquetamab or GPRC5D CAR-T) is preferred over another BCMA-targeted therapy",
                    "The CAR-T was defective; repeat manufacturing with a different BCMA CAR-T product will succeed",
                    "BCMA expression always recovers; proceed with teclistamab as BCMA is still present"
                ],
                correct: 1,
                explanation: "This pattern shows antigen escape - reduced BCMA expression allowing tumor evasion of BCMA-targeting. Targeting an alternative antigen (GPRC5D) is preferred. While some BCMA may remain, the reduced expression suggests diminished efficacy of any BCMA-targeted approach. Re-infusing same product or switching BCMA products less likely to succeed.",
                keyPoint: "Post-CAR-T relapse with âBCMA = antigen escape. Switch targets (GPRC5D preferred). Same target unlikely to work with antigen loss.",
                citation: "Cohen AD, et al. J Clin Oncol. 2022;40:3846-3857"
            },
            {
                type: "simple",
                typeLabel: "Maintenance Nuance",
                difficulty: "jakubowiak",
                question: "Based on the FORTE and CASSIOPEIA trials, which maintenance strategy provides the BEST outcomes for high-risk newly diagnosed myeloma?",
                options: [
                    "Lenalidomide alone is optimal regardless of risk, as shown in CALGB 100104",
                    "Bortezomib-based or daratumumab-based maintenance improves outcomes in high-risk patients compared to lenalidomide alone",
                    "No maintenance is needed after MRD-negative CR",
                    "Ixazomib provides equivalent outcomes to lenalidomide with better tolerability"
                ],
                correct: 1,
                explanation: "FORTE showed carfilzomib-lenalidomide maintenance superior to lenalidomide alone, especially in high-risk. CASSIOPEIA showed daratumumab maintenance benefit. For high-risk, PI-containing maintenance (bortezomib, carfilzomib) or daratumumab maintenance is preferred over lenalidomide alone. Ixazomib maintenance (TOURMALINE-MM3) showed modest benefit but is inferior to these options.",
                keyPoint: "High-risk maintenance: PI-based (KR, VR) or daratumumab preferred over lenalidomide alone. FORTE/CASSIOPEIA support intensified maintenance.",
                citation: "Gay F, et al. Lancet Oncol. 2021;22:1705-1720"
            },
            {
                type: "simple",
                typeLabel: "Transplant Nuance",
                difficulty: "jakubowiak",
                question: "According to current evidence, what is the UPPER age limit for autologous stem cell transplant in myeloma?",
                options: [
                    "65 years is a strict cutoff based on transplant mortality data",
                    "70 years, beyond which transplant is contraindicated",
                    "There is no strict age cutoff; physiologic age, comorbidities, and geriatric assessment determine eligibility, with fit patients up to 75+ potentially benefiting",
                    "80 years, as modern supportive care has eliminated age-related transplant mortality"
                ],
                correct: 2,
                explanation: "Chronologic age alone should not determine transplant eligibility. Frailty assessment, comorbidities, and physiologic reserve are more important. Studies show fit patients 70-75+ can safely undergo ASCT with acceptable TRM and meaningful benefit. IMWG recommends individualized assessment, not arbitrary age cutoffs.",
                keyPoint: "ASCT eligibility: no strict age cutoff. Frailty/fitness assessment (IMWG, GA) more important than chronologic age. Fit elderly can benefit.",
                citation: "Palumbo A, et al. Blood. 2015;125:2068-2074"
            },
            {
                type: "case",
                typeLabel: "Renal Crisis",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 70-year-old presents with new fatigue and leg swelling. Labs show creatinine 6.8 mg/dL (baseline 1.0), urine shows 8g protein/24h with predominantly albumin. Kidney biopsy shows AL amyloidosis with lambda light chain deposits. SPEP shows small M-spike 0.4 g/dL, SFLC lambda 580 mg/L. BM shows 12% clonal lambda plasma cells.",
                    labs: [
                        { name: "Creatinine", value: "6.8 mg/dL", abnormal: true },
                        { name: "SFLC lambda", value: "580 mg/L", abnormal: true },
                        { name: "dFLC", value: "560 mg/L", abnormal: true },
                        { name: "NT-proBNP", value: "2,800 pg/mL", abnormal: true }
                    ]
                },
                question: "This patient has renal-predominant AL amyloidosis with Mayo 2012 Stage II cardiac involvement (NT-proBNP 2800, troponin normal). What is the MOST appropriate initial treatment?",
                options: [
                    "Dara-VCd (daratumumab-bortezomib-cyclophosphamide-dexamethasone) is preferred based on ANDROMEDA trial showing rapid and deep hematologic responses",
                    "Melphalan-dexamethasone is preferred for renal AL to avoid bortezomib nephrotoxicity",
                    "Lenalidomide-dexamethasone is first-line for AL amyloidosis per ECOG data",
                    "Defer treatment until after cardiac stabilization; chemotherapy is contraindicated with elevated NT-proBNP"
                ],
                correct: 0,
                explanation: "ANDROMEDA established Dara-VCd as standard for newly diagnosed AL amyloidosis. It showed superior hematologic CR rates (53% vs 18%) and major organ response. VCd backbone is effective and safe in renal AL. Stage II cardiac is not a contraindication. Early aggressive hematologic control is critical to prevent further organ damage.",
                keyPoint: "AL amyloidosis first-line: Dara-VCd (ANDROMEDA). Rapid hematologic control critical. Stage II cardiac is not contraindication. VCd safe in renal involvement.",
                citation: "Kastritis E, et al. N Engl J Med. 2021;385:46-58",
                pmid: "34192431",
                doi: "10.1056/NEJMoa2028631"
            },
            {
                type: "simple",
                typeLabel: "Drug Interactions",
                difficulty: "jakubowiak",
                question: "Which drug-drug interaction is MOST clinically significant when treating myeloma patients?",
                options: [
                    "Lenalidomide and EPO (increased thrombosis risk)",
                    "Carfilzomib and strong CYP3A4 inhibitors (carfilzomib toxicity)",
                    "Bortezomib and strong CYP3A4 inducers (reduced bortezomib exposure) and concurrent use of drugs associated with peripheral neuropathy",
                    "Daratumumab and any other medication (universal drug interactions via CD38)"
                ],
                correct: 2,
                explanation: "Bortezomib is metabolized by CYP3A4; strong inducers (rifampin, phenytoin) significantly reduce exposure. Additionally, concurrent neurotoxic drugs (amiodarone, statins, isoniazid) synergize with bortezomib neuropathy. Carfilzomib is predominantly cleared non-CYP450. Lenalidomide-EPO interaction is theoretical. Daratumumab has minimal drug-drug interactions.",
                keyPoint: "Bortezomib: avoid CYP3A4 inducers (rifampin), minimize concurrent neurotoxic drugs. Carfilzomib less affected by CYP interactions. Know your P450 pathways.",
                citation: "Lonial S, et al. Blood. 2015;126:5374-5381"
            },
            {
                type: "simple",
                typeLabel: "Bone Biology",
                difficulty: "jakubowiak",
                question: "What is the mechanism by which myeloma causes predominantly LYTIC bone lesions rather than mixed or blastic lesions?",
                options: [
                    "Direct invasion and destruction of bone matrix by plasma cells",
                    "Myeloma cells secrete factors (RANKL, DKK1, sclerostin) that activate osteoclasts while simultaneously suppressing osteoblast function",
                    "Myeloma cells transform into osteoclasts through differentiation",
                    "Bisphosphonate use causes preferential lytic destruction"
                ],
                correct: 1,
                explanation: "Myeloma creates an 'uncoupled' bone microenvironment: increased RANKL/OPG ratio activates osteoclasts, while DKK1 and sclerostin inhibit Wnt signaling in osteoblasts, suppressing bone formation. This uncoupling produces purely lytic lesions without new bone formation. Understanding this informs treatment with bone-modifying agents.",
                keyPoint: "Myeloma bone disease: osteoclast activation (RANKL) + osteoblast suppression (DKK1/sclerostin) = uncoupled remodeling. Pure lytic lesions.",
                citation: "Terpos E, et al. Blood. 2018;131:1589-1600"
            },

            // ADDITIONAL INTERN LEVEL QUESTIONS
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "What is Rouleaux formation and what causes it in myeloma?",
                options: [
                    "Abnormal white blood cells stacking together",
                    "Red blood cells stacking like coins due to high M-protein coating the cells",
                    "Platelet aggregation causing clotting",
                    "Plasma cells forming clusters"
                ],
                correct: 1,
                explanation: "Rouleaux formation occurs when RBCs stack in coin-like rolls. High levels of M-protein (particularly IgA or IgG) coat the red cells and increase their tendency to aggregate. This is seen on peripheral blood smear and contributes to elevated ESR.",
                keyPoint: "Rouleaux = RBCs stacking like coins. Caused by M-protein coating cells. Causes elevated ESR.",
                citation: "Kyle RA, Rajkumar SV. Blood. 2008;111:2962-2972",
                pmid: "18332230",
                doi: "10.1182/blood-2007-10-078022"
            },
            {
                type: "simple",
                typeLabel: "Basics",
                difficulty: "intern",
                question: "What is the 'M-spike' on serum protein electrophoresis (SPEP)?",
                options: [
                    "A marker of kidney function",
                    "A sharp, narrow peak representing monoclonal protein",
                    "Multiple peaks indicating polyclonal response",
                    "A flat line indicating no protein production"
                ],
                correct: 1,
                explanation: "The M-spike (monoclonal spike) appears as a sharp, narrow peak in the gamma region of SPEP, representing the homogeneous monoclonal immunoglobulin produced by the myeloma clone. Normal immunoglobulins produce a broad, diffuse band.",
                keyPoint: "M-spike = narrow peak on SPEP = monoclonal protein. Normal Igs make broad band. Quantify for monitoring.",
                citation: "Dispenzieri A, et al. Mayo Clin Proc. 2007;82:323-341",
                pmid: "17352369",
                doi: "10.4065/82.3.323"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "intern",
                question: "Why should IV contrast be used cautiously in myeloma patients?",
                options: [
                    "It interferes with M-protein measurement",
                    "Increased risk of contrast-induced nephropathy, especially with dehydration and light chain cast nephropathy",
                    "It causes allergic reactions in all myeloma patients",
                    "It reduces the effectiveness of chemotherapy"
                ],
                correct: 1,
                explanation: "Myeloma patients have increased susceptibility to contrast-induced nephropathy due to underlying renal dysfunction from light chain cast nephropathy. Ensure adequate hydration if contrast must be used. Low-dose CT without contrast is preferred for bone imaging.",
                keyPoint: "Contrast nephropathy risk in myeloma. Hydrate well if using contrast. Low-dose CT preferred for bones.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "intern",
                question: "What is the maximum age for autologous stem cell transplant in myeloma?",
                options: [
                    "65 years strict cutoff",
                    "70 years strict cutoff",
                    "No strict age cutoff; based on fitness and comorbidities",
                    "80 years"
                ],
                correct: 2,
                explanation: "There is no strict age cutoff for ASCT. Transplant eligibility is determined by physiologic fitness, comorbidities, and patient preference rather than chronological age alone. Many centers transplant fit patients in their mid-70s.",
                keyPoint: "ASCT eligibility = fitness, not age. Physiologic age > chronologic age. Assess comorbidities.",
                citation: "Munshi NC, et al. JAMA Oncol. 2017;3:28-35"
            },
            {
                type: "simple",
                typeLabel: "Supportive Care",
                difficulty: "intern",
                question: "What is osteonecrosis of the jaw (ONJ) and which medications cause it?",
                options: [
                    "Jaw infection from myeloma cells; caused by IMiDs",
                    "Bone death in the jaw; associated with bisphosphonates and denosumab",
                    "Gum disease; caused by steroids",
                    "Jaw fracture; caused by proteasome inhibitors"
                ],
                correct: 1,
                explanation: "ONJ is necrosis of jawbone associated with bisphosphonates (zoledronic acid, pamidronate) and denosumab. Risk factors include dental procedures, poor dental hygiene, and duration of therapy. Dental evaluation required before starting therapy.",
                keyPoint: "ONJ = jaw necrosis from bisphosphonates/denosumab. Dental clearance before starting. Avoid dental procedures during treatment if possible.",
                citation: "Khan AA, et al. J Bone Miner Res. 2015;30:3-23"
            },

            // ADDITIONAL RESIDENT LEVEL QUESTIONS
            {
                type: "simple",
                typeLabel: "Cytogenetics",
                difficulty: "resident",
                question: "What is the significance of t(11;14) in myeloma?",
                options: [
                    "High-risk cytogenetics with poor prognosis",
                    "Standard-risk; associated with venetoclax sensitivity",
                    "Diagnostic of Waldenstrom macroglobulinemia",
                    "Indicates transformation to plasma cell leukemia"
                ],
                correct: 1,
                explanation: "t(11;14) is considered standard-risk in myeloma and results in cyclin D1 overexpression. Importantly, it predicts sensitivity to venetoclax, making venetoclax-based regimens particularly effective in this subset.",
                keyPoint: "t(11;14) = standard risk + venetoclax sensitive. CCND1 overexpression. Consider venetoclax in regimens.",
                citation: "Kumar S, et al. Blood. 2020;136:2289-2301"
            },
            {
                type: "simple",
                typeLabel: "Monitoring",
                difficulty: "resident",
                question: "What is the difference between serum free light chains (sFLC) and urine protein electrophoresis (UPEP)?",
                options: [
                    "They measure the same thing",
                    "sFLC measures circulating free light chains; UPEP measures light chains excreted in urine over 24 hours",
                    "UPEP is more sensitive than sFLC",
                    "sFLC only works for kappa chains"
                ],
                correct: 1,
                explanation: "sFLC measures free (unbound) kappa and lambda light chains in blood. UPEP measures light chains (Bence Jones protein) excreted in 24-hour urine. sFLC is more sensitive and not dependent on renal function for excretion.",
                keyPoint: "sFLC = blood test, more sensitive. UPEP = 24hr urine. Use sFLC for oligosecretory/non-secretory monitoring.",
                citation: "Dispenzieri A, et al. Leukemia. 2009;23:215-224"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "resident",
                case: {
                    presentation: "A 62-year-old man with IgG kappa myeloma completes 4 cycles of Dara-VRd induction. M-protein decreased from 3.5 to 0.2 g/dL. Immunofixation still positive. He is transplant-eligible.",
                    labs: [
                        { name: "M-protein", value: "0.2 g/dL (from 3.5)", abnormal: false },
                        { name: "IFE", value: "Positive", abnormal: true },
                        { name: "BM plasma cells", value: "3%", abnormal: false }
                    ]
                },
                question: "What is his current response category?",
                options: [
                    "Complete response (CR)",
                    "Stringent complete response (sCR)",
                    "Very good partial response (VGPR)",
                    "Partial response (PR)"
                ],
                correct: 2,
                explanation: "VGPR requires M-protein detectable by IFE but not SPEP, OR â¥90% reduction in serum M-protein. He has positive IFE (so not CR) but M-protein reduced >90%. CR requires negative IFE.",
                keyPoint: "VGPR = IFE+ but SPEP- OR â¥90% M-protein reduction. CR = negative IFE. sCR = CR + normal FLC ratio + no clonal cells.",
                citation: "Kumar S, et al. Lancet Oncol. 2016;17:e328-e346"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What is the typical duration of consolidation therapy after ASCT?",
                options: [
                    "No consolidation needed",
                    "2 cycles of induction-like therapy to deepen response",
                    "6-12 months of intensive chemotherapy",
                    "2 years of consolidation"
                ],
                correct: 1,
                explanation: "Post-ASCT consolidation typically consists of 2 cycles of a VRd-like regimen to deepen response before transitioning to maintenance. Some trials use 4 cycles. The goal is to achieve the deepest response possible.",
                keyPoint: "Post-ASCT: usually 2 cycles consolidation â maintenance. Deepen response before long-term maintenance.",
                citation: "NCCN Guidelines Multiple Myeloma Version 2.2025",
                guideline: { name: "NCCN", url: "https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf" }
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "resident",
                question: "What is plasma cell leukemia and how is it defined?",
                options: [
                    "Any myeloma with bone marrow involvement",
                    "Circulating plasma cells >2 Ã 10^9/L OR â¥20% plasma cells in peripheral blood",
                    "Myeloma with extramedullary disease",
                    "Myeloma that has relapsed"
                ],
                correct: 1,
                explanation: "Plasma cell leukemia (PCL) is defined by circulating plasma cells >2 Ã 10^9/L OR â¥20% of peripheral blood WBCs. Primary PCL presents de novo; secondary PCL transforms from myeloma. Both have poor prognosis requiring aggressive treatment.",
                keyPoint: "PCL = circulating plasma cells >2 Ã 10^9/L or â¥20%. Primary (de novo) vs secondary (transformed). Very aggressive.",
                citation: "Fernandez de Larrea C, et al. Leukemia. 2013;27:780-791"
            },

            // ADDITIONAL FELLOW LEVEL QUESTIONS
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the role of daratumumab maintenance after ASCT?",
                options: [
                    "Not recommended",
                    "Improves PFS compared to lenalidomide alone (CASSIOPEIA, GRIFFIN data)",
                    "Only for high-risk patients",
                    "Replaces lenalidomide maintenance"
                ],
                correct: 1,
                explanation: "Adding daratumumab to lenalidomide maintenance after ASCT improves PFS (CASSIOPEIA, GRIFFIN trials). This is particularly considered for patients who received Dara-containing induction. Dara is given monthly during maintenance.",
                keyPoint: "Dara + Rd maintenance post-ASCT: improves PFS per CASSIOPEIA/GRIFFIN. Consider for Dara-induction patients.",
                citation: "Moreau P, et al. Lancet. 2019;394:29-38"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "fellow",
                case: {
                    presentation: "A 58-year-old woman with high-risk myeloma (del17p, amp1q) after ASCT. Now 18 months post-transplant on lenalidomide maintenance. M-protein stable at 0.1 g/dL. MRD testing performed.",
                    labs: [
                        { name: "M-protein", value: "0.1 g/dL stable", abnormal: false },
                        { name: "MRD", value: "Positive at 10^-5", abnormal: true },
                        { name: "Cytogenetics", value: "del(17p), amp1q21", abnormal: true }
                    ]
                },
                question: "What is the significance of MRD positivity in this high-risk patient?",
                options: [
                    "MRD doesn't matter if M-protein is stable",
                    "MRD positivity in high-risk disease predicts earlier relapse; consider intensification or trial",
                    "Should immediately proceed to allogeneic transplant",
                    "Continue current maintenance without changes"
                ],
                correct: 1,
                explanation: "MRD positivity, especially in high-risk patients, is associated with shorter remission duration. For high-risk patients not achieving MRD negativity, consider adding agents (daratumumab), clinical trials, or allogeneic HCT in selected cases.",
                keyPoint: "High-risk + MRD positive = shorter PFS. Consider intensification, adding Dara, clinical trials, or allo-HCT.",
                citation: "Munshi NC, et al. JAMA Oncol. 2017;3:28-35"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the mechanism of bispecific antibodies (e.g., teclistamab, elranatamab) in myeloma?",
                options: [
                    "Block BCMA signaling",
                    "Redirect T-cells to kill BCMA-expressing myeloma cells",
                    "Enhance NK cell activity only",
                    "Inhibit proteasome function"
                ],
                correct: 1,
                explanation: "Bispecific antibodies (teclistamab, elranatamab, talquetamab) bind BCMA (or GPRC5D) on myeloma cells and CD3 on T-cells, creating an immunologic synapse that redirects T-cells to kill myeloma cells regardless of their own TCR specificity.",
                keyPoint: "Bispecifics: BCMA Ã CD3 (teclistamab, elranatamab) or GPRC5D Ã CD3 (talquetamab). T-cell redirectors. CRS/ICANS risk.",
                citation: "Moreau P, et al. N Engl J Med. 2022;387:495-505"
            },
            {
                type: "simple",
                typeLabel: "CAR-T",
                difficulty: "fellow",
                question: "What are the FDA-approved CAR-T products for myeloma?",
                options: [
                    "Axicabtagene ciloleucel and tisagenlecleucel",
                    "Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel)",
                    "Brexucabtagene autoleucel only",
                    "No CAR-T products approved for myeloma"
                ],
                correct: 1,
                explanation: "Two BCMA-directed CAR-T products are FDA-approved for myeloma: idecabtagene vicleucel (ide-cel, Abecma) and ciltacabtagene autoleucel (cilta-cel, Carvykti). Both are approved for heavily pretreated RRMM.",
                keyPoint: "Myeloma CAR-T: ide-cel (Abecma) and cilta-cel (Carvykti). Both BCMA-directed. Deep responses in RRMM.",
                citation: "Munshi NC, et al. N Engl J Med. 2021;384:705-716",
                pmid: "33626253",
                doi: "10.1056/NEJMoa2024850"
            },
            {
                type: "simple",
                typeLabel: "Cytogenetics",
                difficulty: "fellow",
                question: "What is the significance of gain(1q) in myeloma?",
                options: [
                    "Favorable prognosis",
                    "High-risk feature, especially with â¥4 copies (amp1q21)",
                    "Standard risk like hyperdiploidy",
                    "Only significant when combined with del(17p)"
                ],
                correct: 1,
                explanation: "Gain(1q21) is considered high-risk, especially when â¥4 copies are present (amp1q21). It's the most common cytogenetic abnormality (~40% of patients). Two high-risk features (e.g., 1q + del17p) define 'double-hit' myeloma.",
                keyPoint: "Gain(1q21): high-risk, especially amp1q (â¥4 copies). Most common abnormality (~40%). Double-hit = 2 high-risk features.",
                citation: "Sonneveld P, et al. Blood. 2016;127:2955-2962"
            },

            // ADDITIONAL JAKUBOWIAK (EXTREME) LEVEL QUESTIONS
            {
                type: "case",
                typeLabel: "Ultra-Complex",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 52-year-old man with myeloma refractory to Dara-VRd, Dara-Pd, and carfilzomib-based therapy. Also received ide-cel CAR-T with relapse at 6 months. Now considering next therapy.",
                    labs: [
                        { name: "Prior lines", value: "5+", abnormal: true },
                        { name: "CAR-T", value: "Relapsed at 6 months", abnormal: true },
                        { name: "Cytogenetics", value: "del(17p), t(4;14)", abnormal: true },
                        { name: "Performance status", value: "ECOG 1", abnormal: false }
                    ]
                },
                question: "What is the most evidence-based next therapy?",
                options: [
                    "Repeat CAR-T with same product",
                    "Bispecific antibody (teclistamab or elranatamab) given different mechanism",
                    "Best supportive care only",
                    "Re-challenge with bortezomib"
                ],
                correct: 1,
                explanation: "Post-CAR-T relapse can still respond to bispecific antibodies as they work through a different mechanism (T-cell redirection vs CAR-T expansion). BCMA bispecifics show activity post-CAR-T. Alternatively, GPRC5D-directed talquetamab targets a different antigen.",
                keyPoint: "Post-CAR-T relapse: bispecifics are effective. BCMA bispecifics or switch target (GPRC5D = talquetamab). Sequence matters.",
                citation: "Lesokhin AM, et al. Blood. 2023;141:1934-1941"
            },
            {
                type: "simple",
                typeLabel: "Novel Therapies",
                difficulty: "jakubowiak",
                question: "What is the mechanism and key toxicity of CELMoDs (e.g., mezigdomide, iberdomide)?",
                options: [
                    "Proteasome inhibitors; neuropathy",
                    "Next-generation cereblon E3 ligase modulators causing enhanced degradation of Ikaros/Aiolos; cytopenias",
                    "BCMA-targeted antibodies; CRS",
                    "XPO1 inhibitors; nausea"
                ],
                correct: 1,
                explanation: "CELMoDs (cereblon E3 ligase modulators) are next-generation IMiDs with enhanced binding to cereblon, causing more potent degradation of Ikaros/Aiolos. Mezigdomide and iberdomide show activity in lenalidomide/pomalidomide-refractory disease. Main toxicities are cytopenias and infections.",
                keyPoint: "CELMoDs: enhanced cereblon modulators. More potent Ikaros/Aiolos degradation. Active in IMiD-refractory. Main toxicity = cytopenias.",
                citation: "Richardson PG, et al. Blood. 2021;138:1667-1670"
            },
            {
                type: "simple",
                typeLabel: "Drug Resistance",
                difficulty: "jakubowiak",
                question: "What are mechanisms of venetoclax resistance in t(11;14) myeloma?",
                options: [
                    "Increased CD38 expression only",
                    "BCL-2 mutations, MCL-1 upregulation, BIM silencing",
                    "P-glycoprotein efflux pumps only",
                    "Loss of t(11;14) translocation"
                ],
                correct: 1,
                explanation: "Venetoclax resistance in myeloma involves BCL-2 family remodeling: MCL-1 upregulation (most common), BCL-XL upregulation, BIM silencing, or rarely BCL-2 mutations. Understanding this informs combination strategies (adding dexamethasone upregulates BIM).",
                keyPoint: "Venetoclax resistance: MCL-1 upregulation (main), BCL-XL increase, BIM loss. Combinations combat resistance.",
                citation: "Touzeau C, et al. Blood. 2019;134:1585-1597"
            },
            {
                type: "case",
                typeLabel: "Rare Complications",
                difficulty: "jakubowiak",
                case: {
                    presentation: "A 60-year-old woman on teclistamab develops Grade 3 CRS on day 1. Treated with tocilizumab and steroids with improvement. Day 14: new cerebellar ataxia, dysarthria, and tremor. Brain MRI negative. CSF: no malignant cells.",
                    labs: [
                        { name: "CRS", value: "Grade 3, resolved", abnormal: true },
                        { name: "Neurologic exam", value: "Cerebellar signs", abnormal: true },
                        { name: "Brain MRI", value: "Negative", abnormal: false },
                        { name: "CSF", value: "No malignant cells", abnormal: false }
                    ]
                },
                question: "What is the most likely diagnosis?",
                options: [
                    "CNS myeloma",
                    "ICANS (immune effector cell-associated neurotoxicity syndrome)",
                    "Stroke",
                    "Paraneoplastic syndrome"
                ],
                correct: 1,
                explanation: "ICANS can occur with bispecific antibodies, similar to CAR-T. It may present days after CRS. Movement disorders including cerebellar signs can occur. MRI may be negative. Treatment is steroids. Tocilizumab doesn't cross BBB well for isolated ICANS.",
                keyPoint: "Bispecific ICANS: can occur post-CRS. Cerebellar signs, tremor, encephalopathy. MRI often negative. Treat with steroids.",
                citation: "Lee DW, et al. Biol Blood Marrow Transplant. 2019;25:625-638",
                pmid: "30592986",
                doi: "10.1016/j.bbmt.2018.12.758"
            },

            // ============ H&E HISTOPATHOLOGY QUESTIONS ============
            {
                type: "case",
                typeLabel: "Histopathology",
                difficulty: "intern",
                case: {
                    presentation: "A 68-year-old presents with back pain and anemia. Bone marrow aspirate shows the cells pictured. SPEP shows an M-spike.",
                    labs: [
                        { name: "Hemoglobin", value: "9.2 g/dL", abnormal: true },
                        { name: "M-spike", value: "3.8 g/dL", abnormal: true },
                        { name: "Creatinine", value: "1.4 mg/dL", abnormal: true },
                        { name: "BM Plasma cells", value: "45%", abnormal: true }
                    ],
                    histopath: {
                        type: "plasma_cell",
                        description: "Plasma cells with eccentric (off-center) nucleus, characteristic 'clock-face' or 'spoke-wheel' chromatin pattern, perinuclear clear zone (hof = Golgi apparatus), and deeply basophilic cytoplasm from high immunoglobulin content."
                    }
                },
                question: "What is the characteristic cell type shown, and what features identify it?",
                options: [
                    "Lymphocyte - small round cells with scant cytoplasm",
                    "Plasma cell - eccentric nucleus, clock-face chromatin, perinuclear hof, basophilic cytoplasm",
                    "Myeloblast - large cells with prominent nucleoli",
                    "Monocyte - cells with folded nuclei"
                ],
                correct: 1,
                explanation: "Normal and myeloma plasma cells have eccentric (off-center) nuclei with characteristic 'clock-face' or 'spoke-wheel' chromatin pattern, a perinuclear clear zone (hof = Golgi apparatus), and deeply basophilic cytoplasm from high immunoglobulin content.",
                keyPoint: "Plasma cells: eccentric nucleus, clock-face chromatin, perinuclear hof, basophilic cytoplasm.",
                citation: "Swerdlow SH, et al. WHO Classification 2017"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "intern",
                question: "What plasma cell percentage in bone marrow is required for diagnosis of multiple myeloma?",
                options: [
                    "â¥5%",
                    "â¥10%",
                    "â¥20%",
                    "â¥30%"
                ],
                correct: 1,
                explanation: "Multiple myeloma requires â¥10% clonal bone marrow plasma cells (or biopsy-proven plasmacytoma) PLUS evidence of end-organ damage (CRAB criteria) OR myeloma-defining events (SLiM criteria: â¥60% plasma cells, sFLC ratio â¥100, >1 focal lesion on MRI).",
                keyPoint: "Myeloma = â¥10% clonal plasma cells + CRAB or SLiM. MGUS = <10% PC + M-protein <3g/dL.",
                citation: "Rajkumar SV, et al. Lancet Oncol. 2014;15:e538-e548"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "resident",
                question: "What morphologic features suggest high-grade or aggressive myeloma on bone marrow?",
                options: [
                    "Mature plasma cells with eccentric nuclei",
                    "Plasmablastic morphology: immature cells with prominent nucleoli, high N:C ratio, and mitotic figures",
                    "Russell bodies only",
                    "Flame cells only"
                ],
                correct: 1,
                explanation: "Plasmablastic morphology indicates aggressive disease: immature plasma cells with prominent central nucleoli, high nuclear-to-cytoplasmic ratio, dispersed chromatin, and frequent mitoses. Associated with poor prognosis, higher proliferation index.",
                keyPoint: "Plasmablastic morphology = aggressive: prominent nucleoli, high N:C ratio, mitoses. Poor prognosis.",
                citation: "Greipp PR, et al. J Clin Oncol. 2005;23:3412-3420"
            },
            {
                type: "case",
                typeLabel: "Histopathology",
                difficulty: "resident",
                case: {
                    presentation: "Bone marrow aspirate from a myeloma patient shows plasma cells with the inclusions shown.",
                    labs: [
                        { name: "IgG", value: "4,200 mg/dL", abnormal: true },
                        { name: "Kappa FLC", value: "890 mg/L", abnormal: true },
                        { name: "K/L Ratio", value: "112", abnormal: true }
                    ],
                    histopath: {
                        type: "dutcher_bodies",
                        description: "Plasma cells with Russell bodies (eosinophilic cytoplasmic inclusions of immunoglobulin) and Dutcher bodies (intranuclear pseudoinclusions that are actually cytoplasmic invaginations containing Ig). Both indicate active immunoglobulin synthesis."
                    }
                },
                question: "What are the inclusions shown, and what do they indicate?",
                options: [
                    "Viral inclusions indicating CMV infection",
                    "Russell bodies (cytoplasmic) and Dutcher bodies (intranuclear) - accumulated Ig indicating active synthesis",
                    "Bacterial inclusions requiring antibiotics",
                    "Drug crystallizations from chemotherapy"
                ],
                correct: 1,
                explanation: "Russell bodies are eosinophilic cytoplasmic inclusions of accumulated immunoglobulin ('grape cells' when abundant). Dutcher bodies are intranuclear Ig pseudoinclusions (actually cytoplasmic invaginations). Both indicate active Ig synthesis.",
                keyPoint: "Russell bodies = cytoplasmic Ig. Dutcher bodies = intranuclear Ig pseudoinclusion. Both = active Ig synthesis.",
                citation: "Kyle RA, Rajkumar SV. Blood. 2008;111:2962-2972"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "resident",
                question: "What is the significance of 'flame cells' on bone marrow examination?",
                options: [
                    "Indicate bacterial infection",
                    "Plasma cells with fiery red cytoplasm; often seen in IgA myeloma",
                    "Normal plasma cell variant",
                    "Artifact of staining"
                ],
                correct: 1,
                explanation: "Flame cells are plasma cells with bright red/pink cytoplasmic periphery, classically associated with IgA myeloma. The glycoprotein-rich IgA accumulates at the cell periphery creating the 'flaming' appearance. Also called 'flaming plasma cells.'",
                keyPoint: "Flame cells = red cytoplasmic periphery = think IgA myeloma. Glycoprotein-rich IgA causes this.",
                citation: "Strobeck J, et al. Am J Clin Pathol. 1982;77:619-623"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "fellow",
                question: "What bone marrow pattern indicates poor prognosis in myeloma?",
                options: [
                    "Interstitial pattern of plasma cells",
                    "Diffuse/packed pattern with >50% cellularity replacement by plasma cells",
                    "Nodular pattern only",
                    "Paratrabecular pattern"
                ],
                correct: 1,
                explanation: "Bone marrow infiltration patterns: interstitial (scattered among normal cells) < nodular (discrete clusters) < diffuse/packed (sheets replacing marrow). Diffuse pattern with high plasma cell burden indicates more advanced disease and worse prognosis.",
                keyPoint: "BM patterns: interstitial (best) â nodular â diffuse/packed (worst). Pattern correlates with tumor burden.",
                citation: "Bartl R, et al. Br J Haematol. 1987;65:57-62"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "fellow",
                question: "What is amyloid and how does it appear on bone marrow biopsy?",
                options: [
                    "Calcium deposits; appears white",
                    "Misfolded light chains; appears as amorphous eosinophilic material, apple-green birefringence with Congo red",
                    "Iron deposits; blue on Prussian blue stain",
                    "Fat necrosis"
                ],
                correct: 1,
                explanation: "AL amyloidosis involves misfolded light chains (usually lambda) depositing as insoluble fibrils. On H&E: amorphous pink/eosinophilic extracellular deposits. Congo red stain shows apple-green birefringence under polarized light - pathognomonic for amyloid.",
                keyPoint: "Amyloid: Congo red + polarized light = apple-green birefringence. Usually lambda light chains in AL.",
                citation: "Merlini G, et al. J Clin Oncol. 2011;29:1924-1933"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "fellow",
                question: "How do you distinguish clonal plasma cells from reactive plasmacytosis?",
                options: [
                    "Cell morphology alone",
                    "Light chain restriction (kappa or lambda only by IHC or flow); aberrant CD56 expression; cyclin D1 in t(11;14)",
                    "Location in marrow",
                    "Rouleaux formation"
                ],
                correct: 1,
                explanation: "Clonal plasma cells show: light chain restriction (kappa-only or lambda-only rather than mixed), often aberrant CD56 expression (normally negative), loss of CD19/CD45, and specific markers like cyclin D1 in t(11;14). Reactive plasma cells are polytypic with normal phenotype.",
                keyPoint: "Clonal vs reactive: light chain restriction, aberrant CD56, loss of CD19. Use flow or IHC to confirm clonality.",
                citation: "Kumar S, et al. Blood. 2008;111:558-565"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "attending",
                question: "What histopathologic finding on bone biopsy suggests POEMS syndrome?",
                options: [
                    "Diffuse plasma cell infiltrate â¥30%",
                    "Usually <5% plasma cells, often clustered, with associated sclerotic bone lesions",
                    "Plasmablastic morphology",
                    "Amyloid deposits"
                ],
                correct: 1,
                explanation: "POEMS paradoxically has low plasma cell burden (<5% in 80% of cases) but significant systemic effects. Plasma cells often cluster around blood vessels. Associated with sclerotic (not lytic) bone lesions. Lambda light chain restriction in >95%.",
                keyPoint: "POEMS: low PC burden (<5%), clustered pattern, SCLEROTIC lesions (not lytic), lambda restricted.",
                citation: "Dispenzieri A. Blood. 2017;129:135-145"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "attending",
                question: "What renal histopathology is characteristic of myeloma cast nephropathy?",
                options: [
                    "Immune complex glomerulonephritis",
                    "Tubular casts of eosinophilic material (Tamm-Horsfall protein + light chains) with surrounding giant cell reaction",
                    "Minimal change disease",
                    "IgA nephropathy"
                ],
                correct: 1,
                explanation: "Myeloma cast nephropathy (myeloma kidney): tubular casts composed of light chains bound to Tamm-Horsfall protein. Casts are eosinophilic, often fractured/angular, surrounded by multinucleated giant cells (foreign body reaction). Tubular damage and interstitial fibrosis follow.",
                keyPoint: "Cast nephropathy: eosinophilic tubular casts + giant cell reaction. Light chains + Tamm-Horsfall protein.",
                citation: "Leung N, et al. Blood. 2019;133:2673-2684"
            },
            {
                type: "simple",
                typeLabel: "Histopathology",
                difficulty: "jakubowiak",
                question: "What is light chain deposition disease (LCDD) and how does it differ from AL amyloidosis histologically?",
                options: [
                    "They are identical",
                    "LCDD: granular deposits along basement membranes, Congo red NEGATIVE; AL: fibrillar, Congo red POSITIVE",
                    "LCDD is Congo red positive",
                    "AL involves only kidneys"
                ],
                correct: 1,
                explanation: "Both are monoclonal light chain deposition disorders. LCDD: non-fibrillar (granular) deposits along basement membranes, Congo red NEGATIVE, usually kappa. AL amyloidosis: fibrillar beta-pleated sheet deposits, Congo red POSITIVE with apple-green birefringence, usually lambda.",
                keyPoint: "LCDD: granular, Congo red negative, usually kappa. AL: fibrillar, Congo red positive, usually lambda.",
                citation: "Bridoux F, et al. Blood. 2015;125:1606-1615"
            },

            // ============ ADDITIONAL QUESTIONS ============
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "intern",
                question: "What class of drug is bortezomib?",
                options: [
                    "IMiD (immunomodulatory drug)",
                    "Proteasome inhibitor",
                    "Monoclonal antibody",
                    "Alkylating agent"
                ],
                correct: 1,
                explanation: "Bortezomib was the first proteasome inhibitor, targeting the 26S proteasome. It disrupts protein degradation, leading to accumulation of pro-apoptotic proteins and plasma cell death. Key side effects: peripheral neuropathy, thrombocytopenia.",
                keyPoint: "Bortezomib: first-gen proteasome inhibitor. Main toxicity = peripheral neuropathy. SQ preferred over IV.",
                citation: "Richardson PG, et al. N Engl J Med. 2003;348:2609-2617"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "intern",
                question: "What is the mechanism of action of lenalidomide?",
                options: [
                    "Proteasome inhibition",
                    "Cereblon binding leading to degradation of Ikaros/Aiolos transcription factors",
                    "CD20 targeting",
                    "Direct DNA damage"
                ],
                correct: 1,
                explanation: "Lenalidomide binds cereblon (CRBN), part of an E3 ubiquitin ligase complex. This causes ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for myeloma cell survival. Also has immunomodulatory effects.",
                keyPoint: "IMiDs bind cereblon â degrade Ikaros/Aiolos â myeloma cell death. Also immune effects (NK, T-cell).",
                citation: "Lu G, et al. Science. 2014;343:305-309"
            },
            {
                type: "simple",
                typeLabel: "Prognosis",
                difficulty: "resident",
                question: "What is the Revised International Staging System (R-ISS) for myeloma?",
                options: [
                    "Based on M-protein level only",
                    "Combines ISS (albumin, Î²2M) with LDH and high-risk cytogenetics",
                    "Based on bone lesion count",
                    "Based on light chain type"
                ],
                correct: 1,
                explanation: "R-ISS combines: ISS stage (albumin + Î²2-microglobulin) + serum LDH + high-risk cytogenetics (del17p, t(4;14), t(14;16)). R-ISS I: ISS I + standard-risk + normal LDH. R-ISS III: ISS III or high-risk cytogenetics or elevated LDH. R-ISS II: neither I nor III.",
                keyPoint: "R-ISS = ISS + LDH + cytogenetics. Stage I best, III worst. High-risk cyto: del17p, t(4;14), t(14;16).",
                citation: "Palumbo A, et al. J Clin Oncol. 2015;33:2863-2869"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "resident",
                question: "What is hyperviscosity syndrome and which myeloma subtype is most at risk?",
                options: [
                    "Low blood viscosity; IgG myeloma",
                    "High blood viscosity from elevated M-protein; IgA and especially IgM (Waldenstrom's)",
                    "Only occurs in light chain disease",
                    "Related to platelets"
                ],
                correct: 1,
                explanation: "Hyperviscosity occurs when high M-protein levels increase blood viscosity. Symptoms: mucosal bleeding, visual disturbances, neurologic changes, heart failure. Most common in Waldenstrom's (IgM), then IgA myeloma (IgA polymerizes). IgG rarely causes it. Treat with plasmapheresis.",
                keyPoint: "Hyperviscosity: bleeding, vision, neuro sx. IgM > IgA > IgG risk. Plasmapheresis for acute management.",
                citation: "Gertz MA. Clin Lymphoma Myeloma Leuk. 2013;13:109-114"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "fellow",
                case: {
                    presentation: "A 68-year-old woman with newly diagnosed myeloma. M-protein 4.2 g/dL, FISH shows t(11;14). Bone marrow 45% plasma cells. She declines transplant.",
                    labs: [
                        { name: "M-protein", value: "4.2 g/dL", abnormal: true },
                        { name: "t(11;14)", value: "Positive", abnormal: false },
                        { name: "BM plasma cells", value: "45%", abnormal: true }
                    ]
                },
                question: "What treatment consideration is important for t(11;14) myeloma?",
                options: [
                    "Avoid all proteasome inhibitors",
                    "Venetoclax-based regimens may be particularly effective due to BCL-2 dependence",
                    "Only use lenalidomide monotherapy",
                    "Immediate allogeneic transplant required"
                ],
                correct: 1,
                explanation: "t(11;14) myeloma overexpresses BCL-2 (cyclin D1 is a marker, BCL-2 the target). These patients are often sensitive to venetoclax. BELLINI and other trials showed efficacy of venetoclax combinations in t(11;14) myeloma, even frontline.",
                keyPoint: "t(11;14) = venetoclax-sensitive (BCL-2 dependent). Consider venetoclax-based regimen especially if refractory.",
                citation: "Kumar S, et al. Blood. 2020;136:2289-2301"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the role of selinexor (Xpovio) in myeloma?",
                options: [
                    "First-line induction",
                    "XPO1 inhibitor for heavily pretreated myeloma; approved with dexamethasone (Selinexor-dex) or with bortezomib-dex (SVd)",
                    "Maintenance therapy only",
                    "CAR-T bridging therapy"
                ],
                correct: 1,
                explanation: "Selinexor is a selective inhibitor of nuclear export (SINE) compound targeting XPO1. Approved for penta-refractory myeloma (Selinexor-dex, STORM trial) and for 1-3 prior lines with bortezomib-dex (SVd, BOSTON trial). Key toxicities: nausea, fatigue, cytopenias.",
                keyPoint: "Selinexor: XPO1 inhibitor. With dex for penta-refractory (STORM), with VD for earlier lines (BOSTON). GI toxicity common.",
                citation: "Chari A, et al. N Engl J Med. 2019;381:727-738"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "attending",
                question: "What distinguishes smoldering myeloma from MGUS and active myeloma?",
                options: [
                    "Bone lesions present",
                    "BM plasma cells 10-60% OR M-protein â¥3g/dL, but NO CRAB criteria or myeloma-defining events",
                    "Any detectable M-protein",
                    "Symptoms present"
                ],
                correct: 1,
                explanation: "Smoldering myeloma (SMM): â¥10% BM plasma cells and/or M-protein â¥3g/dL, but no CRAB (hypercalcemia, renal, anemia, bone) and no myeloma-defining events (â¥60% PC, sFLCâ¥100, >1 MRI lesion). Higher progression risk than MGUS. Currently no standard treatment.",
                keyPoint: "SMM: meets MM criteria but no end-organ damage. Higher risk than MGUS. Watch carefully or consider trials.",
                citation: "Kyle RA, et al. Leukemia. 2010;24:1121-1127"
            },
            {
                type: "simple",
                typeLabel: "Molecular",
                difficulty: "jakubowiak",
                question: "What is the GEP (gene expression profiling) risk score used for in myeloma?",
                options: [
                    "Diagnosis only",
                    "70-gene signature (GEP70) identifies high-risk myeloma independent of cytogenetics; prognostic",
                    "Treatment selection",
                    "Response assessment"
                ],
                correct: 1,
                explanation: "GEP70 is a 70-gene expression signature that identifies high-risk myeloma with worse outcomes independent of ISS and cytogenetics. High-risk by GEP70 (~15% of patients) has significantly shorter PFS and OS. Increasingly used to identify ultra-high-risk patients.",
                keyPoint: "GEP70: 70-gene signature identifies high-risk independent of FISH. ~15% patients. Research tool becoming clinical.",
                citation: "Shaughnessy JD, et al. Blood. 2007;109:2276-2284"
            },

            // ============ ROUND 2: MORE CLINICAL QUESTIONS ============
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "intern",
                question: "What defines myeloma bone disease and what imaging is preferred?",
                options: [
                    "Any bone pain; X-ray only",
                    "Lytic lesions best detected by low-dose whole-body CT or PET/CT; plain X-rays miss ~40% of lesions",
                    "Blastic lesions; MRI only",
                    "Bone scan is preferred"
                ],
                correct: 1,
                explanation: "Myeloma causes purely lytic lesions (no new bone formation). Low-dose whole-body CT (WBCT) or PET/CT preferred over plain X-rays which miss ~30-40% of lesions. Bone scans are NOT useful (no osteoblastic activity to detect). MRI for spinal cord compression.",
                keyPoint: "Myeloma = lytic lesions. WBCT or PET/CT preferred. Plain X-rays miss 30-40%. Bone scan NOT useful.",
                citation: "Hillengass J, et al. Lancet Oncol. 2019;20:e302-e312"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "What are the CRAB criteria for myeloma?",
                options: [
                    "Cancer, Renal failure, Arthritis, Bleeding",
                    "Calcium elevation (>11 or >1 above ULN), Renal insufficiency (Cr >2 or CrCl <40), Anemia (Hgb <10 or >2 below LLN), Bone lesions",
                    "Complete remission, Relapse, Adverse genetics, Burden",
                    "Clonal plasma cells only"
                ],
                correct: 1,
                explanation: "CRAB criteria define end-organ damage requiring treatment: Calcium >11 mg/dL or >1 above ULN, Renal (Cr >2 or CrCl <40), Anemia (Hgb <10 or >2 below LLN), Bone (â¥1 lytic lesion on imaging). Meeting any CRAB criterion upgrades smoldering myeloma to active myeloma.",
                keyPoint: "CRAB: Ca >11, Cr >2/CrCl<40, Hgb <10, Bone lesions. Any CRAB = active myeloma requiring treatment.",
                citation: "Rajkumar SV, et al. Lancet Oncol. 2014;15:e538-e548"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What is the preferred induction regimen for transplant-eligible myeloma?",
                options: [
                    "Melphalan + prednisone",
                    "Daratumumab + VRd (Dara-VRd) per GRIFFIN/PERSEUS or VRd alone",
                    "Lenalidomide monotherapy",
                    "High-dose cyclophosphamide alone"
                ],
                correct: 1,
                explanation: "For transplant-eligible patients, Dara-VRd (daratumumab + bortezomib + lenalidomide + dexamethasone) is now preferred based on GRIFFIN and PERSEUS trials showing deeper responses. VRd alone remains an excellent option. Typically 4-6 cycles before stem cell collection.",
                keyPoint: "Transplant-eligible induction: Dara-VRd preferred (GRIFFIN, PERSEUS) or VRd. 4-6 cycles before ASCT.",
                citation: "Voorhees PM, et al. Blood. 2020;136:936-945"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What conditioning regimen is used for autologous transplant in myeloma?",
                options: [
                    "Total body irradiation",
                    "High-dose melphalan (200 mg/mÂ², or 140 mg/mÂ² if renal impairment)",
                    "BEAM (carmustine, etoposide, cytarabine, melphalan)",
                    "Busulfan + cyclophosphamide"
                ],
                correct: 1,
                explanation: "High-dose melphalan (MEL200, 200 mg/mÂ²) is standard conditioning for myeloma ASCT. Dose-reduced melphalan (140 mg/mÂ²) used for renal dysfunction or elderly. BEAM is used for lymphoma, not myeloma. TBI not typically used in myeloma.",
                keyPoint: "Myeloma ASCT conditioning: MEL200 (200 mg/mÂ²). MEL140 if renal dysfunction/elderly. Not TBI or BEAM.",
                citation: "NCCN Guidelines Multiple Myeloma 2025"
            },
            {
                type: "case",
                typeLabel: "Clinical Case",
                difficulty: "fellow",
                case: {
                    presentation: "A 72-year-old man with newly diagnosed myeloma, ECOG 2, CrCl 35 mL/min, LVEF 45%. Not considered transplant-eligible.",
                    labs: [
                        { name: "ECOG", value: "2", abnormal: true },
                        { name: "CrCl", value: "35 mL/min", abnormal: true },
                        { name: "LVEF", value: "45%", abnormal: true }
                    ]
                },
                question: "What is the preferred initial therapy?",
                options: [
                    "VRd followed by ASCT",
                    "Daratumumab + lenalidomide + dexamethasone (Dara-Rd) or VRd with dose adjustments",
                    "High-dose melphalan",
                    "Observation only"
                ],
                correct: 1,
                explanation: "For transplant-ineligible patients, Dara-Rd (daratumumab-lenalidomide-dexamethasone) is preferred based on MAIA trial showing PFS and OS benefit. VRd is also effective. Lenalidomide requires dose adjustment for renal dysfunction. Continue until progression.",
                keyPoint: "Transplant-ineligible: Dara-Rd (MAIA) or VRd. Continue until progression. Adjust doses for renal function.",
                citation: "Facon T, et al. N Engl J Med. 2019;380:2104-2115"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is talquetamab and its unique toxicity profile?",
                options: [
                    "BCMA bispecific with only CRS",
                    "GPRC5D Ã CD3 bispecific; unique skin (nail changes, rash) and taste alterations (dysgeusia) in addition to CRS/ICANS",
                    "CD38 antibody",
                    "CAR-T product"
                ],
                correct: 1,
                explanation: "Talquetamab is a GPRC5DÃCD3 bispecific antibody. GPRC5D is expressed on myeloma cells and also keratinocytes/taste buds, leading to unique on-target/off-tumor effects: nail changes, skin rash/peeling, and significant dysgeusia (taste loss). Also CRS and infections.",
                keyPoint: "Talquetamab: GPRC5D bispecific. Unique: nail changes, skin effects, dysgeusia (taste buds). Different target than BCMA.",
                citation: "Chari A, et al. N Engl J Med. 2022;387:2232-2244"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "attending",
                question: "What is the recommended management of newly diagnosed myeloma with spinal cord compression?",
                options: [
                    "Start chemotherapy only",
                    "Urgent dexamethasone, emergent spine MRI, urgent radiation and/or surgical decompression, then systemic therapy",
                    "Observation with repeat imaging in 1 month",
                    "Bisphosphonates alone"
                ],
                correct: 1,
                explanation: "Spinal cord compression is an oncologic emergency. Immediate high-dose dexamethasone (reduces edema), urgent MRI whole spine (rule out additional levels), emergent radiation (most common) and/or surgical decompression (if unstable spine or neurologic decline). Then start systemic therapy.",
                keyPoint: "Cord compression: emergency! High-dose dex immediately, MRI whole spine, urgent RT Â± surgery, then chemo.",
                citation: "NCCN Guidelines Multiple Myeloma 2025"
            },
            {
                type: "simple",
                typeLabel: "Supportive Care",
                difficulty: "attending",
                question: "What is the role of IVIG in myeloma?",
                options: [
                    "Used for all patients routinely",
                    "For patients with recurrent infections AND documented hypogammaglobulinemia (IgG <400-500)",
                    "Contraindicated in myeloma",
                    "Only after transplant"
                ],
                correct: 1,
                explanation: "IVIG is considered for myeloma patients with recurrent serious bacterial infections (â¥2 requiring hospitalization or IV antibiotics in 12 months) AND hypogammaglobulinemia (typically IgG <400-500 mg/dL). Not routine prophylaxis for all patients.",
                keyPoint: "IVIG: recurrent infections + hypogammaglobulinemia (IgG <400-500). Not for all patients routinely.",
                citation: "Snowden JA, et al. Br J Haematol. 2017;179:553-574"
            },
            {
                type: "simple",
                typeLabel: "Emerging Therapy",
                difficulty: "jakubowiak",
                question: "What is belantamab mafodotin and why was it withdrawn then re-approved?",
                options: [
                    "Never withdrawn",
                    "BCMA-ADC causing corneal toxicity; withdrawn after DREAMM-3, re-approved after DREAMM-7/8 showed PFS benefit in combinations",
                    "CAR-T product",
                    "Bispecific antibody"
                ],
                correct: 1,
                explanation: "Belantamab mafodotin is a BCMA-directed ADC with MMAF payload. Initially approved (DREAMM-2) but withdrawn after DREAMM-3 failed vs PomDex. DREAMM-7 (with VD) and DREAMM-8 (with PomD) showed significant PFS benefit, leading to reintroduction. Requires ophthalmology monitoring for keratopathy.",
                keyPoint: "Belantamab: BCMA-ADC. Withdrew after DREAMM-3, back after DREAMM-7/8 combination success. Eye toxicity needs monitoring.",
                citation: "Dimopoulos MA, et al. N Engl J Med. 2024;391:406-417"
            },
            // ============ ROUND 3: ADDITIONAL CLINICAL QUESTIONS ============
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is ciltacabtagene autoleucel (cilta-cel) and its key features?",
                options: [
                    "Bispecific antibody",
                    "BCMA-directed CAR-T with two BCMA-binding domains; approved for R/R myeloma after 4+ prior lines including PI, IMiD, and anti-CD38",
                    "CD19 CAR-T for myeloma",
                    "First-line treatment option"
                ],
                correct: 1,
                explanation: "Cilta-cel is a BCMA-directed CAR-T with unique two BCMA-binding domains for increased avidity. CARTITUDE-1 showed 98% ORR with deep responses. Approved after 4+ prior lines. CARTITUDE-4 now shows benefit in 1-3 prior lines. Movement of Parkinsonism reported in some patients.",
                keyPoint: "Cilta-cel: BCMA CAR-T with dual binding domains. High response rates. Watch for delayed neurotoxicity/parkinsonism.",
                citation: "Martin T, et al. N Engl J Med. 2023;389:335-347"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the mechanism of selinexor and when is it used?",
                options: [
                    "Proteasome inhibitor",
                    "XPO1 (exportin-1) inhibitor; forces nuclear retention of tumor suppressors; used in penta-refractory myeloma",
                    "IMiD",
                    "CD38 antibody"
                ],
                correct: 1,
                explanation: "Selinexor is a first-in-class selective inhibitor of nuclear export (SINE) targeting XPO1/CRM1. Forces nuclear retention of tumor suppressors (p53, IkB). STORM trial in penta-refractory myeloma. Also approved with dexamethasone (SeLECTor) and with VD (BOSTON). Major toxicities: fatigue, nausea, thrombocytopenia.",
                keyPoint: "Selinexor: XPO1 inhibitor. Nuclear retention of tumor suppressors. For heavily pretreated. GI and fatigue common.",
                citation: "Chari A, et al. N Engl J Med. 2019;381:727-738"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "How does carfilzomib differ from bortezomib?",
                options: [
                    "No difference",
                    "Carfilzomib is irreversible proteasome inhibitor with less neuropathy but more cardiotoxicity; IV only",
                    "Carfilzomib has more neuropathy",
                    "Bortezomib is IV only"
                ],
                correct: 1,
                explanation: "Carfilzomib is an irreversible (covalent) proteasome inhibitor vs bortezomib's reversible binding. Carfilzomib has significantly less peripheral neuropathy but higher cardiac toxicity (HTN, CHF, arrhythmias). Given IV only (bortezomib can be SubQ). ENDEAVOR showed PFS benefit of KRd over VRd.",
                keyPoint: "Carfilzomib: irreversible PI, less neuropathy, more cardiac. IV only. Bortezomib: reversible, SubQ option, more neuropathy.",
                citation: "Dimopoulos MA, et al. Lancet Oncol. 2016;17:27-38"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "fellow",
                question: "Which cytogenetic abnormalities define high-risk myeloma?",
                options: [
                    "Hyperdiploidy only",
                    "t(4;14), t(14;16), t(14;20), del(17p), gain(1q), and TP53 mutation define high-risk disease",
                    "Normal karyotype is high-risk",
                    "Trisomies are high-risk"
                ],
                correct: 1,
                explanation: "High-risk cytogenetics include: t(4;14) - intermediate to high, t(14;16) and t(14;20) - high, del(17p)/TP53 mutation - high, gain(1q) especially â¥4 copies - high. Double/triple hit with multiple abnormalities is ultra-high risk. These patients may benefit from tandem transplant, intensified regimens.",
                keyPoint: "High-risk: t(4;14), t(14;16), t(14;20), del(17p), gain(1q), TP53 mut. Double-hit = ultra-high risk.",
                citation: "Sonneveld P, et al. Blood. 2023;142:1524-1547"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "What is the significance of minimal residual disease (MRD) negativity in myeloma?",
                options: [
                    "No prognostic value",
                    "MRD-negativity (by NGS or flow at 10â»âµ-10â»â¶) predicts significantly longer PFS and OS across treatment settings",
                    "MRD testing is not standardized",
                    "Only matters in transplant-eligible"
                ],
                correct: 1,
                explanation: "MRD-negativity at 10â»âµ or deeper by next-generation sequencing (clonoSEQ) or next-generation flow (EuroFlow) is a powerful prognostic marker. IMWG criteria include MRD for response. MRD-negative patients have ~2x longer PFS. Increasingly used as trial endpoint and to guide therapy duration.",
                keyPoint: "MRD: 10â»âµ by NGS or flow. MRD-negative = better PFS/OS. Becoming standard assessment. May guide treatment.",
                citation: "Munshi NC, et al. JAMA Oncol. 2017;3:28-35"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "resident",
                question: "What defines extramedullary myeloma and its prognosis?",
                options: [
                    "Normal myeloma presentation",
                    "Plasmacytomas outside bone marrow (soft tissue, organs); associated with aggressive biology and poor prognosis",
                    "Only affects bone",
                    "Better prognosis than standard myeloma"
                ],
                correct: 1,
                explanation: "Extramedullary myeloma (EMD) refers to plasmacytomas outside the bone/bone marrow. Can be at diagnosis or relapse. Associated with high-risk genetics, aggressive biology, and poor prognosis. May require local radiation. Patients may benefit from novel agents (CAR-T, bispecifics). PET-CT important for detection.",
                keyPoint: "EMD: plasmacytomas outside marrow. Aggressive, poor prognosis. PET-CT for detection. Consider CAR-T/bispecifics.",
                citation: "Bhutani M, et al. Blood Cancer J. 2020;10:88"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "jakubowiak",
                question: "What is the current evidence for treating high-risk smoldering myeloma?",
                options: [
                    "Never treat SMM",
                    "Select high-risk SMM may benefit from early intervention; CESAR trial showed deep responses with intensive therapy; ongoing trials exploring lenalidomide-based treatment",
                    "All SMM should be treated",
                    "Only observation is acceptable"
                ],
                correct: 1,
                explanation: "High-risk SMM (2/20/20 model, Mayo 2018) has ~50% progression at 2 years. CESAR showed intensive therapy could achieve MRD-negativity. QuiRedex showed lenalidomide delayed progression. E3A06 showed lenalidomide benefit in high-risk. Debate continues; clinical trial enrollment preferred for many high-risk patients.",
                keyPoint: "High-risk SMM: consider treatment/trial. CESAR, QuiRedex, E3A06 support intervention. Risk stratification crucial.",
                citation: "Lonial S, et al. J Clin Oncol. 2020;38:1126-1137"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is elotuzumab and its mechanism?",
                options: [
                    "CD38 antibody",
                    "SLAMF7 (CS1) antibody that enhances NK cell-mediated killing; approved with lenalidomide-dex or pomalidomide-dex",
                    "BCMA antibody",
                    "PD-1 inhibitor"
                ],
                correct: 1,
                explanation: "Elotuzumab targets SLAMF7 (CS1), a glycoprotein highly expressed on myeloma cells. Dual mechanism: direct SLAMF7 targeting and enhanced NK cell activation via SLAMF7 on NK cells. ELOQUENT-2 showed PFS benefit with ERd. Less infusion reactions than CD38 antibodies.",
                keyPoint: "Elotuzumab: anti-SLAMF7. Activates NK cells. ERd or EPd regimens. Less infusion reactions than anti-CD38.",
                citation: "Lonial S, et al. N Engl J Med. 2015;373:621-631"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "What is the difference between solitary plasmacytoma and multiple myeloma?",
                options: [
                    "No difference",
                    "Solitary plasmacytoma: single lesion, no marrow involvement, no other CRAB features; treated with radiation; ~50% progress to MM within 3-5 years",
                    "Solitary plasmacytoma is worse prognosis",
                    "MM always starts as plasmacytoma"
                ],
                correct: 1,
                explanation: "Solitary plasmacytoma is a single plasma cell tumor (bone or extramedullary) without clonal marrow plasma cells (<10%), no other lytic lesions, and no myeloma-defining events. Treatment is definitive radiation (40-50 Gy). ~50% progress to MM within 3-5 years; surveillance with labs and imaging required.",
                keyPoint: "Solitary plasmacytoma: single lesion, <10% marrow PCs, no CRAB. RT is curative. 50% progress to MM.",
                citation: "Caers J, et al. Haematologica. 2018;103:1586-1599"
            },
            // ============ ROUND 4: ADDITIONAL CLINICAL QUESTIONS ============
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "attending",
                question: "When is venetoclax particularly effective in myeloma?",
                options: [
                    "All myeloma patients equally",
                    "Patients with t(11;14) translocation; BCL-2 dependence makes them highly sensitive to venetoclax",
                    "Only after CAR-T failure",
                    "Never used in myeloma"
                ],
                correct: 1,
                explanation: "Myeloma with t(11;14) overexpresses BCL-2 (cyclin D1 dysregulation) and shows high sensitivity to venetoclax. BELLINI trial and other studies show excellent responses in t(11;14)+ patients. Not broadly approved in myeloma; use in t(11;14)+ relapsed setting. CYP3A4 interactions important.",
                keyPoint: "Venetoclax: highly effective in t(11;14) myeloma due to BCL-2 dependence. BELLINI trial. CYP3A4 interactions.",
                citation: "Kumar S, et al. Lancet Oncol. 2020;21:1630-1642"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is the mechanism of pomalidomide and when is it used?",
                options: [
                    "Proteasome inhibitor",
                    "Third-generation IMiD with cereblon binding; used in lenalidomide-refractory myeloma as PVd or EPd",
                    "CD38 antibody",
                    "First-line only"
                ],
                correct: 1,
                explanation: "Pomalidomide is a third-generation IMiD that binds cereblon with higher affinity than lenalidomide, leading to degradation of IKZF1/3 transcription factors. Active in lenalidomide-refractory disease. Common regimens: PVd (OPTIMISMM), DPd, EPd. Toxicities similar to other IMiDs (VTE, myelosuppression, teratogenicity).",
                keyPoint: "Pomalidomide: 3rd gen IMiD, higher cereblon affinity. For lenalidomide-refractory. PVd, DPd, EPd regimens.",
                citation: "Richardson PG, et al. Blood. 2019;134:123-133"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "jakubowiak",
                question: "What is the first-line treatment for AL amyloidosis?",
                options: [
                    "Same as myeloma",
                    "Daratumumab-bortezomib-cyclophosphamide-dexamethasone (Dara-VCd); ANDROMEDA trial showed superior hematologic response",
                    "Radiation",
                    "Observation"
                ],
                correct: 1,
                explanation: "ANDROMEDA trial established Dara-VCd as standard for newly diagnosed AL amyloidosis. Daratumumab added to VCd improved hematologic CR (53% vs 18%) and organ response. Goal is rapid, deep hematologic response to prevent ongoing organ damage. Auto-HCT for select patients.",
                keyPoint: "AL amyloidosis: Dara-VCd (ANDROMEDA). Deep hematologic response crucial for organ protection. Select patients for HCT.",
                citation: "Kastritis E, et al. N Engl J Med. 2021;385:46-58"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What is teclistamab and its toxicity profile?",
                options: [
                    "ADC drug",
                    "BCMA Ã CD3 bispecific antibody; step-up dosing to mitigate CRS; also ICANS, infections (hypogammaglobulinemia)",
                    "CAR-T product",
                    "Oral medication"
                ],
                correct: 1,
                explanation: "Teclistamab is a BCMAÃCD3 bispecific T-cell engager. Given step-up dosing (0.06â0.3â1.5 mg/kg) to reduce CRS severity. Approved for R/R myeloma after 4+ lines. Main toxicities: CRS, ICANS, infections (severe in ~40-50%), cytopenias. Hypogammaglobulinemia requires IVIG prophylaxis.",
                keyPoint: "Teclistamab: BCMAÃCD3 bispecific. Step-up dosing. CRS, ICANS, infections common. IVIG for hypogammaglobulinemia.",
                citation: "Moreau P, et al. N Engl J Med. 2022;387:495-505"
            },
            {
                type: "simple",
                typeLabel: "Complications",
                difficulty: "resident",
                question: "What is hyperviscosity syndrome and how is it managed?",
                options: [
                    "Only occurs in IgA myeloma",
                    "Elevated serum viscosity causing bleeding, vision changes, neurologic symptoms; treated with emergent plasmapheresis",
                    "Only treated with chemotherapy",
                    "Spontaneously resolves"
                ],
                correct: 1,
                explanation: "Hyperviscosity occurs mainly with IgM (Waldenstrom's) or high IgA/IgG3 levels. Symptoms: mucosal bleeding, visual changes (dilated retinal veins, hemorrhages), confusion, dyspnea. Treat emergently with plasmapheresis (removes IgM best, larger molecule). Start systemic therapy concurrently. IgM: 1-2 exchanges; IgG/A: may need more.",
                keyPoint: "Hyperviscosity: vision changes, bleeding, confusion. Plasmapheresis urgent. Most common in IgM, less IgA/IgG.",
                citation: "Stone MJ, et al. Blood. 2012;119:2929-2936"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "fellow",
                question: "What are special considerations for myeloma patients with renal failure?",
                options: [
                    "Never use bortezomib",
                    "Bortezomib preferred (no renal adjustment); avoid lenalidomide unless dose-reduced; hydration crucial; consider rapid reduction therapy",
                    "Use full-dose lenalidomide",
                    "Transplant is contraindicated"
                ],
                correct: 1,
                explanation: "Bortezomib is preferred as it doesn't require renal adjustment and can reverse renal failure. Lenalidomide requires dose reduction (5mg with dialysis). Rapid reduction of light chains important to preserve renal function. High-dose dexamethasone if acute kidney injury. ~30% may recover off dialysis with treatment.",
                keyPoint: "Myeloma + renal failure: bortezomib preferred (no adjustment). Reduce lenalidomide dose. Rapid light chain reduction.",
                citation: "Dimopoulos MA, et al. J Clin Oncol. 2016;34:1544-1557"
            },
            {
                type: "simple",
                typeLabel: "Treatment",
                difficulty: "resident",
                question: "What is the optimal timing for stem cell collection in myeloma?",
                options: [
                    "After prolonged lenalidomide exposure",
                    "Early, after 3-4 cycles of induction; lenalidomide impairs collection if prolonged; goal â¥4Ã10â¶ CD34+ cells/kg",
                    "After transplant",
                    "Collection not needed for transplant"
                ],
                correct: 1,
                explanation: "Collect stem cells early (after 3-4 induction cycles) before extensive lenalidomide exposure, which impairs mobilization. Mobilize with G-CSF Â± plerixafor (CXCR4 inhibitor). Goal: â¥4Ã10â¶ CD34+ cells/kg for one transplant, â¥6-8Ã10â¶ if considering tandem. Prior melphalan also impairs collection.",
                keyPoint: "Collect early (3-4 cycles) before prolonged lenalidomide. G-CSF Â± plerixafor. Goal â¥4Ã10â¶ CD34+ cells/kg.",
                citation: "Giralt S, et al. Biol Blood Marrow Transplant. 2014;20:295-308"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "intern",
                question: "How should MGUS be monitored?",
                options: [
                    "No follow-up needed",
                    "Annual labs (SPEP, CBC, creatinine, calcium); progression rate ~1%/year; educate on myeloma symptoms",
                    "Monthly bone marrow biopsies",
                    "Immediate treatment"
                ],
                correct: 1,
                explanation: "MGUS requires monitoring as it can progress to MM at ~1%/year. Annual follow-up: SPEP (M-spike), CBC, creatinine, calcium. Risk of progression: higher M-spike, non-IgG isotype, abnormal FLC ratio. Educate patients on CRAB symptoms. No imaging unless symptoms. Lifelong monitoring recommended.",
                keyPoint: "MGUS: annual SPEP, CBC, Cr, Ca. ~1%/year progression. Risk factors: M-spike size, non-IgG, abnormal FLC.",
                citation: "Kyle RA, et al. N Engl J Med. 2018;378:241-249"
            },
            {
                type: "simple",
                typeLabel: "Diagnosis",
                difficulty: "attending",
                question: "What is light chain only myeloma and its diagnostic challenges?",
                options: [
                    "No M-protein ever detectable",
                    "~20% of myeloma; no intact immunoglobulin, only FLC; SPEP may be negative; requires serum FLC assay for diagnosis and monitoring",
                    "Always IgG type",
                    "Best prognosis"
                ],
                correct: 1,
                explanation: "Light chain only myeloma (~15-20%) produces only kappa or lambda light chains, no intact immunoglobulin. SPEP may show nothing or small band (light chains small, may escape detection). Serum free light chain (FLC) assay essential for diagnosis and monitoring. Often has renal involvement (cast nephropathy).",
                keyPoint: "Light chain myeloma: ~20%, FLC only, SPEP may be negative. FLC assay essential. Often renal involvement.",
                citation: "Dispenzieri A, et al. Leukemia. 2009;23:215-224"
            }
        ];

        // ASH Image Bank URLs for H&E histopathology images
        const histopathImages = {
            plasma_cell: {
                url: "https://imagebank.hematology.org/getimagebyid/61459?size=3",
                source: "ASH Image Bank #61459",
                author: "ASH Image Bank"
            },
            myeloma_bm: {
                url: "https://imagebank.hematology.org/getimagebyid/63227?size=3",
                source: "ASH Image Bank #63227",
                author: "David Israel Garrido, MD"
            },
            plasmablast: {
                url: "https://imagebank.hematology.org/getimagebyid/2403?size=3",
                source: "ASH Image Bank #2403",
                author: "ASH Image Bank"
            },
            russell_bodies: {
                url: "https://imagebank.hematology.org/getimagebyid/10938?size=3",
                source: "ASH Image Bank #10938",
                author: "ASH Image Bank"
            },
            dutcher_bodies: {
                url: "https://imagebank.hematology.org/getimagebyid/63562?size=3",
                source: "ASH Image Bank #63562",
                author: "ASH Image Bank"
            },
            amyloid: {
                url: "https://imagebank.hematology.org/getimagebyid/62419?size=3",
                source: "ASH Image Bank #62419",
                author: "ASH Image Bank"
            }
        };

        function selectDifficulty(difficulty) {
            selectedDifficulty = difficulty;
            document.querySelectorAll('.difficulty-btn').forEach(btn => {
                btn.classList.remove('selected');
            });
            document.querySelector(`.difficulty-btn.${difficulty}`).classList.add('selected');

            // Toggle hell mode for Dr. Jakubowiak level
            if (difficulty === 'jakubowiak') {
                document.body.classList.add('hell-mode');
                createHellFlames();
                playHellSound();
            } else {
                document.body.classList.remove('hell-mode');
                clearHellFlames();
            }

            initAudio();
            playCoinSound();
        }

        // Create flames for hell mode
        function createHellFlames() {
            const container = document.getElementById('hellFlames');
            if (!container) return;
            container.innerHTML = '';
            const flameCount = Math.ceil(window.innerWidth / 50);
            for (let i = 0; i < flameCount; i++) {
                const flame = document.createElement('div');
                flame.className = 'flame';
                flame.style.left = (i * 50 + Math.random() * 20) + 'px';
                flame.style.animationDelay = (Math.random() * 0.5) + 's';
                container.appendChild(flame);
            }
        }

        function clearHellFlames() {
            const container = document.getElementById('hellFlames');
            if (container) container.innerHTML = '';
        }

        // Evil hell sound
        function playHellSound() {
            const ctx = initAudio();
            const now = ctx.currentTime;

            // Ominous descending sound
            const notes = [
                { freq: 220, time: 0, dur: 0.3 },
                { freq: 185, time: 0.15, dur: 0.3 },
                { freq: 147, time: 0.3, dur: 0.3 },
                { freq: 110, time: 0.45, dur: 0.5 },
            ];

            notes.forEach(n => {
                const osc = ctx.createOscillator();
                const gain = ctx.createGain();
                osc.connect(gain);
                gain.connect(getOutput());
                osc.type = 'sawtooth';
                osc.frequency.setValueAtTime(n.freq, now + n.time);
                gain.gain.setValueAtTime(0.2, now + n.time);
                gain.gain.exponentialRampToValueAtTime(0.01, now + n.time + n.dur);
                osc.start(now + n.time);
                osc.stop(now + n.time + n.dur + 0.1);
            });
        }

        function startGame() {
            initAudio();
            playPowerUpSound();

            // Calculate hero end position based on screen width
            calculateHeroEndPosition();

            // Filter questions by difficulty
            filteredQuestions = questions.filter(q => q.difficulty === selectedDifficulty);

            // Shuffle questions
            filteredQuestions = filteredQuestions.sort(() => Math.random() - 0.5);

            // Take up to 10 questions
            filteredQuestions = filteredQuestions.slice(0, 10);

            currentQuestion = 0;
            score = 0;
            streak = 0;
            correctAnswers = 0;

            // Reset lives system
            lives = 3;
            heroPosition = HERO_START_POS;
            isHeroDead = false;
            showLivesDisplay();
            updateLivesDisplay();
            updateHeroPosition();

            // Show the princess waiting to be rescued
            showPrincess();

            document.getElementById('startScreen').style.display = 'none';
            document.getElementById('gameScreen').style.display = 'block';
            document.getElementById('resultsScreen').style.display = 'none';

            // Start the runner scene (enemies spawn when questions are answered)
            clearEnemies();
            startRunnerScene();

            updateStats();
            loadQuestion();
        }

        function loadQuestion() {
            if (currentQuestion >= filteredQuestions.length) {
                showResults();
                return;
            }

            const q = filteredQuestions[currentQuestion];
            const card = document.getElementById('questionCard');

            const difficultyLabel = q.difficulty === 'jakubowiak' ? 'DR. JAKUBOWIAK' : q.difficulty.toUpperCase();
            let html = `
                <span class="question-type type-${q.type}">${q.typeLabel}</span>
                <span class="difficulty-badge ${q.difficulty}">${difficultyLabel}</span>
                <div class="question-number">WORLD ${currentQuestion + 1} OF ${filteredQuestions.length}</div>
            `;

            if (q.case) {
                html += `
                    <div class="case-presentation">
                        <h4>ð PATIENT FILE</h4>
                        <p>${q.case.presentation}</p>
                        ${q.case.labs ? `
                            <div class="lab-values">
                                ${q.case.labs.map(lab => `
                                    <div class="lab-item ${lab.abnormal ? 'abnormal' : ''}">
                                        <strong>${lab.name}:</strong> ${lab.value}
                                    </div>
                                `).join('')}
                            </div>
                        ` : ''}
                        ${q.case.histopath && histopathImages[q.case.histopath.type] ? `
                            <div class="histopath-container">
                                <div class="histopath-panel">
                                    <div class="histopath-panel-label">H&E Morphology</div>
                                    <div class="histopath-image-wrapper">
                                        <img src="${histopathImages[q.case.histopath.type].url}"
                                             alt="Histopathology"
                                             onerror="this.style.display='none'; this.nextElementSibling.style.display='flex';">
                                        <div class="histopath-fallback" style="display:none;">Image from ASH Image Bank</div>
                                    </div>
                                    <div class="histopath-caption">${histopathImages[q.case.histopath.type].source}</div>
                                </div>
                                <div class="histopath-panel">
                                    <div class="histopath-panel-label">Key Features</div>
                                    <div class="histopath-description">${q.case.histopath.description}</div>
                                </div>
                            </div>
                        ` : ''}
                    </div>
                `;
            }

            html += `<div class="question-text">${q.question}</div>`;

            html += `<div class="options">`;
            const letters = ['A', 'B', 'C', 'D'];
            q.options.forEach((opt, i) => {
                html += `
                    <div class="option" onclick="selectAnswer(${i}, event)">
                        <span class="option-letter">${letters[i]}</span>
                        <span class="option-text">${opt}</span>
                    </div>
                `;
            });
            html += `</div>`;

            html += `
                <div class="explanation" id="explanation">
                    <h4>â­ POWER-UP KNOWLEDGE!</h4>
                    <p>${q.explanation}</p>
                    <div class="key-point">
                        <strong>ð Key Point:</strong>
                        <p>${q.keyPoint}</p>
                    </div>
                    <div class="citation">ð ${q.citation}${renderReferenceLinks(q)}</div>
                </div>
                <button class="next-btn" id="nextBtn" onclick="nextQuestion()">NEXT LEVEL â</button>
            `;

            card.innerHTML = html;

            // Update progress bar
            const progress = (currentQuestion / filteredQuestions.length) * 100;
            document.getElementById('progressFill').style.width = progress + '%';
        }

        function selectAnswer(selected, event) {
            const q = filteredQuestions[currentQuestion];
            const options = document.querySelectorAll('.option');
            const rect = event.target.getBoundingClientRect();

            options.forEach((opt, i) => {
                opt.classList.add('disabled');
                if (i === q.correct) {
                    opt.classList.add('correct');
                } else if (i === selected && selected !== q.correct) {
                    opt.classList.add('incorrect');
                }
            });

            // Spawn a myeloma cell from pipe near the hero
            const spawnResult = spawnEnemyFromPipe();

            // Animation delay before showing next button
            let animationDelay = 2500;

            if (selected === q.correct) {
                playCoinSound();
                streak++;
                correctAnswers++;
                const points = 10 + (streak - 1) * 5;
                score += points;
                showCoinPopup(rect.left + 50, rect.top, `+${points}`);

                // Wait for pipe + enemy to emerge, then hero jumps and stomps
                // Pipe appears: 350ms, Enemy emerges: 700ms, then stomp
                setTimeout(() => {
                    const enemyObj = spawnResult ? spawnResult.getEnemy() : null;
                    if (enemyObj) {
                        heroStompNewEnemy(enemyObj);
                        // Remove pipe after stomp
                        setTimeout(() => {
                            removeDynamicPipe(spawnResult.pipe);
                        }, 800);
                    }
                }, 1100);

                animationDelay = 2800;

                if (streak >= 3) {
                    setTimeout(() => {
                        play1UpSound();
                        show1UpPopup(rect.left + 100, rect.top - 20);
                    }, 1800);
                }
            } else {
                playWrongSound();
                streak = 0;

                // Wait for pipe + enemy to emerge, then hero loses a life
                setTimeout(() => {
                    loseLife();

                    // After death animation, make enemy exit left off stage
                    if (spawnResult) {
                        const enemyObj = spawnResult.getEnemy();
                        if (enemyObj && enemyObj.element) {
                            // Start enemy exit animation after hero death (500ms delay)
                            setTimeout(() => {
                                enemyObj.element.classList.add('exit-left');
                                // Remove enemy after exit animation completes
                                setTimeout(() => {
                                    if (enemyObj.element.parentNode) {
                                        enemyObj.element.remove();
                                    }
                                    enemies = enemies.filter(e => e.element !== enemyObj.element);
                                }, 1300);
                            }, 500);
                        }
                        // Remove pipe after death animation starts
                        setTimeout(() => {
                            removeDynamicPipe(spawnResult.pipe);
                        }, 500);
                    }
                }, 1100);

                animationDelay = 3500;
            }

            if (streak > maxStreak) maxStreak = streak;

            updateStats();

            // Show explanation immediately but delay the next button
            document.getElementById('explanation').classList.add('show');

            // Delay showing next button until animation completes
            setTimeout(() => {
                document.getElementById('nextBtn').classList.add('show');
            }, animationDelay);
        }

        function nextQuestion() {
            currentQuestion++;

            // Move hero right as questions progress
            updateHeroPosition();

            loadQuestion();
            playCoinSound();
        }

        function updateStats() {
            document.getElementById('scoreValue').textContent = score;
            document.getElementById('streakValue').textContent = streak;
            document.getElementById('correctValue').textContent = `${correctAnswers}/${currentQuestion > 0 ? currentQuestion : filteredQuestions.length > 0 ? filteredQuestions.length : '?'}`;
        }

        function showResults() {
            // Stop runner scene and clear enemies
            gameActive = false;
            pauseRunnerScene();
            clearEnemies();

            const percentage = Math.round((correctAnswers / filteredQuestions.length) * 100);

            // Check if player won (completed with lives remaining and good score)
            const playerWon = lives > 0 && percentage >= 50;

            if (playerWon) {
                // Move hero to princess and play victory animation
                heroPosition = HERO_END_POS;
                updateHeroPosition();

                // Delay to let hero reach princess
                setTimeout(() => {
                    playVictoryAnimation();
                }, 500);

                // Show results after victory animation
                setTimeout(() => {
                    hideVictoryOverlay();
                    hidePrincess();
                    document.getElementById('gameScreen').style.display = 'none';
                    document.getElementById('resultsScreen').style.display = 'block';
                    displayResults(percentage);
                }, 6000);
            } else {
                // Player lost - show results immediately
                hidePrincess();
                document.getElementById('gameScreen').style.display = 'none';
                document.getElementById('resultsScreen').style.display = 'block';
                displayResults(percentage);
            }
        }

        function displayResults(percentage) {
            document.getElementById('finalScore').textContent = percentage + '%';

            // Animate score circle
            document.getElementById('scoreCircle').style.background =
                `conic-gradient(var(--coin-gold) ${percentage}%, rgba(0,0,0,0.3) ${percentage}%)`;

            let grade, message, color;
            if (percentage >= 90) {
                grade = 'â­ SUPERSTAR! â­';
                message = 'You rescued Princess Hematopoiesis! Mastery achieved!';
                color = 'var(--coin-gold)';
                playPowerUpSound();
            } else if (percentage >= 70) {
                grade = 'ð POWER UP!';
                message = 'Great job! The Princess is safe thanks to you!';
                color = 'var(--mario-green)';
                playPowerUpSound();
            } else if (percentage >= 50) {
                grade = 'ð KEEP RUNNING!';
                message = 'You saved the Princess, but barely! Review and try again!';
                color = 'var(--mario-blue)';
            } else {
                grade = 'ð GAME OVER';
                message = 'The myeloma cells won this time. Study up and try again!';
                color = 'var(--mario-red)';
                playWrongSound();
            }

            document.getElementById('gradeText').textContent = grade;
            document.getElementById('gradeText').style.color = color;
            document.getElementById('resultsMessage').textContent = message;
        }

        function restartGame() {
            document.getElementById('resultsScreen').style.display = 'none';
            document.getElementById('startScreen').style.display = 'block';
            hideVictoryOverlay();
            hidePrincess();
            hideLivesDisplay();
            clearEnemies();
            playCoinSound();
        }

        // Initialize
        document.addEventListener('DOMContentLoaded', () => {
            // Load saved volume
            const savedVolume = localStorage.getItem('myelomaman-volume');
            if (savedVolume) {
                musicVolume = parseInt(savedVolume) / 100;
                document.getElementById('volumeSlider').value = savedVolume;
                document.getElementById('volumeValue').textContent = savedVolume + '%';
            }
        });
    </script>
</body>
</html>
